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Summary
Lung cancer is the most common cancer worldwide with 1.3 million new cases 
diagnosed each year. The 5-year survival rate is much lower than other 
common cancers such as breast and prostate cancer. Several large-scale 
screening programmes using existing technologies over the past 40 years have 
not yet reduced mortality rates from lung cancer. We have studied new 
technologies on sputum and exhaled breath to assess their potential for 
diagnosis. Reliable, non-invasive and cheap diagnostic tests are the 
cornerstone for any future screening programme. The first study tests the sputa 
of patients with suspected lung cancer and healthy controls with Fourier 
Transform Infra-Red (FTIR) spectroscopy. We developed a predictive model 
based on two wavenumbers, to differentiate those with proven lung cancer 
versus healthy controls with a sensitivity of 93% and specificity of 91%. When 
we included the sputa of patients having tests for lung cancer initially but with 
no evidence of cancer after one year (“high-risk” group), this only partially 
reduced the model’s predictive ability. The second study assessed the sputa 
from the same cohorts with a panel of gene antibodies (p16, p53, p63, EGFR 
and cyclin D1). Results were not discriminatory with low sensitivity (8-42%), 
suggesting immunohistochemistry on sputa cells will not be a useful diagnostic 
tool. Our final study assessed exhaled volatile organic compounds (VOCs) in 
\ the breath of newly diagnosed lung cancer patients and in healthy controls
j using gas chromatography -  mass spectrometry. 29 cancer-exclusive VOCs
were identified and 25 further VOCs were universally higher in the cancer 
cohort, allowing correct classification of 89% of cancer patients. We conclude 
that two of the three novel techniques (sputum FTIR and exhaled VOCs) could 
successfully distinguish cancer from healthy control subjects and show 
potential as screening modalities in further larger scale studies.
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PART 1: INTRODUCTION
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Chapter 1. An overview of lung cancer
Introduction
Lung cancer is a disease which occurs when there is uncontrolled cell growth 
within the lung fields or the bronchial airways. [1] The cancerous growth may 
either invade major structures such as the heart and mediastinum locally or 
metastasise to organs outside the thoracic cavity such as liver, adrenal glands, 
brain or bones. Lung cancer is the most common cause of cancer related death 
in men and second in women worldwide. [2, 3] The most common cause of 
lung cancer is tobacco smoking, which contributes to 85-90% of all lung 
cancers. [4-7] The potential mechanisms of how smoking may cause cancer 
are discussed in Chapter 3. However, other factors have also been implicated 
in lung carcinogenesis including genetic factors, radon gas, asbestos exposure 
and air pollution such as metal air pollutants and passive (second hand) 
smoking. [8-16] It is thought that the majority of lung cancers result from many 
complex genetic and environmental factors over time. [17, 18]
Lung cancer is divided histologically into two main groups: small cell lung 
cancer (SCLC) and non-small cell lung cancer (NSCLC). It is an important 
differentiation to make as the treatment modalities will be dependent on the 
histological subtype and the prognosis also varies depending on the tissue 
typing. Despite advances in radiological techniques, chemotherapeutic drugs 
and radiotherapy, the overall 5-year survival rates remain low (10.9% in 
Europe) [19] and have not changed significantly over the last 30 years. [20]
This can be seen in Figure 1.1
One of the main reasons for such poor survival rates is the late presentation of 
patients to medical practitioners. This is predominantly due to symptoms only 
becoming apparent in a later, more advanced stage of disease. There is a 
further delay as smokers who do have symptoms often do not seek help 
immediately, are misdiagnosed or are partially treated with antibiotics, inhalers 
and painkillers. Therefore, various methods have been studied to attempt to 
detect lung cancer at an earlier stage thus allowing potentially curative / radical
22
therapy. Although the technology is advancing there has been as yet no 
definitive screening tool that has reduced mortality rates significantly. These 
studies will be discussed further in Chapter 2.
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Epidemiology of lung cancer
Worldwide
Lung cancer is the most common cancer worldwide in terms of both incidence 
and mortality with 1.3 million new cases being diagnosed each year and 1.3 
million deaths, with Europe and North America having the highest rates. [21-23] 
Famous people who have died from lung cancer include Walt Disney, Nat 
“King” Cole and Yul Brenner. With increasing smoking in developing countries, 
the incidence is expected to increase in the next few years, especially in China 
and India. [24, 25]
United Kingdom
In the UK, lung cancer is the second most commonly diagnosed cancer overall 
with only breast cancer having more cases. There were 33,000 new cases 
diagnosed in England and Wales alone in 2006. [26] 2146 new cases were 
diagnosed in Wales in 2005, which is higher than the UK average. [27] In men 
there are less lung cancer cases diagnosed per year than prostate cancer, 
however there are more lung cancer deaths. In women, less lung cancer cases 
are diagnosed per year than breast cancer, but again there are more lung 
cancer deaths. The incidences of the most common cancers are shown in 
Figure 1.2. [28-31]
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Figure 1.2: The 20 most commonly diagnosed cancers in the UK 2005, 
excluding non-melanoma skin cancer [28-31]
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Histological subtype
In terms of histological subtype, NSCLC (80.4%) occurs more frequently then 
SCLC (16.8%). The remaining 2.8% is made up of carcinoid, sarcoma and 
unspecified lung cancer. [32-34] The prevalence of NSCLC subtypes are 
further delineated in Table 1.1, which is based on a retrospective cohort study 
of 730 NSCLC patients diagnosed in USA between 1999 and 2005.
27
Histological sub-type
Frequency of non-small cell lung 
cancers (%)
Smokers Never-smokers
Squamous cell lung carcinoma (SCC) 42 33
Adenocarcinoma
Adenocarcinoma 39 35
Bronchioalveolar
carcinoma
4 10
Carcinoid 7 16
Other 8 6
Table 1.1: Subtypes of non-small cell lung cancer in smokers and never 
smokers [35]
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Survival in lung cancer
Lung cancer is a devastating disease with a low 5-year survival rate, especially 
if one compares it with other common and usually more publicised cancers 
such as prostate or breast cancer. Recent data shows that the 5-year survival 
rates for lung cancer in Europe are 10.9%, compared with a 5-year survival of 
79% for breast cancer and 77.5% for prostate cancer. [19] The overall 5-year 
survival rate in America for lung cancer is slightly higher than in Europe at 16% 
although this figure is possibly less accurate of true survival rates and has been 
criticised because it is calculated from only a quarter of the population and also 
excludes those without histological confirmation of diagnosis. [36] These latter 
patients are likely to be more elderly and frail so unable to tolerate radical 
treatments and are therefore likely to have a shorter survival times.
One of the major reasons for the poor survival data is the identification of lung 
cancer at an already advanced stage of disease. Compared with breast and 
prostate cancer there is as yet no suitable screening program. In breast 
oncology, mammograms have been used for screening since 1976 and for 
prostate cancer the availability of a simple blood test such as Prostate Specific 
Antigen (PSA) can help identify those with the disease, importantly often whilst 
it is still localised. To illustrate the importance of early detection of lung cancer 
one can reflect on the survival data according to radiological staging. Figure 1.3 
shows the Tumour Node Metastasis (TNM) staging for NSCLC. The TNM 
system for staging cancer was first proposed by Denoix in 1946 and developed 
for lung cancer by The Union Internationale Contre le Cancer (UICC) and the 
American Joint Committee for Cancer Staging (AJCC) in 1972 and modified 
now to the international classification system applied by all teams managing 
lung cancer. [37-40]
In late 2009, a new TNM staging system for lung cancer was introduced for all 
those newly diagnosed. [41] We used the TNM staging described in Figure 1.3 
as our patients were all recruited before the establishment of the 7th edition of 
the TNM staging.
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TNM STAGING OF LUNG CANCER
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Figure 1.3: TNM staging in NSCLC [37]
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Following complete surgical resection for stage IA disease the 5-year survival is 
67% and with stage IB disease, 57%. [38] The 5-year survival rate for stage IV 
NSCLC, which is the most advanced stage (with distant metastases), is only 
1%. [4] Small cell lung cancer in particular has usually spread widely (hence the 
staging term ‘extensive’) by the time the patient presents with symptoms. The 
5-year survival rate for small cell lung cancer is 5%. [42]
Signs and symptoms of lung cancer
The most common symptoms that a patient with lung cancer may present with 
include new onset of breathlessness (dyspnoea), coughing of blood 
(haemoptysis), chronic cough or change to regular cough pattern, chest pain, 
weight loss (cachexia), hoarse voice (dysphonia) and less common 
presentations such as difficulty swallowing (dysphagia), finger clubbing and 
facial swelling which suggests superior vena cava obstruction (SVCO). [43] 
Long-term smoking, even in the absence of lung cancer can result in many of 
these symptoms, such as breathlessness, cough and occasional haemoptysis 
and contributes to patients and medical practitioners dismissing it as related to 
smoking rather than to potential cancer. This is a contributory factor to the late 
diagnosis of lung cancer.
The type of symptoms the patient presents with may give a clue to the location 
of the primary tumour. Thus, if the symptoms include wheeze particularly 
inspiratory or monophonic in nature, or the patient has stridor, then this 
suggests a central endobronchial (airway) tumour or a tumour pressing on the 
proximal airway. Similarly, bright red / fresh haemoptysis may signify 
endobronchial bleeding from a proximal endobronchial tumour. If the 
predominant symptom is of chest pain then this may reflect a peripheral tumour 
abutting the chest wall and causing damage to nearby sensory nerves. 
However, to confirm the presence and location of the tumour, further imaging is 
required (first line is a chest X-radiograph (CXR)). Some symptoms / signs are 
not directly due to the primary lesion itself, but from its spread to the lymph 
nodes or metastases to other parts of the body. Examples of this include SVCO 
or dysphagia caused by enlargement of the mediastinal lymph nodes, jaundice
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caused by metastatic spread to the liver or musculoskeletal pain from bone 
metastases. The most likely sites of metastasis from lung cancer are contra­
lateral (opposite side) lung, liver, adrenal glands, bone and brain and symptoms 
such as back pain, headaches or fits can often be the first manifestation of lung 
cancer and difficult symptoms to control as the cancer progresses.
Only about 10% of people with lung cancer do not have symptoms at diagnosis 
with the cancer being found incidentally, for example on a CXR arranged for 
alternative reasons. [42]
Diagnosis of lung cancer
Patients are usually referred to specialist chest clinics when they have 
developed symptoms and often will have a CXR that identifies an abnormality 
consistent with an underlying tumour. Figure 1.4 shows the typical finding on a 
CXR. Once an abnormality such as this has been identified then the patient 
usually undergoes an urgent Computed Tomography (CT) of their thorax 
(Figure 1.5) and abdomen to obtain greater detail about the size, location and 
nature of the primary lesion, whether there is lymph node involvement and 
whether there is metastatic spread above or below the diaphragm.
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Figure 1.4: Left upper lobe rounded opacity consistent with lung cancer
Figure 1.5: CT Thorax of patient in Figure 1.4. The distance and optimal 
direction for a planned CT-guided biopsy is marked (images taken from 
www.wikipedia.org)
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Sputum cytology was first used in the mid-1930s but studies have shown that 
conventional cytology has a low sensitivity, especially with peripheral lesions. A 
systematic review included 16 studies and pooled 28,477 patients using 
sputum cytology and the overall sensitivity and specificity was 66% and 99% 
respectively. The indication for the sputum cytology was mixed in the studies 
which may have led to a degree of heterogeneity of the results. Thus 8 studies 
of 2,455 patients having sputum evaluated pre-bronchoscopy (for suspected 
lung cancer) resulted in sensitivity of only 22%. [44] An additional study not in 
the review included 60 consecutive patients suspected of lung cancer. Again 
the sensitivity in this group was very low at only 33%. [45] Thus the National 
Institute of Clinical Excellence (NICE) guidelines suggest that the use of 
sputum cytology may only be useful in those with central masses who are 
unable or unwilling to undergo bronchoscopy or any other invasive procedure. 
[46]
The majority of the patients will undergo a fibre-optic bronchoscopy to visualise 
the trachea and early bronchial divisions. During this procedure, if abnormal 
mucosa or tumour is seen (Figure 1.6 shows an example of this) then 
brushings and biopsies of the lesion are taken to provide a 
cytological/histological diagnosis.
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Figure 1.6: Erosion of the right main bronchus by a tumour seen by 
bronchoscopy [47]
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If an abnormality is not identified, then distal bronchial washings (obtained by 
washing a particular lobe with 10 -  20ml of normal saline) are often performed 
in the lobe of the lung where the abnormality is seen on CT. Alternatively, if the 
mass is very peripheral and close to the chest wall, then a diagnosis may be 
obtained by a biopsy or Fine Needle Aspiration (FNA) performed under CT 
guidance (see Figure 1.5). On the rare occasions when a diagnosis is not 
possible using these means then a biopsy may be performed on a metastatic 
lesion (e.g. adrenal or bone metastasis). Other ways of obtaining a diagnosis 
are by sampling abnormal looking mediastinal or hilar lymph nodes (based on 
the CT) by techniques such as Transbronchial Needle Aspiration (TBNA) which 
uses the CT scan to ‘map out’ the lymph nodes which can be sampled, 
Endobronchial Ultrasound (EBUS) where the lymph nodes are directly 
visualised by ultrasound then a needle used to sample them, or even a 
mediastinoscopy which is a surgical procedure where the lymph nodes within 
the mediastinum are sampled. If the patient is too frail to have any invasive 
investigations or it is proving difficult to obtain suitable material for a histological 
diagnosis, then a diagnosis of lung cancer can be made radiologically and 
clinically.
Treatment of lung cancer
The basis of any treatment regime planned for a patient depends on the type of 
lung cancer they have, their physical and mental well-being (co-morbidity), the 
staging of the disease and their personal wishes. Surgery is an option in 
patients with early stage lung cancer who have no serious co-morbidities such 
as severe coronary heart disease, and have reasonable respiratory reserve as 
assessed by pulmonary function tests. Since the vast majority of lung cancers 
are smoking related, a large proportion of potentially operable cancers will not 
proceed to surgery due to the presence of significant chronic obstructive 
pulmonary disease (COPD). A recent study of over 4,000 patients showed that 
surgery itself has an operative death rate of 4.4%, depending on the patient’s 
age, lung function and other risk factors. [48] If the tumour is operable but the 
patient is either not fit enough for surgery or decides against it, then radical 
radiotherapy can be given with curative intent. Should the cancer be deemed
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inoperable then radiotherapy and chemotherapy can be given on a palliative 
basis. Patients who are too unwell for any palliative chemotherapy will usually 
be treated very conservatively with the management aim being symptom 
control.
Treatment options should be put to the patients and their relatives and they 
should be allowed time and questions before any decision is made on 
treatment. Specialist nurses often see patients repeatedly before and after they 
have had tests and treatment to provide some continuity in what can be a 
confusing and frightening process. The various treatment modalities used in 
lung cancer will now be discussed in more detail.
Surgery
Surgery as a management option for lung cancer is usually performed with 
curative intent. In 1933, Graham and Singer performed the first 
pneumonectomy (removal of a whole lung) for lung cancer in a one stage 
operation for a carcinoma which originated in the left upper bronchus. [49] This 
was thought to be the standard surgical operation of choice for lung cancers for 
several years. In the 1950s and 60s, the role of pneumonectomy and 
lobectomy (removal of a lobe of the lung) with mediastinal lymph node 
dissection was standardised and are similar to the operations carried out today. 
[50, 51]
Surgery is usually an option in NSCLC limited to one lung up to stage IIIA. [38] 
The earlier the cancer is detected the better the staging is likely to be and if 
surgically resected the better the chance of long-term survival. The 5-year 
survival rate for fully resected stage IA disease is 67%, IB is 57%, falling to 
23% for IIIA disease. [38] Should the patient have stage II or III disease then 
adjuvant chemotherapy (chemotherapy after surgery) has been shown to 
increase the 5-year survival by up to 15%. [52, 53]
Once lung cancer has been diagnosed and CT-staging favours surgical 
resection, then a Positron Emission Tomography (PET) scan should be
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performed to confirm the staging of the disease. The PET scan uses the 
increased glucose metabolism seen by cancer cells to detect where the 
cancerous cells are in the body. If the PET scan corroborates the staging, then 
extensive preoperative investigations must be carried out to assess the 
suitability of the individual for surgery.
Age:
Although age is not a contra-indication to surgery, increasing age has been 
associated with increased peri-operative morbidity. Elderly patients undergoing 
lung resection are more likely to require intensive peri-operative support. [54]. 
There is a higher mortality risk if over 80, and if pneumonectomy rather than 
lobectomy (14% mortality versus 7% respectively). [55-57]
Lung function (Spirometry):
Since smoking is the major contributing factor for lung cancer, impaired 
spirometry is likely to stop a patient from undergoing surgery. Three large 
studies in the 1970s had data from over 2,000 patients and showed that 
mortality of under 5% should be expected if the pre-operative Forced Expiratory 
Volume in 1 second (FEVi) is > 1.5 litres for a lobectomy and > 2 litres for a 
pneumonectomy. [58-60]
Cardiovascular disease:
Pre-existing coronary artery disease increases the risk of non-fatal myocardial 
infarction or death within 30 days of non-cardiac surgery. [61] Patients who 
have had a myocardial infarction (Ml) within 6 weeks should not be operated 
on. If they have had an Ml in the last 6 months and are planning to have 
thoracic surgery then a cardiology opinion is required. [54]
Cerebrovascular disease:
All patients who have a history of previous stroke, transient ischaemic attacks, 
or carotid bruits should be assessed by carotid doppler studies (ultrasound of 
the carotid arteries). Patients with evidence of significant stenosis (for example, 
over 70%) should be assessed by a vascular surgeon or consultant in stroke
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medicine pre-operatively and their management discussed with the thoracic 
surgeon. [54]
Nutrition and performance status:
A history of weight loss, poor nutritional status and poor performance status 
(World Health Organisation (WHO) or Eastern Cooperative Oncology Group 
(ECOG) scales, see Figure 1.7) have all been independently associated in lung 
cancer with advanced disease and a poor overall prognosis. [62-64]
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0 -  Fully active, no restrictions on activities
1 -  Unable to do strenuous activities, but able to carry out light housework and 
sedentary activities
2 -  Able to walk and manage self-care, but unable to work. Out of bed more 
than 50% of waking hours
3 -  Confined to bed or a chair more than 50% of waking hours. Capable of 
limited self-cares
4 -  Completely disabled. Totally confined to a bed or chair. Unable to do any 
self-care
Figure 1.7: ECOG/WHO Performance Status [65]
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Types of surgery
There are several approaches to surgery, which can be taken depending on the 
location of the tumour. Localized tumours for patients with a good FEVi can be 
treated by lobectomy or bi-lobectomy, or a pneumonectomy if the tumour 
involves more than one or two lobes or has ipsilateral (same side) hilar node 
involvement. Pneumonectomy and lobectomy have mortality rates of 6-8% and 
2-4% respectively. [66-70]
Sublobar resection was common in the treatment of tuberculosis and it was 
only a matter of time before it was used in the management of lung cancer. [71] 
It involves resecting the tumour with very little of the lung parenchyma 
removed. This is used usually when the tumour is peripheral with clear regional 
lymph nodes and when the pre-operative FEVi is markedly reduced. The 
mortality rates from this higher risk group of patients range from 1.4% to 3.5%. 
[72-75] However, the local recurrence rate is higher, up to 23%. [76] Long-term 
survival is 5 to 10%, which is worse than with a lobectomy. [74, 76]
Sleeve resections involve a lobectomy and removal of the part of the bronchus 
involving the tumour, forming an anastomosis (joining) between the bronchus 
proximal and distal to it. This particular surgical procedure may avoid the need 
for a pneumonectomy.
Post-operative complications
Such major surgery always entails the risk of post-operative complications. 
These include the risk of broncho-pleural fistula (connection between the 
bronchus and pleura), respiratoryfailure, infection, phrenic nerve damage 
causing diaphragm paralysis, recurrent laryngeal nerve damage leading to a 
hoarse voice and prolonged chest wall pain.
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Chemotherapy
Small cell lung cancer is the most aggressive all the lung cancer subtypes. At 
presentation the disease has usually already spread beyond the point that 
surgery will be curative. Hence, the usual treatment modalities involve 
chemotherapy with radiotherapy. In small cell lung cancer, cisplatin and 
etoposide are most commonly used chemotherapeutic agents. [77]
There has been increasing evidence for the role of chemotherapy in advanced 
NSCLC. Benefits have been shown in palliation, survival, quality of life, 
symptom control and cost. There have been 13 studies that have assessed the 
effect of combination chemotherapy versus supportive care only. Two thirds of 
the trials showed a survival benefit, which was statistically significant and so 
unlikely to have occurred through chance. The median survival differences from 
the studies ranged from 9 - 2 2  weeks which is likely to be clinically important 
for patients. [78-90] The American College of Chest Physicians has guidelines 
which summarise how symptom control has been demonstrated showing an 
improvement for cough, haemoptysis, pain, dyspnoea, weight loss, anorexia 
and malaise. [91] Eight trials assessed quality of life, with a significant 
improvement in the chemotherapy arm in all but one of the trials. [78, 81, 88,
89, 92-95] Interestingly, chemotherapy appears cheaper than best supportive 
care alone. [96] Platinum based regimes are the most commonly used first line 
treatments combined with older drugs such as vindesine, mitomycin C and / or 
ifosfamide, or new agents such as gemcitibine, docetaxel or vinorelbine. 
Polychemotherapy is associated with better results than single agent treatment. 
[97-99] Two drug regimes are superior to one drug in terms of tumour response 
and improved survival. Adding a third drug has a weaker effect on tumour 
response and no effect on survival. [100]
When chemotherapy is used in addition to (after) surgery this is termed 
adjuvant chemotherapy, and it is used to improve outcomes. During surgery, 
lymph nodes are also sampled. If these contain cancer cells then depending on 
which lymph nodes are involved, the patient has stage II or III disease.
Adjuvant chemotherapy in these situations has been shown to improve survival 
at 5 years by up to 15%. [52, 53]
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Chemotherapy does, however, carry the risk of side effects and complications. 
Patients can develop anorexia, nausea, vomiting, fatigue and neuropathy. The 
more severe complications include toxicity and neutropenic sepsis (secondary 
to profound bone marrow suppression).
Radiotherapy
Radiotherapy can be given alone with curative intent in patients with early stage 
NSCLC who are not eligible for surgery. This is termed radical radiotherapy and 
involves high intensity radiotherapy. It is also given in combination with 
chemotherapy such as in limited disease (confined to one hemithorax) small 
cell lung cancer, which is potentially curable. [101] Patients with limited small 
cell lung cancer may also receive prophylactic cranial irradiation (PCI) to 
reduce the risk of brain metastases. [102] There is now increasing evidence 
that PCI has a role in extensive small cell lung cancer as it has been shown to 
reduce the cumulative risk of brain metastases within one year from 40.4% to 
14.6%. The same study also shows a 1-year survival in the irradiated group of 
27.1% compared with 13.3% in the control group. [103]
The role of adjuvant radiotherapy in patients whom have undergone curative 
surgery is limited. If there is a role then, its benefit has only been shown in 
patients who had N2 disease. No benefit was identified in those with NO or N1 
disease. [104]
Radiotherapy has a specific role in helping NSCLC and small cell lung cancer 
patients with significant symptoms such as bone pain or haemoptysis. Palliative 
radiotherapy involves smaller doses of radiation to the chest wall and it is 
aimed to provide symptom control.
Brachytherapy (localised radiotherapy) is a more recent introduction. It can be 
given directly into the airway via bronchoscopy when the cancer affects a short 
section of bronchus. It can also be used as a palliative modality when there is 
blockage of a large airway by an inoperable lung cancer. [105,106]
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Targeted Therapy
Receptor tyrosine kinases (RTK) are transmembrane receptor-linked kinases 
that have a pivotal role in diverse cellular activities including growth, 
differentiation, metabolism, adhesion, motility, and death. [107] Many RTKs are 
involved in oncogenesis either by gene mutation or chromosome translocation. 
[108] In recent years tyrosine kinase inhibitors have been developed for the 
treatment of advanced lung cancer which targets the tyrosine kinase domain of 
the epidermal growth factor receptor (EGFR) expressed in many cases of 
NSCLC. Erlotinib (Tarceva) has been shown to increase survival in lung cancer 
patients and has been approved as a second line treatment of NSCLC. [109]
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Figure 1.8: Proposed mechanism of how EGFR may cause or support the 
inappropriate cell growth that leads to proliferation, migration, and survival of 
cancer cells (image taken from www.gene.com)
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Angiogenesis, the growth of new vessels from pre-existing vessels, is a 
fundamental step in tumour growth and progression. Vascular endothelial 
growth factor (VEGF) is a key angiogenic factor implicated in tumour blood 
vessel formation and permeability. Over-expression of VEGF has been 
observed in a variety of cancers and has been associated with a worse relapse- 
free and overall survival. The angiogenesis inhibitor bevacizumab (a 
monoclonal antibody directed against VEGF) in combination with paclitaxel and 
carboplatin improves survival of patients with advance NSCLC (stage 11 lb and 
IV) but does increase the risk of lung bleeding, particularly in patients with 
squamous cell carcinoma. [110,111]
Supportive treatment only (Palliation)
Many of the patients diagnosed with advanced lung cancer will have significant 
co-morbidity and poor performance status and the decision has to be made 
whether to give any treatment such as palliative chemotherapy or radiotherapy 
or just to give best supportive care. The patient themselves are central in the 
decision making along with the multi-disciplinary team (MDT) which usually 
consists of a radiologist, chest physician, oncologist, thoracic surgeon and 
palliative care specialist. Once best supportive care is decided as the best 
management course than it is important to make sure the patient is comfortable 
in their remaining days. Adequate analgesia, diet and even oxygen maybe 
required as well as palliative radiotherapy if deemed appropriate.
Figure 1.9 shows a typical diagnostic pathway for the diagnosis and 
management of lung cancer.
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Conclusion: An overview of lung cancer
Lung cancer is usually a devastating disease and is often silent until the 
advanced stages. There are various ways a patient may present and then 
certain pathways in which to diagnose the cancer. Only a small number will be 
diagnosed early enough and will be fit enough, for potential surgery and thus 
curative treatment. The majority, however, will have inoperable lung cancer and 
will therefore require a combination of chemotherapy or radiotherapy alone or in 
combination or management by best supportive care. Whatever the treatment 
modality overall 5-year survival rates for lung cancer are worse than other 
common cancers.
Two potential ways of tackling lung cancer are:
1) to detect the cancer early enough so that it can be treated with curative 
intent;
2) to prevent it from occurring.
One of the key ways of detecting the disease early is by screening and this will 
be discussed in Chapter 2. Smoking causes 85 - 90% of lung cancers, thus by 
reducing the number of people who smoke and the number of cigarettes that 
are smoked, this would hopefully reduce the number of lung cancer cases in 
the future. It is important to develop smoking cessation programmes worldwide 
in order to help individuals to stop smoking and I have discussed the role 
smoking has in cancer in Chapter 3.
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Chapter 2. Screening in lung cancer
Principles of screening
Screening is an important process in medicine, which is used to identify a 
disease process within a defined population early thus enabling earlier 
intervention and management in the hope to reduce mortality and suffering 
from a disease. [112] In 1968 the World Health Organisation published 
guidelines on the principles of screening. [113] For a screening tool to be 
effective, certain principles must be adhered to:
a) The condition should be an important health problem.
Lung cancer is the most common cancer worldwide with 1.3 million new cases 
diagnosed each year. [21] There were an estimated 33,000 new cases 
diagnosed in the England and Wales alone in 2006. [26]
b) The disease has significant mortality and morbidity.
In Europe, lung cancer has an overall 5-year survival of only 10.9% (compared 
to a 5-year survival of 79% for breast cancer and 77.5% for prostate cancer). 
[19]
c) There should be a latent phase of the disease.
Lung cancer usually presents when a patient develops symptoms. In the 
majority of cases, the cancer is already in an advanced stage at the time 
symptoms develop. The aim of screening is to detect these cancers in the 
earlier asymptomatic / latent phase.
d) Intervention earlier in the disease process can improve outcomes.
The 5-year survival for NSCLC is much higher in less advanced disease. 
Patients with Stage IA NSCLC who have undergone complete surgical 
resection of the tumour have a 5-year survival rate of 67%. This compares with 
a 5-year survival of 1% for Stage IV NSCLC. [38]
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e) The screening test itself should have certain characteristics.
It must be sensitive (to avoid false negatives and inappropriate reassurance) 
and specific (to avoid too many false positives leading to unnecessary worry 
and further expensive / invasive testing). The test should also cause little harm 
(or much less than the disease), and should be acceptable to the population to 
be screened.
f) The cost of finding a case using the screening technique should be balanced 
in relation to medical expenditure as a whole.
During this chapter I will discuss various screening modalities which have been 
studied over the last 30 years, firstly reviewing the role of radiology, then more 
simple sputum cytological techniques used in conjunction with simple chest 
radiographs before discussing in more detail newer biological techniques which 
have been studied and are still currently being evaluated.
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Low-dose spiral CT scans and screening for lung cancer
This is probably the most widely tested screening modality for lung cancer to 
date. There have been many observational studies assessing the feasibility of 
using low-dose spiral CT (LDCT) of the thorax in detecting lung cancer at an 
earlier stage and thus allowing curative treatment. The advantage of using such 
a technology is that it allows detection of much smaller nodules (2-3mm), which 
would almost certainly not be visible on a CXR. One of the earliest studies was 
carried out in Japan by Kaneko et al, where 3,457 people underwent LDCT 
scan and CXR. The results confirmed detection of peripheral lung cancers in 15 
of the 3,457 cases (0.3%). 11 of the 15 cases had negative CXRs (73%). Thus 
the detection rates were 0.43% (15 from 3457) with CT scans and 0.12% (4 
from 3,457) with CXRs. 14 of the 15 new cases (93%) of cancer were stage I. 
[114] This early study strongly suggested that low-dose spiral CT was a 
superior radiological modality compared with CXR in the early detection of lung 
cancer.
The Early Lung Cancer Action Project (ELCAP) was a major study published in 
1999 by Henschke et al, where a study population of 1,000 participants 
underwent yearly LDCT scans and CXR in a single-arm study. They compared 
the number of lung nodules detected by CXR and CT. They went on to analyse 
how many of these pulmonary nodules were malignant and the radiological 
staging of the cancer cases. 233 (23%) participants were found to have non­
calcified nodules by CT scan at baseline compared with 68 (7%) by CXR. 27 
nodules (2.7%) were found to be malignant, with 20 of these not being found on 
CXR. 23 out of 27 (85%) of these malignant nodules were classified as Stage I 
with 26 (97%) being resectable. In the second year of screening, a further 7 
cancers were detected with 6 of these in Stage I. The conclusions of the study 
were that LDCT scan was four-times as sensitive as CXR in detecting lung 
cancers, and six times more sensitive at detecting stage I disease. [115]
Subsequent studies continue to show a similar trend. Soube et al screened 
1,611 participants every 6 months with LDCT scan, CXR and sputum cytology. 
186 (11.5%) of the 1,611 patients were found to have a “positive” CT scan
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compared with 55 (3.4%) with a “positive” CXR. 14 (0.87%) of the 1,611 cases 
were found to have lung cancer with 77% of these in stage I. On repeated 
screening, 7,891 examinations were carried out and 22 (0.28%) new lung 
cancers were diagnosed, 82% of these stage I. The 5-year survival rate for all 
incidence cancers discovered via screening was 65%. [116] Swensen etaI 
discussed their Mayo Clinic results in 2003. The study involved 1,520 
participants aged 50 years or older with a greater than 20 pack year smoking 
history. Participants had 3 annual LDCT scans of thorax / abdomen and sputum 
cytology. 1,049 (69%) had non-calcified pulmonary nodules (2,832 nodules 
were identified in total) with 26 baseline cancer cases diagnosed. 10 further 
cases were diagnosed during screening on CT alone. 2 were picked up on 
sputum cytology alone and 2 further cases presented as interval cancers (i.e. 
developed symptoms in between scans). Thus 40 primary lung cancer cases 
were diagnosed (2.6%) which equates to 1.4% of the 2,832 nodules. [117]
Diederich etal studied 817 individuals. These were deemed a high-risk 
population with age > 40 years and smoking history £ 20 pack years. Each of 
the participants underwent LDCT scan of thorax. 350 (43%) out of 817 had 
non-calcified pulmonary nodules. If the nodules were greater than 10mm, they 
were considered potentially malignant and either biopsy was attempted, or 
follow-up CT scans were recommended to assess for any growth. For all other 
lesions, follow-up CT scan was recommended. 32 nodules in 29 participants 
were > 10mm. Biopsy of 15 lesions revealed 12 lung cancers in 11 cases 
(1.3%) and of these 7 (64%) were stage I and 2 (18%) stage II. The 17 other 
nodules > 10mm were followed up for 24 months with serial CT scans and did 
not show any growth. [118] Diederich et al published further work on the same 
cohort of participants assessing the annual follow up with CT scan in 
asymptomatic patients. Follow up of non-calcified nodules present at baseline 
CT scan showed growth in 11 of 792 subjects. 8 of the 11 growing nodules 
were biopsied, identifying 7 lung cancers. A further 174 new nodules were 
identified, 3 representing lung cancer. 7 of the 10 newly diagnosed cancers 
were stage I. [119] Further studies continue to show this trend of CT scans 
being much more sensitive for detecting lung cancers than plain CXRs. [120- 
122]
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All the above trials are very promising but questions along the same themes 
were raised throughout:
a) False positives:
There were an extremely large number of non-calcified nodules detected within 
the screening population. The majority of these nodules were ultimately benign. 
However, after detecting such nodules at baseline, they required following up 
with interval scans for at least 2 years, and some participants would have 
undergone biopsies on the lesions before they could be concluded as being 
benign. The presence of an abnormality on a CT scan such as a nodule is likely 
to cause a high degree of anxiety and this will be protracted over a 2 year 
period within which follow-up scans are performed. Bearing in mind the large 
number of the study population with nodules found on their CT scan, this could 
be a concern. Many of these healthy individuals will elect to undergo invasive 
procedures such as biopsy or even surgical resection, with the potential 
morbidity associated with it.
b) Overdiagnosis, lead-time bias and length-time bias.
Even nodules that turn out to be lung cancer may be indolent, very slow 
growing and ultimately would not have spread or caused death in the individual 
due to their co-existing morbidity. Thus in normal clinical practice these tumours 
are unlikely to be diagnosed prior to death and if they were found on screening 
and treated would not have altered the life expectancy of the individual.
Overdiagnosis Bias (Pseudodisease)
No screen
A m n n i
Screen CT Dx
Screening detects cancer (pseudodisease) that vwould 
remain subclinical before death from other causes.
Dx = Diagnosis
Death Autopsy 
Other causes Dx
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This is termed overdiagnosis and when a disproportionately large percentage of 
these slow growing tumours are detected by screening it results in a higher 5- 
year survival rate. This is called length-time bias. Again this carries the burden 
of anxiety to the individual diagnosed with lung cancer in this situation within 
the screened population.
Length Bias
Screening 
Indolent Cancer 
Begins
Sx & Dx
Death
Detectable f l
Preclinical Phase
Aggressive Cancer s x & D x  
Bet Death Screening tends to 
detect more indolent 
cancers.
Sx = Symptoms 
Dx - Diagnosis
Lead-time bias is when the lung cancer has been detected earlier by the 
screening modality but the time of death has remained the same. This again 
gives the impression of improved survival rates; however this is purely due to 
earlier detection rather than later death.
Lead-time Bias
No Screen Sx-Dx D ea th
Scree n C T -D x
S urvrval
1
D eath
Lead-tim e
W ith  screening,  the  lead time in diagnosis prolongs survival  
even if death is not de layed.
Sx = S ymptom s  
Dx - Diagnos b
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Thus, it is due to overdiagnosis, lead-time bias and length-time bias, that an 
increase in 5-year survival rates can be quoted in the studies, however the lung 
cancer mortality rates are similar to the unscreened population. To be beneficial 
screening tests should detect disease before signs or symptoms occur and 
must lead to decreased mortality.
c) Cost-effectiveness:
LDCT screening on a population level carries a significant cost implication. The 
initial screening with the requirement of follow-up scan for the large number 
with nodules, along with the potential for invasive procedures and specialist 
consultations will all amount to a high cost. This cost of course may be 
acceptable, but this will only be if the screening reduces mortality rates.
d) Direct harm:
There is also the controversial issue of risk of cancer associated with diagnostic 
CT scanning. Berrington de Gonzalez and Darby [123] estimated that the 
attributable risk percentage of cancers from diagnostic x-rays ranged from 0.6% 
to 1.8% of all cancers in most developed countries. However this is likely to be 
debated for many years to come.
LDCT scanning as a screening tool in early lung cancer is promising. There are 
issues associated with detection of large numbers of benign lesions, and 
overdiagnosis of malignant lesions that will not have an impact on life 
expectancy. Both these issues could adversely affect patients. CT screening 
has detected more stage I cancers, and if used with a good diagnostic 
algorithm, may still prove effective in improving survival and mortality rates. In 
terms of meeting the criteria of what makes a beneficial screening test, this 
continues to be debated. At present the studies have not shown a significant 
reduction in mortality rates, and some individuals have required follow-up tests, 
some of which have been invasive and most of the studies have been 
observational, proof-of-principle studies. What is urgently required is a large, 
randomised, controlled trial to see if CT scanning will have an impact on lung 
cancer mortality.
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One such study has just been published. The DANTE (Detection and Screening 
of Early Lung Cancer by Novel Imaging Technology and Molecular Essays) trial 
was a randomised control trial looking at LDCT in one arm and a non­
investigated control arm. All subjects (males aged 60 -  75 years, > 20 pack 
year smoking history) had a baseline CXR and 3 day pooled sputum sample. 
Those excluded were those with less than 5 year life expectancy, those with 
cancer within the last 10 years, and those unable to comply with follow-up. The 
LDCT arm (n=1,276) had a scan performed at baseline and then once a year 
for four further years (with a yearly medical interview) and the control arm 
(n=1,196) had a yearly medical interview and provided there was no clinical 
indication, no further investigations were required. The results showed that at a 
median follow up of 33 months, lung cancer was detected in 60 (4.7%) of the 
LDCT arm and 34 (2.8%) of the control arm (p=0.016) with the resectability rate 
similar in both groups. More patients in the LDCT arm were detected in stage I 
(54% v 34%; p=0.06) and the number of advanced cases were similar for both 
arms. 20 (1.6%) of patients in the LDCT died from lung cancer as did 20 (1.7%) 
from the control group, again showing that additional scanning of the study arm 
had no impact on the overall mortality. [124]
Two further studies are ongoing: The Prostate, Lung, Colorectal and Ovarian 
Cancer screening trial (PLCO study) has been instituted by the National Cancer 
Institute (NCI) and includes over 150,000 men and women aged 55 to 74 who 
are split into two trial arms. One arm undergoes intervention (screening) whilst 
those in the other control arm continue their normal health care routine. [125] 
The National Lung Screening Trial (NLST), launched in 2002, is a randomised 
control study, looking at LDCT and CXRs as screening techniques for lung 
cancer. Nearly 50,000 subjects have been enrolled into the study consisting of 
current and former smokers. They have recruited a large enough cohort in 
order to determine if there is a 20% reduction in mortality using LDCT 
compared to CXR. [126] The long-term survival outcomes from these studies 
are due to be reported in the next 5 to 10 years.
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Sputum cytology and screening for lung cancer
Sputum is a good biological specimen to conduct screening because it is 
usually readily accessible (i.e. non-invasive). Sputum cytology in combination 
with CXRs has been attempted as a screening strategy for detecting (early) 
lung cancer.
The Memorial Sloan-Kettering Study
The Memorial Sloan-Kettering Study was sponsored by the NCI; it commenced 
in 1974. The study cohort consisted of 10,040 male volunteers, from New York, 
over 45 years old who smoked. They had a baseline postero-anterior and 
lateral CXR, then 4,968 were randomised to have annual CXRs together with 
sputum cytological examinations every 4 months for 5-8 years (dual -  screened 
arm) and the other 5,072 men received an annual CXR for 5-8 years. At 
baseline, the dual screening group had 30 (0.6%) lung cancers detected (29 of 
which were NSCLC), with sputum cytology alone detecting 9, CXR alone 
detecting 14 and 7 cancers detected by both. There were 23 lung cancers (all 
NSCLC) detected at baseline in the CXR only arm. Complete resection was 
possible in 18 of the 30 baseline cancers in the dual group and 11 of the 23 in 
the CXR only group. On follow-up screening, 114 incident cases were identified 
in the dual screening arm (14% by sputum cytology alone) and 121 were 
detected in the CXR alone arm. Of the 288 cancers diagnosed throughout the 
study a high proportion (40%) were stage I (whose 5-year survival was 76%). 
The overall 5-year survival in both arms was identical at 35% and was higher 
than the generally reported 5-year survival of 10% at the time. However, there 
were no differences in mortality rate of 2.7 per 1,000 person-years. The 
potential reasons for the higher survival rates are discussed later. [127-129]
The John Hopkins Study
The John Hopkins Study applied a similar protocol to a target population from 
the Baltimore metropolitan area. 10,387 male, smoking (and ex-smoking) 
volunteers had baseline CXRs. The 5,226 receiving annual CXRs combined
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with 4 monthly sputum cytology examinations were found to have 39 (0.75%) 
lung cancers (36 NSCLC) on initial screening (11 by cytology alone, 20 by CXR 
alone, 8 by both modalities). The 5,161 men receiving CXRs only had a similar 
number of 40 (0.78%) lung cancers (32 NSCLC) detected at baseline and the 
numbers of incident cancers were similar in both groups over the next 8 years 
(194 in the dual group and 202 in the annual CXR only group). The overall 5- 
year survival rate for those diagnosed with lung cancer in both groups was 20% 
and most importantly, the overall group mortality rates were similar not only to 
each other but to mortality rates of the unscreened population. [127, 130]
The Mayo Lung Project
The Mayo Lung Project was the third NCI sponsored randomised controlled trial 
(RCT) investigating lung cancer screening. Outpatients undergoing medical 
examinations in the Mayo Clinics were invited for screening if they were men 
aged 45 years or older and smoked at least 20 cigarettes/day in the preceding 
year. 10,933 men, had baseline CXRs and 3 days pooled sputum cytology 
examinations. 79 cases of NSCLC and 12 cases of SCLC were diagnosed 
(initial CXR alone n=59, sputum cytology alone n=17, both n=15). The 
remainder either received a CXR and 3 day pooled sputum examination every 
4 months or every 12 months (at that time deemed ‘usual care’), for 6 years. Of 
the original 91 (0.83%) lung cancer cases diagnosed, the 5-year survival was 
good at 40%, increasing to 70%, for those with stage I or II disease.
During the follow-up period, more cancers (n=206) were diagnosed and more of 
these were resectable (48%) in the ‘screened’ group than in the ‘usual care’ 
group (n=160 of which 32% were resectable). The 5-year survival in the 
screened group was also higher at 33% compared with 15%. Initially this was 
felt to be very promising but the improved survival in the screened group could 
have been explained by overdiagnosis, as there were more lung cancers in this 
group overall, than the control group despite randomisation. This is supported 
by the lack of statistically significant advantage in the overall mortality rates (3.2 
versus 3.0 per 1000 person-years, respectively) at 6 years or even after 20 
years. [131-134]
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The Czechoslovakia Study
The final major study investigating the role of CXR combined with sputum 
cytology screened 6,364 males aged 40 -  64 years, whom had smoked 
approximately 150,000 cigarettes throughout their lifetime and were smoking at 
the time of enrolment. 18 cancers (0.3%), were diagnosed on initial testing, 6 
(33%) of which underwent curative resection. The remaining 6,346 either 
received CXRs and sputum cytology performed every 6 months for 3 years, or 
CXR and sputum cytology performed 3 years after the initial examination. 
Subjects in both arms were then screened annually for 3 further years. There 
was statistically no difference in the survival or mortality rates between the two 
arms and indeed the majority of cancers in the control arm were found from 
interim tests as new symptoms developed. [135] There was no difference in 
mortality rates after 15 years. [136]
These studies suggest that screening with CXRs does not influence mortality 
and adding regular sputum cytology screening to CXRs also offers no further 
long-term survival advantage for the screened population. Some of the 
improved early survival rates were once again likely to be due to a combination 
of overdiagnosis, lead-time bias and length-time bias.
An interesting and consistent finding from the studies is the high frequency of 
detection of squamous cell carcinoma (SCC) in the sputum cytology groups, 
which is theoretically the most amenable to radical treatment.
As CT screening and CXRs with or without sputum cytology have made little 
impact on lung cancer mortality, other researchers are looking at other 
biomarkers for diagnosing early lung cancer.
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The principle of biomarkers and lung cancer- underlying histological and 
cellular changes
A biomarker can be defined as a substance used as an indicator of a biologic 
state. [137] A good biomarker should require none or a minimally invasive 
technique of sampling. [138] As the understanding of the biology of lung cancer 
develops, easily accessible body tissues such sputum or serum will be sampled 
for other non-cytological biomarkers (or even a panel of biomarkers) that could 
help in the early detection of early or even premalignant lesions. Biomarkers 
are also being evaluated to monitor and even predict treatment response. An 
example of this would be the serum biomarker, prostate-specific antigen (PSA) 
that is used to monitor response after radical surgery or chemotherapy in 
prostate cancer.
Both squamous dysplasia and carcinoma-in-situ are deemed pre-neoplastic 
changes, which often but not always lead to squamous cell carcinoma of the 
lung. [139] Pre-neoplastic changes in lung adenocarcinoma and carcinoid 
include atypical adenomatous hyperplasia and diffuse idiopathic pulmonary 
neuroendocrine cell hyperplasia. [139] When developing biomarkers, 
researchers have monitored these cellular alterations, in particular the gene 
expression and chromosome structure, which take place within these pre­
neoplastic lesions. Some of these changes include mutations in the p53 and 
ras genes that are associated with hyper-proliferation and loss of cell cycle 
control, aberrant gene promoter methylation, increased vascular growth and 
altered protein expression. [139-141]
Sputum biomarkers and screening for lung cancer
Gene Promoter Methylation
This is a very promising modality for lung cancer screening. Early in the 
development of lung cancer, methylation of promoter sequences in multiple 
different tumour suppressor genes occurs associated with the silencing of 
transcription and inactivation of these tumour suppressor genes. This has a
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crucial role in triggering malignant transformation and progression. [141] 
Detection of methylation is performed by specific polymerase chain reaction 
analysis. Hypermethylation was investigated in a small ‘proof-of-concept’ study 
looking at methylation of p16 and 0 6-methylguanine-DNA methyltransferase 
(MGMT) gene promoters in a high-risk population. The sputum samples of 21 
patients with squamous cell carcinoma were investigated. The presence of one 
or both gene promoters was found in all 21 sputum samples irrespective of 
whether they were taken up to 3 years (n=10) before or at the time of diagnosis 
(n=11). This compares to 15% (methylation of p16) and 25% (methylation of 
MGMT) in 123 controls, deemed high risk through a smoking history and/or 
radon exposure. Most interestingly, 48% of the squamous cell cancer patients 
had methylation of both genes compared to only 4% of controls (p<0.001). On 
follow-up, 3 lung cancers were diagnosed in the controls between 1 and 3 
years after sputum collection with the MGMT gene being methylated in two of 
the subjects. [142]
Other studies report the potential of gene-specific methylation as a biomarker 
for lung cancer. Belinsky et al postulated that a panel of methylated genes 
would yield greater sensitivity and specificity. They recruited subjects older than 
25 years, with > 30 pack-year smoking history and a forced expiratory volume 
in 1 s (FEV-i) < 75% and FEVi/FVC (forced vital capacity) < 0.75. They 
excluded anyone with any cancer diagnosed in the previous 5 years. 3,259 
subjects provided pooled sputum for 3 days in 1 container and the next 3 days 
in a second container. The sputum from the second container was used as 
samples for the study. 182 subjects were diagnosed with (incident) lung cancer 
with 1,353 cohort deaths. Once sufficient quality of DNA was analysed the 
study cohort consisted of 98 subjects (cases) and the non-cancer cohort was 
used to form a group of 92 controls matched for age, gender and month of 
enrolment. There were 26 current smokers in the control group compared with 
42 in the cases; however the total number of pack years was similar. Fourteen 
genes were analysed for promoter methylation, including p16 and MGMT. They 
found that 6 of the 14 genes (p16; MGMT; DAPK; RASSFIA; PAX5 p and 
GATA5) were individually associated with a > 50% increased risk of lung 
cancer. Sputum collected within 18 months of a diagnosis of lung cancer had
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more methylated gene promoters than sputum from the same subject collected 
more than 18 months before the diagnosis. The concomitant methylation of 3 or 
more genes was associated with a 6.5-fold increased risk of lung cancer with 
receiver operating characteristics of a specificity of 64% and sensitivity of 64%. 
[143] This is the first study to show how a panel of genes can be used as 
potential biomarkers in screening a high-risk population for lung cancer. They 
did conclude that the level of specificity obtained is not yet high enough for 
prospective screening studies but called for more evaluation candidate gene 
panels -  especially as technology improves.
Serum biomarkers and screening for lung cancer
Serum biomarkers have been used to screen for and assess treatment 
response in different cancers. These include prostate-specific antigen (PSA) for 
prostate cancer, carcino-embryonic antigen (CEA) and carbohydrate antigen 
(CA) 19-9 in colonic cancer and CA125 in ovarian cancer. Serum has been 
used as a screening biofluid for lung cancer.
Circulating DNA and genetic changes
Elevated levels of circulating cell-free DNA in the blood of cancer patients were 
first reported in 1987. Although the precise mechanism of DNA release into the 
blood remains obscure, it appears that much of this circulating DNA is derived 
from apoptotic and necrotic tumour cells. [144] Patients with lung cancer have 
genetic and epigenetic changes consisting of chromosome loss, oncogene 
activation and tumour suppressor gene methylation [145, 146] and if this 
abnormal DNA can be detected in the serum, it may allow development of 
specific markers. Levels of circulating cell-free DNA are generally higher in the 
blood of patients with lung cancer compared with healthy controls [147, 148], 
but their specificity / sensitivity and receiver operator curves specific to 
differentiate lung cancer have still not been clarified.
K-ras and p53 are well characterised common mutations in human lung cancer 
and pre-neoplasia, thus are the most commonly studied genetic mutations.
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Overall, k-ras mutations have been found in serum of 20-30% of lung cancer 
patients with only one study detecting the mutation within the control group, 
although the characteristics of the controls were not specified. [149-152] P53 
mutations have been found in the serum of 10-30% of lung cancer patients 
compared to minimal detection in the healthy control groups. [153] One study 
found p53 mutations in 41% of lung tumours with the identical mutation 
identified in the plasma of 73% of them. [154]
Vascular Endothelial Growth Factor (VEGF)
The role of VEGF in carcinogenesis has been discussed in Chapter 1. Recent 
preliminary data found significantly increased VEGF concentration (measured 
using enzyme immunoanalysis) in the serum of 7 patients with NSCLC 
compared to 5 healthy smokers and 7 healthy non-smoking controls (p=0.033). 
[155]
Proteomics
Proteomics is the study of proteins and two approaches have been applied to 
lung cancer. Protein profiling is where patterns of protein expression are used 
and the other is to identify individual proteins. A recent study analysed serum 
from 158 lung cancer patients and 50 controls using a mass spectrometry 
technique. 74 lung cancer serum samples and 20 healthy controls were used to 
develop a training set. From this, a specific pattern consisting of five protein 
peaks in the serum was chosen as serum biomarkers that could diagnose 
NSCLC and this pattern was used (in a blinded fashion) to try and discriminate 
the remaining serum samples of 84 lung cancer patients and 30 healthy 
controls. The pattern of proteins was used to differentiate the samples with a 
sensitivity of 86.9% and specificity of 80%. [156] These proteomic techniques 
are also being evaluated to look for patterns in serum that are associated with 
premalignant changes in the lungs of high-risk individuals. [157]
Unfortunately, the lack of adequate sensitivity, specificity and reproducibility 
has meant that no single specific biomarker associated with specific cell
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changes has yet been identified. By understanding the biology of lung 
carcinogenesis in more detail, various groups are developing high throughput 
techniques, using panels of biomarkers associated with these cellular changes 
for early detection of lung cancer.
Breath biomarkers and screening for lung cancer
Volatile Organic Compounds in Breath (VOCs)
Exhaled breath samples are even more accessible than sputum or serum and 
more than 200 different measurable chemicals are exhaled in the human 
breath. [158] In 1985, Gordon et al studied VOCs in exhaled air from 12 
patients with histologically confirmed NSCLC and 9 healthy controls (2 of which 
were heavy smokers). Gas chromatography combined with mass spectrometry 
was used to identify peaks representing individual and combination of VOCs 
from the breath samples. The results showed 4 separate peaks occurred in 
more than half of the lung cancer patients, which were completely absent in the 
control group; the authors suggested that unique VOCs are exhaled in the 
breath of lung cancer patients, which could have potential diagnostic 
usefulness. However, they recommended that this technique be tested in a 
larger population to assess its true effectiveness. [159]
Phillips etal, from the USA, collected exhaled breath in 108 fasting patients 
about to undergo a bronchoscopy for an abnormal CXR. Lung cancer was 
confirmed histologically in 60 patients (50 NSCLC, 10 SCLC) and excluded in 
48. Many VOCs were common to both sets of breath samples but a group of 22 
of these VOCs were able to distinguish between lung cancer and control cases 
according to risk weighting attached to the test. For example, the VOCs had 
100% sensitivity (i.e. no false negatives) and 81% specificity for stage I lung 
cancer if the receiver operator accepted a post-test probability of 0.46. A post­
test probability of 0.9 yielded lower 66.7% sensitivity but 100% specificity (no 
false positives). The abnormal VOCs consisted of mainly alkanes and benzene 
derivatives. Smoking status alone did not account for the benzene derivatives 
since these were also present in the breath of non-smokers and ex-smokers, so
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it was likely to be a genuine marker for lung cancer. Surprisingly, there were no 
significant differences in sensitivity and specificity of VOCs between early and 
advanced lung cancer. These researchers also concluded that patterns of 
VOCs could act as a ‘finger-print’ for lung cancer but would need validation in a 
larger general population before they could recommend the test as a diagnostic 
screening tool. [160]
The same researchers compared exhaled VOCs in patients with biopsy proven 
primary lung cancer (n=67); non-lung cancer metastasising to the lungs (n=15); 
abnormal CXRs but no histological evidence of lung cancer (n=5) and healthy 
volunteers from the general population (n=41). The breath test identified over 
80 different alkanes and mono-methylated alkanes that were then used via 
discriminant functional analysis to generate a predictive model using a panel of 
9 VOCs. These 9 VOCs, in combination yielded a sensitivity of 89.6% and a 
specificity of 82.9% (using a post-test probability of 0.5) of identifying primary or 
secondary lung cancer. Again, there were only minor differences when subjects 
were stratified according to history of tobacco smoking, histological cancer 
type, or lung cancer staging. [161] The authors concluded that their test was 
sensitive, cost effective and easy to perform and could be used to complement 
other modalities, but again called for further evaluation.
Poli et al, from Italy, looked at VOCs in a smaller number of lung cancer cases 
but a wider variety of control groups. They measured 13 VOCs (7 aliphatic and 
6 aromatic compounds) in 36 early NSCLC cases, 25 controls with clinically 
stable mild-moderate chronic obstructive pulmonary disease (COPD), 35 
asymptomatic smokers with normal spirometry and 50 healthy non-smokers 
with normal spirometry. The NSCLC, COPD and smoking controls had 
generally higher levels of exhaled VOCs than the non-smoking controls 
suggesting, unlike the American group, that smoking status was very important. 
Although no single VOC could distinguish NSCLC from the other groups, their 
panel of 13 VOCs could be used to correctly classify 72.2% of subjects as 
having NSCLC. On the basis of the results the overall sensitivity was 72.2% 
and specificity 93.6%. All 36 NSCLC cases underwent surgical resection and 
26 of the NSCLC patients agreed to have post-operative breath collection. In
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this subgroup, post-operatively there was a significant reduction in exhaled 
isoprene and decane levels. However, the low sensitivity and specificity of the 
VOCs for such an important disease led Poli et al to conclude that ‘using VOCs 
alone in the early detection of lung cancer cannot be recommended at this 
stage’. [162]
The most recent study, published early this year, looked at exhaled breath from 
43 NSCLC patients and 41 healthy controls who were non-smokers all from 
China. Of the cancer arm, 11 patients received 1 cycle of chemotherapy and 
the breath sample was obtained 4 weeks after the treatment, and the rest of the 
cancer cohort did not receive any type of treatment. The patients were fasted 
overnight and 15 ambient air samples were taken from the room where the 
patients gave their samples. All the samples were analysed using GC-MS.
They identified 2 particular VOCs which were significantly higher in the cancer 
group compared to the controls (p<0.001). [163]
The studies discussed thus far involve mass spectrometry for the measurement 
of VOCs. This equipment is expensive (over £300,000) and available only in 
research facilities. Moreover the technique is often laborious and time 
consuming needing highly specialised technicians. New techniques to detect 
VOCs have recently been developed. One such system consists of a 
colorimetric sensor array which has 36 spots made up of different chemically 
sensitive compounds. The colours of the spots change depending on the 
chemical it comes into contact with. A study using this technology was 
performed by Mazzone etal. 143 subjects were included in the study, 49 had 
NSCLC, 73 had various chronic lung diseases such as COPD, idiopathic 
pulmonary fibrosis, pulmonary arterial hypertension and sarcoidosis. There 
were 21 healthy controls. A prediction model was developed using 70% of the 
subjects, then tested. It was able to predict the presence of lung cancer in the 
remaining 30% of subjects with a sensitivity of 73.3% and specificity of 72.4%. 
Although this suggests only moderate accuracy of diagnosis, the study does 
show the potential of this measuring technique, which is a lot cheaper and 
quicker to employ than gas chromatography. [164]
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Bronchoscopy and screening for lung cancer
The role of bronchoscopy in the diagnosis and particularly treatment of lung 
cancer is still developing. White light bronchoscopy is used conventionally as a 
diagnostic tool for staging and obtaining endobronchial samples mainly in 
symptomatic patients or those with imaging suggesting a central cancer. There 
have also been studies examining the role of bronchoscopy in the early 
detection of (central) lung cancer, i.e. before it has become advanced and still 
in the premalignant cyto-pathological stages.
Autofluorescent Bronchoscopy
The principle behind autofluorescent bronchoscopy is that when blue light 
(wavelength 380 -  460nm) is shone onto abnormal mucosa there is reduced 
fluorescence, thus giving potential for abnormal mucosa and thus premalignant 
lesions to be identified. A review suggests that autofluorescent bronchoscopy 
(in experienced hands) can diagnose carcinoma in situ in 1.6% and moderate 
and severe dysplasia in 19% of current heavy or former smokers with sputum 
atypia. Moreover, the pre-invasive lesions found were small with 55% being < 
1.5mm in greatest diameter. [165] Over 1,000 cases comparing white light and 
autofluorescent bronchoscopy has shown that 40% of pre-invasive lesions were 
detected by white light bronchoscopy alone but an average of 80% were 
detected with the addition of autofluorescent bronchoscopy. [166]
A recent study combining autofluorescent bronchoscopy, sputum cytology and 
spiral CT surveillance in a very high-risk group was published in 2007. In order 
to be eligible for screening, participants required two or more of: > 20 pack year 
history of tobacco use; asbestos-related lung disease on CXR; FEVi < 70% of 
predicted ortreated prior aero-digestive cancer, with no evidence of disease for 
> 2 years. 186 patients were enrolled and 169 completed the baseline tests. 
66% of the patients had squamous metaplasia or worse with 13/169 (7%) 
diagnosed with lung cancers. Sputum cytology missed 100% of the dysplasia 
and 68% of the metaplasia detected by autofluorescent bronchoscopy, and 
failed to detect any cases of carcinoma or carcinoma in situ. Patients who had
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pulmonary nodules on spiral CT scan were 3.2 times more likely to exhibit 
premalignant changes on autofluorescent bronchoscopy and this was 
statistically significant (p<0.001). The study concluded that autofluorescent 
bronchoscopy should be carried out on high-risk individuals regardless of the 
results of conventional sputum cytology. [167]
Other studies have found no increased detection rates of carcinoma in situ or 
dysplasia using autofluorescent bronchoscopy compared to white light 
bronchoscopy in current and former smokers. [168] This suggests that 
autofluorescent bronchoscopy is best used in highly selected cohorts of 
patients, such as those with sputum atypia or if with multiple risk factors for lung 
cancer and is very operator dependant.
Genetic testing of epithelial cells from endobronchial brushings obtained at 
bronchoscopy
Spira et al investigated whether gene expression profiling of large airway 
epithelial cells could be used as biomarkers in histologically normal bronchial 
mucosa obtained by bronchial brushings. 129 current or former smokers who 
underwent fibre-optic bronchoscopy for a clinical suspicion of lung cancer were 
included in the study. Each subject was followed up until a final diagnosis was 
made. 60 were diagnosed with lung cancer and 69 without lung cancer. Lung 
cancer was diagnosed if bronchoscopy or subsequent lung biopsy yielded lung 
tumour cells. Subjects were classified as non-cancer if their investigations 
yielded a non-cancer pathology or if the radiological abnormality resolved on 
follow-up. From a training set (n=77), which represented a spectrum of clinical 
risk for lung cancer, an 80-gene biomarker panel was identified and was able to 
distinguish smokers with and without lung cancer. The panel of genes was 
tested prospectively on the remaining 52 cases, obtaining an accuracy of 83% 
(80% sensitivity, 84% specificity). A comparison was made with traditional cyto- 
pathology of cells obtained by biopsy, washings and brushings of the affected 
area on bronchoscopy. 32 of the same 60 (53%) lung cancer cases and 5 of 69 
(7%) non-cancer pathologies were diagnosed by traditional bronchoscopy 
techniques. Among the non-diagnostic bronchoscopies (n=92), the panel of
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gene biomarker’s accuracy was 85% (89% sensitive, 83% specific). By 
combining the tests such that a diagnosis of lung cancer could be made from 
either traditional cyto-pathology or the biomarker panel, the diagnostic 
sensitivity improved to an impressive 95% with a 95% negative predictive 
value. They concluded that gene-expression in cytologically normal bronchial 
epithelial cells can serve as a lung cancer biomarker. [169]
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Conclusions: screening in lung cancer
Lung cancer continues to be a major cause of mortality and morbidity.
Currently, only a small proportion of patients presenting to physicians for help, 
survive more than 5 years, often because the disease is far advanced at 
presentation. Screening studies using conventional techniques such as CXR 
and sputum cytology analysis have not shown group mortality benefit. Low- 
dose spiral CT scans are still being evaluated but advancing technology is 
allowing a range of biological markers to be tested in the early detection of lung 
cancer. Better understanding of the biology of lung carcinogenesis and 
improved techniques in DNA analysis are being combined to develop cost- 
effective, high throughput technologies that are being applied to readily 
accessible bio-fluids such as blood, sputum and even exhaled breath. It is likely 
that combinations of biomarkers, perhaps using combinations of bio-fluids will 
lead to non-invasive, and hopefully cost-effective screening tools to improve 
outcomes in this devastating and common disease.
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Chapter 3. The effect of smoking in cancer
Introduction
Years of research have shown clear links between tobacco smoking and 
cancer. Smoking is the single biggest cause of cancer worldwide and accounts 
for 25% of UK cancer deaths. It has been a causal or contributory agent in 
many cancers including lung, oropharynx, oesophagus, liver, pancreas, kidney, 
stomach, bladder, cervix and myeloid leukaemia. Figure 3.1 shows the organs 
affected.
Why does smoking cause cancer?
Each cigarette contains nearly 60 known carcinogens i.e. tumour initiators, or 
tumour promotors. Particularly ‘strong’ carcinogens are the tobacco-specific 
nitrosamines, such as 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone also 
known as NNK and N’-nitrosonornicotine (NNN); other strong carcinogens 
include polycyclic aromatic hydrocarbons, such as benzo[a]pyrene and 
aromatic amines. ‘Weak’ carcinogens like acetaldehyde are even more 
abundant. The total amount of carcinogen adds up to 1-3mg per cigarette 
resulting in a cumulative dose effect over a life-time of smoking. [170]
These different agents act on different biological pathways to have their 
carcinogenic effect. P53 is a tumour suppressor gene that detects any errors 
when cell division takes place and triggers DNA repair or cell death (apoptosis) 
if the damage persists. Benzo[a]pyrene, a potent mutagen in cigarette smoke, 
directly damages p53 rendering it inactive. Identical damage to p53 has been 
demonstrated in lung cancer patients. [171] Nicotine itself activates protein 
kinase C which reverses the growth inhibition induced by cellular opioids in lung 
cancer cells, thus reducing apoptosis and acting as a tumour promoter [172]. 
In-vitro studies show that nicotine also inhibits apoptosis through multiple 
intracellular signal transduction pathways such as activation of the protein 
kinase signalling pathway seen in lung cancer [173].
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Figure 3.1: The different sites of cancer caused by cigarette smoking (image 
taken from www.cancerresearchuk.org)
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Tobacco-specific nitrosamines such as NNK have induced lung tumours when 
applied directly to the skin of mice, or injected into the bladders or swabbed in 
the oral cavities of rats.
Smoking and lung cancer
The most widely studied cancer with respect to smoking is lung cancer. As well 
as the main cause of lung cancer, smoking status appears to be important after 
diagnosis. There is increasing evidence to suggest that smoking cessation 
even at the time of lung cancer diagnosis has a significant beneficial effect.
Smoking and survival in lung cancer
An observational study followed 112 patients with small cell lung cancer. 20 
patients had stopped smoking permanently before diagnosis, 35 stopped at 
diagnosis and 57 continued to smoke. The patients had a treatment regime 
consisting of chemotherapy +/- radiotherapy. Those who had already stopped 
smoking had the best survival followed by those who stopped at the time of 
diagnosis. The group who continued smoking had the worst survival rates with 
no-one surviving more than 2 years compared with 9-15% in the other groups 
surviving (disease free) for at least 2-4 years. These results were statistically 
significant. [174].
A more recent paper in 2005, prospectively recorded smoking status in 311 
patients operated for non-small cell lung cancer (NSCLC) by a single surgeon. 
At surgery, 54% were current smokers, 8% non-smokers, 26% former smokers 
and 12% were recent quitters. Even in this best lung cancer prognostic cohort, 
current smoking was an independent predictor of reduced survival (p=0.001) 
(along with older age and presence of lymph node metastases). Compared to 
current smokers, non-smokers (p=0.042), former smokers (p=0.006) and even 
recent quitters (p=0.004) all had a significantly better prognosis and disease- 
free survival. See Figure 3.2. These results suggest that it is beneficial to stop 
smoking prior to surgery for NSCLC and that continued smoking is associated 
with a poorer prognosis. [175]
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Figure 3.2: Overall survival according to smoking status. The differences 
between current smokers versus non-smokers (p=0.0263), former smokers 
(p=0.0109) and recent quitters (p=0.0051) were significant. [175]
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A retrospective study looking at a 10 year period followed 237 patients who 
received radiotherapy alone or chemoradiotherapy for NSCLC and had 
smoking status recorded. Among those with less advanced disease 
radiologically (stage I/ll), current smokers had a 2-year survival of 41% (median 
survival 13.7 months) compared to non-smokers 2-year survival of 56% 
(median survival 27.9 months). Groups were similar at baseline and again this 
was statistically significant (p=0.01) as well as being clinically important. There 
was no statistical differences among those with more advanced (stage III) 
disease. [176]
Smoking complicating treatment for lung cancer
Does smoking status influence complication rates associated with 
chemotherapy and radiotherapy? Monson et al investigated the side effects of 
treatment in 83 patients receiving curative radiotherapy for lung cancer 
between 1989 and 1993. 20% developed clinically detectable radiation 
pneumonitis with an incidence which was significantly increased in those with 
low performance status, low pulmonary function test, co-morbid lung disease, 
no surgical resection and those with a significant smoking history. [177]
A retrospective review of 186 patients receiving six-cycles of chemotherapy 
with concurrent radiotherapy during cycle 2 or 3 for limited-stage small cell lung 
cancer (between 1989 and 1999) found that continuing smokers (42%) did not 
have a greater incidence of toxicity-related treatment breaks, but those who did 
continue to smoke and did need a treatment break had the poorest survival 
outcome. Median survival (18 versus 13.6 months) and 5-year survival (8.9% 
versus 4%) was greater for former smokers than for continued smokers. [178]
Smoking and quality of life in lung cancer
A large study investigated the quality of life (QOL) experienced by lung cancer 
survivors, using a lung cancer symptom scale. 1,028 patients were included in 
the study and the group differences adjusted for age, gender, stage and time of 
assessment. At time of diagnosis 18% were never smokers, 58% were former 
smokers and 24% were current smokers. Appetite, fatigue, cough, shortness of
75
breath, illness affecting normal activities and overall QOL were all statistically 
and clinically worse in the current smokers group compared with the never 
smokers. It was concluded that persistent smoking after lung cancer diagnosis 
negatively impacts QOL scores. [179]
Smoking and other cancers
Continued smoking can impact on other cancers once diagnosed, although this 
has been less well studied. 610 men with localised prostate cancer were 
assessed between 1994 and 1997. High-risk cancers (those with PSA greater 
than 20 nmol/L, Gleason grading greater than 7 or stages T3-4) were more 
common in the 15% who currently smoked compared to former or non-smokers 
(p=0.017). Outcomes and overall mortality following curative external beam 
radiation therapy were poorer in the smoking group, although there was no 
difference in prostate cancer specific mortality. [180]
A small number of studies have looked at the rate of occurrence of second 
primary tumours in patients initially diagnosed with breast cancer. The 
frequency of second malignancies consistently appear to be greater in the 
those who continue to smoke after initial diagnosis with the predominant 
malignancy being lung cancer. [181, 182] Radiation therapy appears to 
increase these risks further. [182]
In patients undergoing breast reconstruction for breast cancer, there is a 
significantly higher risk of mastectomy skin flap necrosis, abdominal flap 
necrosis and hernia from the donor site in current smokers compared to former 
or non-smokers, especially in those with more than a 10-pack year smoking 
history. [183] A case -control study looked at a cohort of patients treated with 
radiotherapy for Hodgkin’s lymphoma. They found that there was a six-fold 
increased risk of developing lung cancer if the patients had a greater than 10 
pack year smoking history compared to those with less than a one pack year 
history. For those that continued to smoke after diagnosis, the increase in risk 
of lung cancer was greater as the radiation dose increased compared to those 
who abstained from smoking. [184]
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What potential mechanisms does continued smoking have on cancer 
cells?
There are biological reasons why continued smoking leads to worse drug 
toxicity and side effects, including direct damage to lung tissue itself, further 
impairment of immune function and increased incidence of infection. Other 
potential hypotheses for why continued smoking is associated with reduced 
survival and treatment efficacy is that tobacco carcinogens are ‘fuelling’ the 
cancer, hence causing more rapid progression and death. Certainly various 
tobacco chemicals can interfere with biological pathways in which 
chemotherapy would usually work, hence inhibiting its action. There is potential 
for nicotine, for example, to decrease the efficacy of various drugs via induction 
of hepatic enzymes, and thus may have some detrimental role in 
chemotherapy, although this needs to be investigated further. [185,186] Many 
retrospective studies not showing any significant differences in outcome 
between smokers and non-smokers have been criticised for not validating or 
even recording smoking status and amount during treatment. [187] Better 
clinically designed studies, hopefully well designed intervention trials and 
further biochemical research identifying these cellular pathways are being 
planned.
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Conclusions: smoking and cancer
All health care professionals try to prevent disease wherever possible, and it is 
very clear that they should be advising all patients of the role smoking has in 
causing cancer and in encouraging and offering cessation advice to reduce the 
cancer burden to society. Probably less known are the benefits of cessation in 
cancer patients. Traditionally, healthcare professionals may not have been 
active in helping patients with cancer quit smoking perhaps believing that the 
benefits in quality and length of life are not worthwhile. [188, 189] There is 
considerable and growing observational evidence to show this attitude is 
probably wrong. Meanwhile, any research into early diagnosis, screening or 
monitoring strategies in lung cancer must account for smoking history and 
validate current smoking status at every assessment for the above reasons.
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Chapter 4. Fourier Transform Infra-Red (FTIR) 
Spectroscopy in Medicine
Introduction
Our first study applies Fourier-transform Infrared Spectroscopy (FTIR) to 
sputum as a way of diagnosing lung cancer. Jean Baptiste Joseph Fourier 
(March 21st, 1768 -  May 16th, 1830) was a French mathematician and physicist. 
He has been credited with the discovery of the Greenhouse effect, where gases 
in the atmosphere are thought to increase the surface temperature on earth. 
Fourier Transform is also named in his honour. [190] In mathematics, Fourier 
Transform is an operation that transforms one complex-valued function of a real 
variable into another. [191]
How FTIR works
FTIR spectroscopy involves shining an infra-red light through a biological 
sample. Some of the infra-red radiation is absorbed by the sample (specifically 
the molecular bonds) and some of it passes through (transmitted). The resulting 
spectrum represents the molecular absorption and transmission, creating a 
molecular fingerprint of the sample. As with fingerprints, no two unique 
molecular structures produce the same spectra. The advantage of such a 
technique is that it can be used to identify any type of compound such as 
carbohydrates, lipids, proteins and DNA. It can determine the quality or 
consistency of a sample and also the amount of components in a mixture. 
Figure 4.1 is an example of an FTIR machine.
The other advantage of FTIR is it allows high-throughput, cost effective analysis 
of the samples. The analysis of one sample is in the region of a few pence. It is 
also more sensitive due to the detectors which are employed, and the optical 
throughput which is higher, resulting in much lower statistical noise levels. The 
moving mirror in the interferometer is the only continuously moving part in the 
instrument, thus giving very little chance of the machine breaking down.
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Figure 4.1: An FTIR machine
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The sample analysis process
The normal instrumental process is as follows.
The source: the infra-red light is emitted from a glowing black-body source and 
passes through an aperture which controls the amount of energy presented to 
the sample.
The interferometer: the beam enters the interferometer and undergoes “spectral 
encoding”. This results in an interferogram signal which then exits the 
interferometer.
The sample: the beam enters the sample compartment where it hits the 
molecular bonds of the sample causing them to rotate and vibrate, giving an 
absorption peak. The rest of the light passes through (transmission).
The detector: the beam finally passes through to the detector for final 
measurement.
The computer: the measured signal is then digitalised and sent to the computer 
where it undergoes Fourier transformation (a specific mathematical equation) 
with the output being an infra-red spectrum for further analysis.
Figure 4.2 represents a schematic of the sample processing.
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Figure 4.2: The FTIR process (image taken from www.thermonicolet.com)
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As there needs to be a relative scale for the absorption intensity, a background 
spectrum must be measured. This is normally a measurement with no sample 
in the beam. This can then be compared to the measurement with the sample 
in the beam to determine the “percent transmittance”. This allows for all the 
instrument characteristics to be removed so one is left with purely the 
characteristics of the sample.
Principal Component Analysis (PCA)
Principal component analysis (PCA) is a statistical method routinely used to 
analyse interrelationships among large numbers of variables revealing common 
underlying factors or components and is used in FTIR analysis. The objective of 
PCA is to reduce the dimensionality (number of variables) of the dataset but 
retain most of the original variability in the data. PCA is referred to as a data 
reduction method. PCA examines the correlations between the original 
variables (in our study the spectra represent the variables) and condenses the 
information contained within these variables into a smaller group of 
components with minimal loss of information. Thus, PCA could reduce a large 
group of individual cases into smaller groups (components) of related cases. 
The association of a case with each component depends on the correlation 
values (loadings) calculated by PCA and the variance shared by the component 
and variable is equal to the square of the correlation. The higher the loading 
value, the better the description of the variable by the component. The first 
component represents the best linear combination of variables, similar to a line 
of best fit, so, the first component may be described as the single best 
summary of linear relationships within the data. The second component is 
derived from the proportion of the variance remaining after the first component 
has been extracted and is the second best linear combination of variables, 
orthogonal (at right angles) to the first component and so on. There is no inter­
correlation between components. PCA is extremely useful for visualizing the 
relationships between cases as the loadings of cases for two or three 
components can be visualized using two dimensional (2D) and three 
dimensional (3D) scatter plots.
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FTIR and cancer
The role of FTIR in medicine has been developing over recent years. Its role in 
lung cancer has been studied on lung cancer tissue and normal lung tissue 
specimens. Using a sample size of 26 patients, Yano et al found that at certain 
wavenumbers there was significantly higher absorbance found in lung cancer 
specimens relative to non-cancer control tissue from the same patients. They 
also found that absorbances for these wavenumbers were higher for 
adenocarcinoma than for SCC. [192, 193] Wang et al reported that there were 
large differences in peak absorbance at certain wavenumbers between lung 
tumour and normal lung cells in pleural fluid of the same patients although this 
was assessed on only 8 subjects. [194]
FTIR has been studied in relation to other cancers such as cervical cancer. 
FTIR and PCA was applied to the exfoliated cervical cells of 272 patients. Six 
spectra were performed for each patient and they were assessed and split into 
two groups. Type 1 exhibited a profile characteristic of normal cervical 
epithelium. Type 2 exhibited features suggestive of dysplasia or malignant 
change. Of the 272 patients, 68.6% had type 1 spectra for all six performed, 
29.4% had at least one type 2 spectra and 2% were inconclusive. Of the 
68.6%, 86% were diagnosed normal by cervical smear with no formal biopsy 
required. 7% were diagnosed abnormal by biopsy and 5% normal by biopsy 
and 2% remained inconclusive. Of the remaining 29.4% of which at least one 
type 2 spectra was obtained, 71% had shown abnormal smear results and went 
on to have biopsies which confirmed 87% of them as abnormal. Thus the study 
showed the early potential of FTIR. [195]
A study in 2004 looked at the potential detection of biomarkers using FTIR in 
cervical cancer and melanoma. Studies were conducted with formalin-fixed 
biopsies of melanoma and cervical cancer by FTIR to detect common 
biomarkers, which occurred in both types of cancer distinguishing them from 
the respective non-malignant tissues. The spectra were analysed for changes 
in levels of biomolecules such as RNA, DNA, phosphates and carbohydrates 
(such as glycogen). The results showed promise for cervical cancer but not so
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for melanoma. [196] More recently, a group from King’s College, London further 
looked at FTIR in cervical cancer. Using a cohort of 53 patients, they compared 
the cervical smear test and FTIR technique against the findings of the 
colposcopists (gynaecologist). The smear test achieved an overall classification 
of 43%, whereas FTIR achieved a rate of 72%. [197] Further work on cervical 
smears was published in 2008. 800 cervical scrapings were analysed using 
FTIR and by cytology which is the gold standard. FTIR was successful at 
distinguishing between cancer and normal tissue with a sensitivity of 85% and 
specificity of 91 %. [198]
In 2002, Lasch et al analysed FTIR spectra performed on 26 patients tissue 
samples which were pathologically diagnosed as colorectal adenocarcinoma. 
Using multivariate statistical techniques such as hierarchical cluster analysis 
(HCA) they were able to correctly characterise 95% of the cases correctly. [199]
FTIR on cancerous breast tissue has shown distinctive spectra different to that 
of normal breast tissue. Using the spectra, close to 100% diagnostic accuracy 
could be obtained and it was also able to discriminate between subtypes of 
breast cancer, such as apocrine, tubular, intraductal and mucinous carcinomas 
and invasive infiltrating ductal carcinomal tissues. [200]
FTIR has also been evaluated in prostate cancer. It has been used on prostate 
biopsies and has shown that it is possible to distinguish between prostate 
confined disease and extra-prostatic cancer. This is not possible with existing 
criteria and is of importance especially when considering treatment regimes. 
FTIR with PCA was also able to distinguish between low and higher grade 
cancers with a sensitivities and specificities as high as 83.6% and 86% 
respectively. [201,202]
The technique has also been used on oesophageal, gastric and oral tissue with 
varying results. [203-206]
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FTIR and lung disease
In order to use FTIR effectively, suitable biofluids are required for sampling. In 
lung disease, sputum is readily available and this has been assessed in chronic 
obstructive pulmonary disease (COPD) albeit with small numbers of study 
patients. 15 patients with COPD were included in the study (FEVi of 40 -  65% 
predicted, 1 0 -40  pack year smoking history, 2 of which were current 
smokers). The control group consisted of 15 healthy volunteers who were never 
smokers and had no evidence of respiratory disease. The results showed no 
significant difference in spectra between current smokers and ex-smokers in 
the COPD group. Significant differences were noted between the spectra of 
COPD and healthy patients in three particular regions, amide A, amide II and 
glycogen rich region. [207] This was the first study using FTIR on sputum. A 
different study looked at pleural fluid, identifying spectral differences between 
the cells for pleural fluid of patients who were normal, had lung cancer and 
those with tuberculosis. Eight patients were included in the study and the FTIR 
spectra on the cell pellets were noted to be different between the 3 groups 
especially the lung cancer group at certain wavenumbers. [194]
In patients with Cystic Fibrosis (CF), sputum production is usually a significant 
symptom due to the presence of bronchiectasis (dilatation and damage to 
bronchial airways, which usually results in chronic sputum production). CF 
patients often get different respiratory infections as their disease progresses 
and identification is important as aggressive, early treatment prevents further 
damage. FTIR has been studied on the sputum of 150 CF patients to identify if 
there are spectral differences that can help identify certain infective organisms. 
The clinical isolates were identified using standard guidelines and then the 
samples underwent FTIR. There were spectral differences and this allowed the 
correct identification of organisms such as Pseudomonas aeruginosa, 
Stenotrophomonas maltophilia, Achromobacter xylosoxidans, Acinetobacter 
spp., Ralstonia pickettii, and Burkholderia cepacia complex bacteria with up to 
98% accuracy. [208]
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Conclusion : FTIR in medicine
There are a small but growing number of studies, which have shown the 
potential of FTIR in medicine. However, the majority of these have involved 
mainly biopsy tissue obtained in an invasive manner. The main aim of the 
technology is to facilitate diagnosis and in terms of cancer the technology could 
be used to detect changes at an earlier more treatable stage. This is 
particularly important in lung cancer for reasons already discussed. There have 
been only a few attempts at studying FTIR in lung cancer. One such study has 
used FTIR analysis on lung cancer tissue and one on pleural fluid of lung 
cancer patients; Two studies have looked at sputum in COPD and CF patients, 
respectively, but no-one, has yet assessed FTIR in the sputum of lung cancer 
patients.
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Chapter 5. Volatile organic compounds (VOCs) in 
lung disease
Introduction
Our third study measures volatile organic compounds (VOCs) in subjects with 
lung cancer and controls. VOCs are organic chemicals that easily vaporise at 
room temperature. [209] As they contain the element carbon within their 
molecular structure they are called organic. They have no colour or taste and 
include a wide range of individual substances, such as hydrocarbons (e.g. 
benzene and toluene), halocarbons and oxygenates. Examples of VOCs 
include methane, which is an important hydrocarbon and has an environmental 
impact principally with its contribution to global warming and the ozone. Some 
VOCs are harmful, including benzene, polycyclic aromatic hydrocarbons (PAH) 
and 1,3 butadiene. Benzene, toluene and xylene may increase susceptibility to 
leukaemia if there is extensive prolonged exposure. PAHs in particular, can 
cause cancer as mentioned in Chapter 3. There is also an apparent correlation 
between butadiene exposure and higher risk of cancer. Sources of 1,3 
butadiene include manufacturing of synthetic rubbers, petrol driven vehicles 
and cigarette smoke.
VOCs and lung disease
The current studies looking at the role of VOCs in diagnosing lung cancer have 
been summarised in Chapter 2. As well as the potential for certain patterns of 
VOCs developing as a result of certain disease processes, VOCs within the 
ambient air in certain environments may have a causative effect in respiratory 
disease. Inhalation of significant amounts of VOCs may lead to respiratory 
problems due to irritation of the airways and can cause symptoms such as one 
gets with asthma.
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VOCs and airway disease
Various studies have shown a correlation with increased airway hyper­
responsiveness in workers exposed to VOCs especially if they are smokers and 
have a background of atopy. [210-213] A study looking specifically at the role of 
VOCs on physician diagnosed asthma showed that there was a significantly 
higher odds of diagnosis following exposure to aromatic compounds. In those 
who were not officially given a diagnosis of asthma, exposure to aromatic 
compounds and chlorinated hydrocarbons significantly increased the odds of 
one or two wheezing attacks. [214]
VOCs and Infection
Phillips et al has studied panels of VOCs for the early detection of lung cancer 
(see Chapter 2). He recently expanded on the potential of the technique to look 
for alterations in VOCs for patients with suspected pulmonary tuberculosis (TB). 
Statistical analysis consisting of linear discriminant analysis and principal 
component analysis built various receiver operator curves that eventually 
allowed a 100% sensitivity and specificity when distinguishing between those 
suspicious of TB and those who were healthy controls. Pattern recognition 
analysis was also used to distinguish those who were sputum culture positive 
(i.e. infective) TB cases with 82.6% sensitivity and 100% specificity. The study 
conclusions suggested that VOCs could be used in pulmonary TB to distinguish 
between well vs. sick (i.e. healthy controls vs. hospitalised due to suspicion of 
TB) and non-infective vs. infective (i.e. those with negative vs. positive sputum 
cultures for TB). [215]
As the understanding of VOCs becomes clearer then one can consider and 
investigate the relationship between VOCs in interstitial lung disease, chronic 
obstructive pulmonary disease and bronchiectasis, especially in exacerbations 
of such diseases.
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VOCs and other cancers
The early mutagenic and potential carcinogenic role of reactive oxygen species 
and oxidative stress is discussed below. In some cancers such as breast 
cancer, it is thought that as well as increased oxidative stress being involved in 
carcinogenesis, the presence of breast cancer itself causes a further increase 
in oxidative stress. [216] Phillips et a/used this theory and assessed exhaled 
VOCs in 51 women with breast cancer and 42 healthy controls and achieved a 
sensitivity of 94% and 74% specificity using a panel of 8 VOCs. When 
assessing 50 patients with abnormal mammogram but no cancer on biopsy the 
sensitivity dropped to 63% and specificity improved to 84%. [217] Further re- 
evaluation with a reduced panel of 5 VOCs, showed that when comparing the 
cancer group with the healthy control, specificity was improved to 84% whilst 
maintaining the high sensitivity (94%). [218]
Potential mechanisms of VOCs production in breath
Only recently has the pathophysiological processes of VOC production 
emerged due to better understanding of the mechanisms behind VOC 
synthesis and clearance. Largely, VOC production revolves around production 
of reactive oxygen species (ROS).
Reactive oxygen species
ROS are ions or very small molecules that include oxygen ions, free radicals, 
and peroxides, both inorganic and organic. They are highly reactive due to the 
presence of unpaired electrons on their outermost electron shell. ROS are 
formed as a natural byproduct of normal oxygen metabolism and have 
important roles in cell signaling. ROS levels increase dramatically due to 
environmental stress such as ultraviolet light / heat exposure and cigarette 
smoke which can result in significant cell structure damage. This is known as 
oxidative stress. ROS can also be formed by ionizing radiation, which can 
penetrate cells and create ions in the cell contents which in turn can cause 
permanent alterations in DNA. [219]
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The general harmful effects of ROS on the cells are:
• Damage of DNA and RNA
• Oxidations of polyunsaturated fatty acids in lipids
• Oxidations of amino acids in protein
• Oxidatively inactivating specific enzymes by oxidation of co-factors
ROS are constantly being produced in the mitochondria and leak into the 
cytoplasm where they cause damage to proteins, polyunsaturated fatty acids 
and DNA by peroxidation. Studies support the experimentally based notion of 
oxidative DNA damage as an important mutagenic and apparently carcinogenic 
factor, however the proof of a direct causal relationship is still lacking. VOCs 
such as alkanes and methylated alkanes in breath are apparent markers of 
oxidative stress, being produced as a result of lipid peroxidation from ROS.
Lipid Peroxidation
Lipid peroxidation refers to the oxidative degradation of lipids. It usually affects 
polyunsaturated fatty acids as they have multiple double bonds in between 
which lie methylene -CH2- groups that possess especially reactive hydrogen. 
During the process, free radicals ‘steal’ electrons from the lipids cell 
membranes, resulting in cell damage. A free radical chain reaction then causes 
the process to proceed. The process takes place in three steps:
1) Initiation -  this is where a fatty acid radical is produced with ROS being 
the most notable of initiators. The ROS, typically OH' combines with the 
hydrogen atom to make water and fatty acid radical.
2) Propagation -  the fatty acid radical is unstable, thus reacts readily with 
oxygen, producing peroxyl-fatty acid radical. This new product is also 
unstable and reacts with another free fatty acid producing a free fatty 
acid radical and a lipid peroxide or cyclic peroxide if it had reacted with 
itself. Since the new free fatty acid radical reacts in the same way, the 
cycle continues.
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3) Termination -  the process is called a free radical chain reaction as when 
a free radical reacts it always produces another free radical. The only 
time this will stop is if two radicals react and produce a non-radical 
molecule and this can occur when there is a high concentration of radical 
species thus giving a high probability of two radicals colliding. [220]
If the chain reaction is not terminated early enough, then damage to the cell 
membrane pursues which consists mainly of lipids. The end products of lipid 
peroxidation may be carcinogenic. [221] Figure 5.1 is a schematic of lipid 
peroxidation.
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Figure 5.1: Lipid peroxidation (image taken from www.wikipedia.org)
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Oxidative stress in cancer patients
It is thought that not only does oxidative stress have a role in the aetiology of 
cancer, but in some cancers, such as breast, the disease itself causes 
increased oxidative stress, and is thus self-perpetuating. [216] Emerging 
research suggests a similar effect in lung cancer. [222-224] Potential 
mechanisms for increased oxidative stress in patients who already have cancer 
have been suggested. The first includes altered energy metabolism which may 
result in symptoms such as cachexia / anorexia, nausea and vomiting, which 
leads to reduced nutritional intake of glucose, proteins and vitamins, and this 
leads to accumulation of ROS. [225] A further mechanism is one of chronic 
activation of the immune system and thus excessive production of pro- 
inflammatory cytokines, which may in turn lead to increased ROS production. 
[226] Interestingly cachexia has also been shown to be associated with high 
levels of pro-inflammatory cytokines. [226-228] 60% of lung cancer patients 
present with cachexia, which is characterised by progressive weight loss with 
predominantly depletion of skeletal muscle and to a lesser extent, reduced 
adipose tissue, reduced dietary intake and poor performance status. [229]
This increases to greater than 80% as the disease advances. [230] There have 
been several links between increased oxidative stress and cachexia including 
the role of TNF-a inducing oxidative stress, a potential role of IL-6 and high 
levels of glycolytic activity and lactate production. [225, 231-236]
As increased oxidative stress appears to be increased in some cancers, and 
VOCs such as alkanes are markers of oxidative stress then one can postulate 
these levels will be higher in the breath of cancer patients. [237-241]
VOCs in exhaled breath
Alkanes, such as ethane and pentane are generated by lipid peroxidation of 
polyunsaturated fatty acids in cell membranes and these are excreted in breath. 
Breath methylated alkanes may be the result of the same process. [239, 240, 
242] The alkanes produced by lipid peroxidation are then metabolised by
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cytochrome P450 (CYP)-mixed oxidase enzymes and result in alkyl alcohols. 
[243]
A number of studies have shown certain CYP enzyme genotypes, such as 
CYP1A1, to be activated in lung cancer. [244-247] There are genetic 
polymorphisms in the inducibility of CYP1A1, with some evidence that high 
inducibility is more common in patients with lung cancer. [248] For example, 
two enzymes of cytochrome P450, CYP1A1 and CYP1A2, are inducible by 
tobacco carcinogens, and animal studies evidenced a genetic polymorphism of 
CYP1A1 associated with tumour occurrence after administration of a polycyclic 
aromatic hydrocarbon. [244] Induction of CYP activity results in accelerated 
metabolism of a number of drugs and the activation of some procarcinogens. 
CYP1A1 has been the most studied genotype with relation to lung cancer and 
has been associated with higher disease recurrence rates and poorer survival 
rates. [249] Thus activation of CYP enzymes in individuals with lung cancer 
may accelerate the degradation of VOCs that are produced as a result of 
oxidative stress. This provides the basis behind exhaled breath testing and is 
represented by the following schematic, Figure 5.2.
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Figure 5.2: Schematic of potential mechanism of VOCs in lung cancer
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Phillips et al suggested a schematic of potential sources of endogenous / 
exogenous VOC production as shown in Figure 5.3. [250] In Figure 5.4,1 have 
incorporated the potential mechanisms of VOCs production in lung cancer 
patients discussed in this Chapter into the schematic.
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Figure 5.3: Potential sources of VOCs in alveolar air. This figure shows that 
VOCs in the breath may be derived from sources either inside the body (as 
products of metabolism) or outside the body (VOCs in the inspired air, food, 
and drugs). [250]
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Figure 5.4: Potential sources of VOCs in alveolar air of lung cancer patients 
with possible mechanisms of production and how the illness may affect them
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Different techniques used to trap then measure Volatile Organic 
Compounds
Mass Spectrometry
Many of the studies using VOCs discussed in Chapter 2 involved the collection 
of exhaled breath and then analysing the breath using gas chromatography -  
mass spectrometry (GC-MS). The results of these studies are promising but the 
accuracies are not yet high enough to be clinically useful. The advantage of the 
GC-MS system is that they are sensitive and can detect specific VOCs and 
measure their concentrations at very small levels. The GC-MS systems 
themselves are currently expensive and analysis can be laborious and time- 
consuming. Also the breath has to be collected and then transported to the GC- 
MS machines which can lead to sample storage / leak and degradation 
problems en route also negating the advantage of patient nearside testing 
favoured by patients and clinicians.
Gaseous chemical sensing devices /  electronic nose (eNOSE)
Gaseous chemical sensing and identification devices such as eNOSEs are able 
to detect a single (or pattern of) odorant molecule(s) such as VOCs, mimicking 
human olfaction. The premise of most of these systems is that absorption of 
gases onto the sensor system causes a change in the conductivity, mass, 
vibration, or colour of the system, thus altering its’ output. This is then 
translated into a digital value (a ‘smellprint’). Figure 5.5 is a representative 
‘smellprint’ of VOC from a lung cancer patient.
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Figure 5.5: ‘Smellprint’ derived from eNOSE from exhaled VOCs from a lung 
cancer patient [251]
The system can be set up to consist of an array of sensors, which can be tuned 
depending on the task. This method has been used in studies looking at lung 
cancer detection from exhaled breath with varying success. The first studies in 
2003 and 2005 looked at variation in oscillating sensor frequencies and the 
reversible change in resistance across the sensor, respectively. [252, 253] The 
first such study identified a ‘smellprint’ which characterised lung cancer and 
control cohorts with 90% accuracy. The subsequent model correctly classified 
100% of cancer patients and 94% of controls. [253] Machado et al used a 32 
sensor eNOSE and found differences in the ‘smellprint’ of lung cancer subjects 
compared to controls, but no signal differences between patients with differing 
disease severity and no confounding effect of cigarette smoking or co-existent 
airways disease (asthma or COPD). [252] Then in 2007, Mazzone used the 
colorimetric sensor described in Chapter 2. [164]
More recently, a study compared 10 patients with lung cancer, 10 COPD 
patients and 10 healthy controls, and using an eNOSE was able to discriminate 
each of the cohorts. [254] This has been developed further looking at non-lung 
cancer cohorts, concentrating on asthma, COPD, smoking controls and non­
smoking controls using eNOSE. The asthma and COPD cohorts could be 
distinguished with 96% accuracy, as could the asthma and smoking and non­
smoking controls. Interestingly the COPD group could not be distinguished from 
the non-smoking controls. [255]
The advantage of this technique of detection over GC-MS is that it is relatively 
inexpensive, and easy to use as a point-of-care test. However and importantly, 
they may not be sensitive enough to detect all the potentially important VOCs in 
breath and it is not possible to identify specific chemical compounds using this 
technique.
Ion Mobility Spectrometry (IMS)
IMS is based on ionisation of gaseous molecules that are separated by short 
impulses in drift tubes of a few centimetres. The small electrical current, which 
is then, generated at a Faraday plate (detection plate) forms the spectrum of
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the running time of the ions. This technique allows a ten-fold higher detection 
rate of VOCs. It offers an immediate two-fold separation of VOCs with 
visualisation in a three-dimensional chromatogram (separating VOCs by 
retention time, drift (mobility) and concentration). This method has been 
evaluated in a study of 32 patients with histologically proven lung cancer (24 
men, 8 women), with a mean age of 65.1 (+/- 9.6) years and 54 healthy 
controls. Of the lung cancer cohort, 17 patients were former smokers, 6 had 
never smoked and 7 were current smokers. Using this method, a combination 
of 23 VOCs from exhaled breath were able to correctly classify lung cancer 
patients or healthy controls with 100% accuracy. The method is quick and 
reliable based on early data; however it does not give any clues as to the 
identity of the molecules which the VOCs actually represent. [256]
Other breath tests for lung cancer:
Exhaled breath condensate (EBC)
EBC is a biological fluid that mainly consists of water, but also contains small 
droplets of airway lining fluid (epithelial lining fluid (ELF)). The advantage of 
EBC is collection of the samples is also completely non-invasive. The EBC can 
then be used to look for any changes in DNA. An example of this technique 
involved patients breathing tidally through a mouthpiece for 20 minutes with the 
condensate collection taking place on ice at -20°C. The patients were informed 
to swallow any saliva produced. The samples were then stored in 1.5ml tubes 
at a temperature of -70°C. [257]. This particular study involved 30 patients with 
NSCLC who were compared with a healthy control group of 20 subjects. The 
results showed 89% of the study group having genetic alterations in the DNA 
from the EBC detected against 35% of the healthy controls. These genetic 
alterations consisted of loss of DNA heterogeneity and microsatellite instability. 
It is thought these microsatellite alterations (MA) take place on chromosome 3p 
where tumour suppressor genes are located. The same research group found 
that not only are there significantly more MAs in the DNA of NSCLC patients 
compared to healthy controls, but also that the MA profile from the EBC
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corresponded to that of the actual tumour tissue of each patient with NSCLC. 
[258]
Two further potential biomarkers in EBC have recently been studied. Cigarette 
smoke has been thought to be the main factor causing the inflammation of the 
airways described in lung cancer patients. Two key components thought to be 
involved in this process are cycloxygenase (COX) and survivin, a COX-2 
dependent factor of apoptosis. In a study comparing not only lung cancer 
versus healthy controls but also looking at the smoking history and status, 
higher levels of survivin and COX-2 were found in the EBC of NSCLC 
compared to healthy smokers and non-smokers. There were also higher VOC 
levels noted in the smokers (containing both healthy and lung cancer patients) 
and ex-smokers, compared to the non-smokers, and a positive correlation 
between EBC survivin and COX-2 levels and the number of cigarettes smoked 
(pack/yrs). There was also a correlation identified between levels of the two 
markers and progression of disease. Thus using EBC, survivin and COX-2 are 
thought to have potential at detecting early lung cancer in the smoking 
population. [259]
p53 mutations have also been detected in EBC. In a small study, p53 mutations 
at exons 5-8 were identified in 4 out of 11 (36.3%) of NSCLC patients and none 
of the healthy volunteers. [260]
Thus the use of EBC has identified various potential markers, however all of the 
studies so far have involved a small number of patients and further analysis is 
required. The technique is non-invasive thus amenable to patients but does 
require some time in terms of sample collection. EBCs contain both volatile and 
non-volatile substances. Volatile substances that are breathed out in a gaseous 
state can be dissolved in condensed water during EBC collection depending on 
their physico-chemical properties. [261] Non-volatile substances, such as salts 
and proteins, are mainly expired in small droplets, and further diluted with 
exhaled water vapours. It is thought that the droplets are formed as a result of 
random convective processes, and may not be directly related to water vapour 
production. This variability in droplet dilution as well as questions over the
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source of the droplets (i.e. not necessarily from the epithelial lining of the 
airways) raises questions over EBC interpretation. Reported increases in EBC 
concentrations may reflect proportionate increases in the total volume rather 
than the concentration of ELF droplets in the collected samples. [261, 262]
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Conclusion: breath sampling for VOCs and other biomarkers in lung 
disease
When considering a test to screen or diagnose a condition, a very important 
consideration is what will be the most comfortable and acceptable test for 
patients to endure. Breath sampling is a non-invasive procedure that is 
comfortable for nearly all patients. There are firm biological reasons why one 
expects differences in the exhaled breath of patients with lung cancer when 
compared to their healthy counterparts. More work needs to be done in refining 
and testing the new technology so eliminate confounders and improve 
accuracy. Studies comparing ways of analysing exhaled breath continue to try 
and answer many remaining questions and hopefully to find a modality which 
will successfully show differences between lung cancer and control or high-risk 
patients to a level of ease, cost and accuracy that would satisfy our screening 
criteria.
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PART 2: METHODS
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Chapter 6. Biological screening for lung cancer 
with sputum
Background
We obtained approval from the Local Research and Ethics Committee (LREC), 
(05/WMW01/75) and Hywel Dda Trust Research and Development Unit. Site- 
specific approvals (Bridgend and Swansea) were obtained as the study 
progressed. Recruitment took place between 2007 and 2008 across 3 
hospitals, Prince Philip Hospital (Llanelli), West Wales Hospital (Carmarthen) 
and Princess of Wales Hospital (Bridgend). All sample processing and analysis 
was performed at Swansea and Aberystwyth Universities.
During the recruitment period, the study was awarded a grant from the Welsh 
Office of Research and Development (WORD) (Application no. H07-3-31) and 
has also been registered with the UK Clinical Research Network (UKCRN) 
portfolio database (UKCRN ID 4682), the Wales Cancer Trials Network 
(WCTN) portfolio and was listed with the National Cancer Institute (ID: 
NCT00899262) in the United States (http://clinicaltrials.gov).
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MATERIALS AND METHODS
a) PATIENTS
Patients were recruited predominantly from Respiratory Out-Patient clinics 
although a small number were recruited after they were admitted to hospital 
with an acute illness. We approached any patient in whom the clinical diagnosis 
of lung cancer was being considered. These included those with a CXR that 
was abnormal and those with particular symptoms (e.g. haemoptysis and 
normal CXR) for which a bronchoscopy was requested to help diagnose or 
exclude lung cancer. CXR abnormalities included an opacity or mass within the 
lung fields, enlarged hilar, unresolving consolidation, unexplained lobar or 
complete lung collapse or cavitation. During the first consultation the patient 
was made aware that they could have a tumour although other diagnoses were 
possible and thus further investigation was needed. At the end of this first 
clinical consultation, the outline of the study was discussed and patients were 
given a Patient Information Sheet (PIS) with further details of the study and 
what it would entail as a participant within it. The PIS included information with 
regards to the sputum samples if they agreed to be part of the study (See 
Appendix 1). We excluded any patient who refused or did not have capacity to 
provide written consent (See Appendix 2), anyone under the age of 18, and any 
patient in whom a bronchoscopy was not planned as part of the diagnostic 
process. See Figure 6.1.
109
Patient Flow Chart
Assessed in Respiratory Clinic
High enough suspicion of lung cancer to warrant referral for bronchoscopy
Initial approach for enrolment and Information Sheet Given
1
Patient attends for bronchoscopy (n=120)
Consent Obtained or excluded from study
Yes (n=110)
Sputum obtained: 
Self expectorated / 
Suctioned during 
bronchoscopy(n=99)
Diagnosis of lung cancer or
no lung cancer made at Lung MDT and
subsequent follow up
Figure 6.1: Patient flow chart for biological screening for lung cancer with 
sputum
No (n=10) 
Exclusion criteria: 
Age <18;
Patient refused 
Bronchoscopy not 
for lung cancer
Standard 
NHS care
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All participants had at least 24 hours to read their PIS before attending for their 
bronchoscopy and before signing and dating the Consent Form; a copy of this 
Consent Form was given to the patient, one placed in the medical notes and a 
copy kept in the master research file. Their General Practitioner (GP) was then 
also informed of their patient’s participation (See Appendix 3).
Data and sample collection
Sociodemographic and medical data was collected at initial interview and 
cross-checked from hospital notes. This included: past medical history 
(including previous cancers), current prescribed medication, smoking history, 
current smoking status, family history of cancer, and any recent respiratory tract 
infection. Specific symptoms were noted: weight loss, hoarse voice, 
haemoptysis, cough, shortness of breath or chest pain. We also recorded CXR 
findings, FEVi, WHO performance status and current or previous occupation.
Smoking status was validated using exhaled carbon monoxide (CO) levels. The 
patients were asked to take a deep breath in and hold at peak inspiration for 15 
seconds, then to exhale slowly into the CO monitor (Bedfont-Micro Smokerlyzer 
®). The peak number registered on the CO monitor was recorded. Those 
reporting smoking or anyone with a CO level >10 ppm (particles per million) 
were considered current smokers. [263] Ex-smokers were those reporting 
smoking no cigarettes within the last 12 months and having exhaled CO (eCO) 
levels <10 ppm. Never smokers were those reporting less than 100 cigarettes 
in their lifetime, none within 12 months and having eCO< 10 ppm.
See Appendix 4 for data collection sheet.
A universal container was provided for the patient to cough sputum prior to 
bronchoscopy. All patients were fasted as per protocol for bronchoscopy (6 
hours). The self-expectorated sputum sample was frozen immediately on dry 
ice.
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The patient then underwent bronchoscopy. They had an intravenous cannula 
inserted through which they had sedation (midazolam). 2% Lignocaine was 
sprayed within the nasal area and oropharynx and then they had further 
lignocaine injected through the cricoid membrane in order to anaesthetise the 
proximal trachea and vocal cords. In a small number of patients, endobronchial 
anaesthesia was performed rather than trans-cricothyroid, due to patient 
preference, recent haemoptysis, thick neck, enlarged thyroid or complex 
anatomy. When the patient was sedated adequately they were usually laid flat 
(supine) and bronchoscopy commenced via nasal or oral approach according 
to clinical discretion. During the procedure, airway secretions were suctioned by 
nursing staff using a standard suction yankeur (Pennine Healthcare, London, 
UK) and placed into a universal container. We therefore obtained 
endobronchial secretions for those patients who were unable to self- 
expectorate any sputum. These samples were frozen immediately on dry ice. It 
was noted whether the sputum samples were self-expectorated (n=42) or taken 
through the bronchoscope.
The bronchial tree was inspected and diagnostic samples taken for clinical 
purposes. Endobronchial appearances were coded in the research database 
as:
1 = normal
2 = external compression of bronchus/ trachea from the tumour
3 = abnormal mucosa
4 = definite tumour endobronchially
Obtaining diagnosis
All the patients had a contrast-enhanced CT scan of thorax and abdomen +/- 
brain. Clinical details, radiology and cyto-histopathology results were discussed 
at each hospital’s Lung Cancer Multi-Disciplinary Team (MDT) meeting. Those 
patients with confirmed lung cancer were split according to histological subtype 
(small cell or NSCLC) and extent of disease (TNM staging). The clinical 
management plan was then formulated which took the course of potential
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surgery, radical radiotherapy, palliative radiotherapy, chemotherapy or best 
supportive care according to current guidelines. [46]
Patients classed as not having lung cancer had to have a normal bronchoscopy 
and radiological abnormalities that resolved, with no evidence of cancer at 1 
year follow-up. Because of their symptoms and usually smoking history they 
were deemed as ‘high-risk’ compared to the background population.
Healthy control cohort
In order to identify what a “normal” sputum FTIR spectra would represent, we 
recruited healthy individuals, that were a mixture of current, former and never 
smokers, who did not have any known respiratory disease nor symptoms 
suggestive of respiratory disease or intercurrent chest or nose infections. They 
were also excluded as controls if they had previous or any type of current 
cancer. Figure 6.2 illustrates the screening questions proforma we used for 
healthy controls.
If they fulfilled the inclusion criteria for a healthy control they were given a 
Healthy Control Information Sheet (Appendix 5) and given at least 24 hours to 
consider participation. Once written informed consent was obtained, they were 
asked to self-expectorate sputum into a universal container, which was then 
immediately stored at -80°C.
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Do you smoke?
Do you currently or have you ever smoked?
Have you smoked for a period longer than 10 years?
Have you lost weight recently (unintentionally)?
Are you troubled by any of the following symptoms at the moment?
-cold or flu 
-chest pain
-wheeze (including at night)
-cough
-increased sputum or spit production 
-breathlessness
Do you take any inhalers or other medications for your chest 
Do you have any respiratory disease or history of this?
Have you ever had cancer of any kind?
Figure 6.2: Screening questionnaire for the healthy control cohort for biological 
screening for lung cancer with sputum
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b) PROCEDURE
Sputum processing for FTIR
Preparation of mucolytic agent
Whilst stored, the unprocessed sputum samples were kept in a freezer (New 
Brunswick Scientific, New Jersey, USA) at -80°C. The samples were frozen for 
between 1-60 days before being processed. They were defrosted at room 
temperature for 12-24 hours. The sputum / bronchial cells were isolated by 
breaking down the mucus with a solution consisting of 2.5g Dithiothreitol (DTT) 
in 31ml Cytolyt (Fluka Biochemika Sigma-Aldrich Chemie GmbH Switzerland) 
mixture which digested the mucus in the specimen. The lifespan of the mixture 
is only a few days and it had to be kept refrigerated.
Preparation of sputum cells for FTIR
15ml Cytolyt was added to the universal container containing the sputum 
sample with a pipette and to this 0.5ml of DTT working solution was added. The 
sample was then placed on the Vortex (IKA Vibrax VXR Basic, IKA ® Werke 
GmbH & Co, Staufen, Germany) for approximately 15 minutes in order to 
obtain a sample of fluid consistency. The sample then underwent centrifugation 
(Hettich Rotina 38, GmbH & Co, Tuttlingen, Germany) at 3000 rpm for 10 
minutes to concentrate the cells. The supernatant was poured off leaving a 
pellet of cells. A proportion of cells were pipetted into a 1.5ml Eppendorf tube. 
These pellets were freeze-dried over night, diluted in 200 pL of sterile distilled 
water, agitated for 5 minutes and split into 20 pL aliquots, which were frozen 
immediately in liquid nitrogen and stored at -80 °C in preparation for FTIR. The 
remaining portion of the cell pellet was prepared for cellblocks to be used in 
cytology and immunohistochemistry.
Estimating the proportion of bronchial epithelial cells per sputum sample
For each sample, 1000 cells were counted per slide. The percentage of 
bronchial epithelial cells for that sample was then estimated from this total
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count. All samples (i.e. cancer, high risk and healthy control) were assessed for 
the presence of bronchial epithelial cells but for analysis purposes, each group 
were represented by randomly selected cases. There were 40 selected cases 
from the cancer group and healthy control group and 36 high-risk cases. These 
were further divided into induced sputum and non-induced cases. The scores 
were recorded and comparisons were made between groups for mean counts 
using the Mann-Whitney U test.
Sputum analysis with FTIR
Samples were spotted on to 96 ‘well’ re-usable silicon sample carrier plates 
(LNC Technology Ltd., Ystrad Mynoch, Hengoed, UK). The silicon plates were 
cleaned in warm 0.5% SDS, rinsed with distilled water, soaked overnight in 5 M 
nitric acid, rinsed again with distilled water and air-dried. The sputum samples 
(after being thawed for 12-24 hrs) were plated randomly across a plate, 
permitting possible variations within or between plates to be taken into account 
during analysis. The loaded sample plates were oven dried at 50°C for 30 
minutes (Sanyo Gallenkamp pic., Loughborough, UK) in order to remove 
extraneous moisture prior to FTIR analysis. Prepared plates were allowed to 
cool and then inserted onto the motorised stage of the diffuse reflectance 
absorbance-scanning accessory, connected to the FTIR spectrometer. We 
used the VERTEX 70 spectrometer (Bruker Optics Ltd, Banner Lane, Coventry, 
UK), equipped with a mercury-cadmium-telluride (MCT) detector cooled with 
liquid nitrogen where the spectra were obtained in reflectance mode. In order to 
minimise carbon dioxide (CO2) and water vapour interference peaks in the mid- 
infrared region of collected spectra, the sampling compartments and 
microscope stage were purged with dry CO2 free air produced from a Peak 
Scientific compressor (Peak Scientific Ltd. Paisley, UK). The spectrum for each 
sample contained 1763 data points, ranging from 4000 to 600 cm-1 
wavenumbers. Each spectrum represented the average of 256 scans which 
improved the signal to noise ratio. The FTIR process took approximately 2 
hours.
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Sputum processing for immunohistochemistry
The preparation of cell pellets was as described above. After a portion of the 
individual cell pellets was used for FTIR, the remaining sample was prepared 
for immunohistochemistry.
Preparation of sputum cells for immunohistochemistry
Whilst preparing the sputum cells for cell block, they had to be formed into a 
clot using plasma and thrombin. Plasma was made up by adding 1ml of distilled 
water to the plasma powder (Dade Ci-trol 1, Dade Behring, Marburg, Germany) 
and allowing the solution to tilt for 15 minutes. The thrombin (Dade Behring, 
Marburg, Germany) was made up by adding 5ml of distilled water to the 
thrombin powder, gently swirling the solution until it had completely dissolved. 
To the centrifuged cell pellet 0.25ml plasma was added and to this a further 
0.5ml of thrombin was added. A clot was formed within seconds and this was 
then used to make a paraffin cell block.
Cell pellets reserved for immunohistochemical analysis were fixed in 10% 
buffered formal saline for 1 to 2 hours, embedded in paraffin and 3-4 pm thick 
sections prepared on positively charged slides before immunohistochemical 
studies. The sections were put directly on Benchmark XT which used EZ prep 
to de-wax the slides. The tissue sections were incubated with p63 antibody 
(1:50 dilution, Menarini, Florence, Italy); EGFR antibody kit (Ventana Biotek 
Solutions, Tucson, Arizona, USA); p16 (pre-diluted, mtm labs, Heidelberg, 
Germany); p53 (1:50 dilution, Novocastra Laboratories Ltd, Newcastle upon 
Tyne, UK) or cyclin D1 (1:100 dilution, Labvision, Newmarket, Suffolk, UK) at a 
concentration of 4pg/slide. For antigen retrieval, the slides were incubated in 
CC1 buffer (Ventana Biotek Solutions, Tucson, Arizona, USA) for an hour on 
heated plates at 100°C on a Benchmark XT processor. Primary antibody 
incubation ranged from 32 to 40 minutes (depending on the antibody) at dilution 
1:100 at 37°C. Positive immunostaining was detected through interaction of 
Avidin Biotin Complex (ABC) with biotin conjugated secondary antibody using a 
Ventana I View DAB detection kit (Ventana Biotek Solutions, Tucson, Arizona,
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USA). The ABC method is a widely used technique for immunohistochemical 
staining. Avidin, a large glycoprotein, can be labelled with peroxidase or 
fluorescein and has a very high affinity for biotin. Biotin, a low molecular weight 
vitamin, can be conjugated to a variety of biological molecules such as 
antibodies. [264] The slides were subsequently counter stained with 
haematoxylin, dehydrated, cleared and mounted in DPX mountant to be 
examined under light microscopy. Each antibody required a control: p16 -  
cervix; EGFR -  skin; p53 -  breast; p63 -  skin; cyclin D1 -  mantle cell 
lymphoma. A negative (no antibody) control section of sputum cells was also 
used.
Sputum analysis with immunohistochemistry
We used a standard immunohistochemical scoring system (IHC). [265, 266] 
Immunohistochemical sections were analysed by myself and Mrs Christine 
Davies (an experienced cytological analyst) using a multi-headed microscope 
(Olympus BX51 at x 20 magnification and Olympus WHN 10 x 22 eyepiece). 
Both assessors were blinded to the patient’s diagnosis, demographics, and any 
other clinical metadata at the time of assessing the slides, using only a unique 
study identifier number. After processing the 99 samples for FTIR, there were 
only 83 samples with enough of a cell pellet left for IHC. The first 66 sputa were 
assessed together with a consensus to allow myself to be trained to an 
adequate level before we assessed the remaining 17 samples individually. We 
applied scoring systems based on techniques established by others. [265, 266] 
The scoring system used varied depending on the antibody. EGFR is a cell 
membrane antigen, whereas p16, p53, p63 and cyclin D1 are nuclear antigens. 
Figure 6.3 shows the IHC scoring systems looking at cell positivity.
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Nuclear Antigens (p16, p53, p63, cyclin D1)
0 = less than 5% of tumour cells staining;
1 = 5-50% of tumour cells staining;
2 = more than 50% of tumour cells staining;
5 = uninterpretable.
Cell Membrane Antigens (EGFR)
0 score = No staining observed, or membrane staining in 
< 10% neoplastic cells. Negative.
1 score = Weak complete and/or incomplete membrane staining 
in > 10% neoplastic cells. Positive.
2 score = Moderate complete and/or incomplete membrane 
staining in > 10% neoplastic cells. Positive.
3 score = Strong complete and/or incomplete membrane 
staining in >10% neoplastic cells. Positive
Figure 6.3: IHC scoring system for both nuclear and cell membrane antigens for 
biological screening for lung cancer with sputum [265, 266]
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c) STATISTICS
FTIR analysis of sputum
Analysis of the demographic data was performed using the Statistical Package 
for Social Sciences (SPSS) version 13.0 (© 2000, The Apache Software 
Foundation, Chicago, Illinois). [267] Data was assessed for normality using the 
Shapiro Wilk and Kolmogorov-Smirnov tests. If there was a discrepancy 
between the two tests then if the sample size was < 50, the result of the 
Shapiro Wilk test was used, and if > 50 samples, Kolmogorov-Smirnov was 
used. Numerical data (e.g. age of subject) that were normally distributed were 
compared using the non-paired Student’s t-test, or if there were more than two 
variables, the analysis of variance (ANOVA) was performed. If the variables 
were not normally distributed then they were compared using the non- 
parametric Mann-Whitney U test. Analysis of categorical data, such as smoking 
status, was performed using Chi-squared.
All FTIR statistical analysis was performed using the R (CRAN) version 8.1 
statistical analysis and programming environment (The R Foundation for 
Statistical computing). [268] FTIR data distributions were assessed for 
normality using the Shapiro Wilk Test. The FTIR spectra were then compared 
against each other using PCA as described in Chapter 4.
FTIR spectra analysis
The raw FTIR spectra initially underwent a 3 stage process:
i) Normalisation.
The various sputa contained a different number of bronchial cells in comparison 
to each other, which may or may not be proven to be statistically significant. As 
a result of this, spectra produced may have been similar with regards to peaks, 
but variable with regard to absorbance. To standardise this, the greatest peak 
on each spectra is given the value 1. The height of the 2nd highest peak is a 
proportion of 1. For example, if the 2nd highest peak was at half the absorbance
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of the highest peak then it has the value 0.5. The y-axis then runs from 0 to 1. 
All the spectra thus were normalised to a similar scale.
ii) Baseline correction.
Many of the spectra may have a sloping baseline. The most important reason 
for the sloping baseline is the formation of a film over the samples, which 
results in scattering of IR light. A two-point baseline correction was applied 
which is a standard procedure. This involves two points of the spectral baseline 
being selected and a straight line drawn between the two points. The spectra 
was then shifted to nullify the slope. We took the first point at wavenumber 
1800 cm-1 and the second point was the final wavenumber, as this was within 
the fingerprint region of interest.
iii) 2nd derivative
The curves produced then underwent a two-step process to develop a 2nd 
derivative spectra. The usually jagged peaks were smoothed out in the first 
step, and then the 2nd derivative spectra were produced where not only the 
height of the peaks is relevant but also the gradient leading up to and away 
from the peak too. This ensured that “peaks” which were not obviously visible 
by looking at 1st derivative spectra were not omitted from analysis. These peaks 
may or may not have been important. Savitzky and Golay described this 
technique in 1964. [269]
Hierarchical Cluster Analysis (HCA)
HCA is a multivariate technique where a set of variables (in this study it will be 
the spectra from each of the cases) is grouped together in clusters depending 
on how similar the cases are. It is developed in a tree-building technique 
starting at the bottom where all cases are independent. As we take the first step 
up the tree (dendrogram), the cases with the highest similarity are linked 
together by a single-linkage. The next cases of highest similarity are then linked 
and so on. Once the tree is fully built all the cases will be linked, however, the 
links at the top of the tree represent the least similar cases (variables) of the 
whole patient sample. HCA therefore gives an immediate idea of how groups of
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cases cluster together according to similarities. Thus, with FTIR spectra, those 
with similar metabolic profiles should cluster together.
Selection of significant wavenumbers
Differences between median absorbances of pairs of wavenumbers were then 
evaluated using the Mann-Whitney U Test. Initial analysis was between the 
cancer and healthy control groups. When applying multiple statistical tests 
simultaneously there is an increasing risk of generating a higher rate of false 
positive results by falsely rejecting the null hypothesis (multiplicity problem). We 
therefore had to address this issue by applying a correction to procedure to 
adjust significance levels (i.e. p values) to minimize the risk of generating false 
positives. A simple procedure was to apply a Bonferroni correction where the p 
value (in this case 0.05) was divided by the number of tests (n) being applied 
(in this case 1763). [270] The problem with the Bonferroni correction is that it is 
too conservative in trying to prevent false positive results, increasing the risk of 
false negatives, so a more robust procedure was called for. A popular variant of 
the Bonferroni correction is the Holm’s sequential Bonferroni correction. [271] 
This procedure ranks the significant p values from the most significant to least 
significant. It then divides the level of significance p value (0.05) by n and then 
sequentially works through the ranked list dividing the p value (0.05) by n -  the 
rank number, to give a new p value. If the old p value < new p value then it kept 
its significance. If the old p value > new p value then it was rejected.
To determine the most optimal wavenumber pair that would discriminate 
between cancer and healthy controls, evaluation was performed using logistical 
regression of each wavenumber pair. A pair of wavenumbers that generated 
the highest accuracy were those that, after being incorporated into a predictive 
model, yielded the lowest rate of false positives (specificity) and false negatives 
(sensitivity). To determine the most optimal wavenumber pair, all pairwise 
combinations of wavenumbers were sequentially evaluated using the R 
statistical package. For each wavenumber pair, a linear model was generated 
that separated cancer and healthy control cases, according to their absorbance 
values. The discriminating line was positioned so that it separates cancer and
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healthy control cases as best it could whilst minimizing both false positives and 
negatives.
Cross-validation with leave-one-out method
Once the model was generated using a combination of wavenumbers, it was 
cross-validated using the leave-one-out method. Using this method, a case was 
taken out of the model and the sensitivity was retested. Subsequently, that 
case was reinstated and the next case was withdrawn and the sensitivity 
retested. This was continued until each case had been “left out”. The results of 
the sensitivities were then plotted on a histogram and in order for the model to 
be robust, the sensitivities need to have been consistently maintained with very 
little spread.
Predictive model equation
Once the model had been developed, the third cohort (high-risk group) was 
then applied to this model using the equation:
z = (coefl x value for wavenumber 1) + (coef2 x value for wavenumber 2) + 
intercept.
A further equation was then applied (logit function): 
f(z) = 1/(1+e'z)
where f(z) is the probability of a particular outcome. The output is between 0 
and 1 .Those with an output > 0.5 were predicted as cancer. Those with an 
output < 0.5 were predicted as not cancer.
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IHC analysis of sputum
All statistical analysis was performed using SPSS for Windows and the R 
statistical analysis and programming environment. Sociodemographic data was 
assessed for normality using Shapiro Wilk / Kolmogorov-Smirnov tests and 
then for normally distributed data, the non-paired Student’s t-test was 
performed, and for non-parametric data, Mann-Whitney U Test. Categorical 
data was assessed by Chi-squared. This allowed a comparison of the cohorts 
baseline characteristics. As the immunostained slides were scored 
independently by two assessors, the Cohan kappa data test was performed to 
analyse concordance between the two sets of scores. [272]
Mann-Whitney U Test was used to look for differences in number of positive 
cells between the individual antibodies between the cancer and high-risk group. 
The sensitivity and specificity for each antibody was then calculated. HCA was 
performed to see if any clusters emerged suggesting similarities in cases based 
on the IHC panel of 5 antibodies.
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Chapter 7. Biological screening for lung cancer 
with exhaled breath
Background
We obtained approval from the Local Research and Ethics Committee (LREC), 
(08/WMW01/21), and Hywel Dda Trust Research and Development Unit in 
March 2008. Site-specific approval in Swansea was obtained as the study 
progressed. Recruitment took place between 2008 and 2009 across 2 
hospitals, Prince Philip Hospital (Llanelli) and Morriston Hospital (Swansea). All 
sample processing took place at The Welsh Centre of Printing and Coating, 
Swansea University and statistical analysis at The Institute of Life Sciences, 
Swansea University and Lampeter University.
MATERIALS AND METHODS
a) PATIENTS
We approached those patients who were newly clinically diagnosed with lung 
cancer. They were recruited within the hospital after they presented to either 
the lung cancer or other respiratory clinics or from the acute medical intake.
The majority (n=35) had histologically confirmed evidence of lung cancer, and a 
small number were diagnosed based on their clinical presentation and 
radiology results. The exclusion criteria were those whom were unable to give 
consent, those under the age of 18 years old, and those unable to carry out the 
breath tests correctly (see Figure 7.1). All were given a PIS and at least 24 
hours to consider whether to take part in the study (See Appendix 6). Following 
written informed consent, physiological and sociodemographic data including 
lung cancer subtype, cancer staging, age, sex, FEVi, past medical history 
(including previous cancer), smoking status, smoking history and date of 
diagnosis were recorded on a study specific form (See Appendix 7). Three 
consent forms were signed, one given to the patient, one for the medical notes
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and one for the research master file (Appendix 8). Their GP was also informed 
(See Appendix 9).
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Patient flow Chart
Assessed in Respiratory Clinic or as In-patient
High enough suspicion of lung cancer to warrant further investigation
1
Initial approach for enrolment and Information Sheet Given
Patient is confirmed as having Lung Cancer (n=57) 
Informed consent obtained
Yes (n=51) No (n=6) 
(standard care)
CO breath test 
VOC breath test x 3 
Ambient air sample
Standard 
clinical 
follow up
Standard 
clinical 
follow up
Figure 7.1: Patient flow chart for biological screening for lung cancer with 
exhaled breath
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Our control group consisted of ‘healthy’ subjects who had no pre-existing lung 
disease according to our simple screening questionnaire as detailed in Figure 
7.2.
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Do you smoke?
How many years have you smoked for and how many per day?
Have you lost weight recently (unintentionally)?
Are you troubled by any of the following symptoms at the moment?
-cold or flu 
-chest pain
-wheeze (including at night)
-cough
-increased sputum or spit production 
-breathlessness
-do you take any inhalers or other medications for your chest
Figure 7.2: Screening questions to establish ‘healthy’ status of Controls for 
biological screening for lung cancer with sputum exhaled breath
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Controls were excluded If they had a known diagnosis or symptoms of 
underlying lung disease or current chest infection. Smokers and non-smokers 
were both included. The potential controls were given a Healthy Controls 
Information Sheet (See Appendix 10) and given at least 24 hours to consider 
their participation. If they agreed to be involved then formal consent was 
obtained and a record of age, sex and smoking status/history was recorded.
b) PROCEDURE
Sample Collection
When collecting the breath samples, all participants were fasted for at least 4 
hours. Although there was no clear guidance in the literature over fasting, it was 
felt that eating certain food or drinking certain beverages might alter the VOC 
components of the breath. Previous studies measuring VOCs fasted the 
patients overnight and performed the breath tests before bronchoscopy. [160, 
161] We felt that 4 hours was a reasonable length of time to be fasted for this 
group of patients. The majority of our patients were sampled immediately prior 
to bronchoscopy but the controls and those who provided breath samples from 
wards or their houses were also fasted.
All subjects were rested in a room with windows and doors shut for 20 minutes 
pre breath test, as there is evidence that acute aerobic and anaerobic exercise 
can increase the oxidative stress within the body. [273, 274] We felt that 20 
minutes provided enough time for the individual to fully recover from any 
exertion and for them to return back to their resting heart and respiratory rate.
We used a Bio-VOC® breath sampler (Markes International Limited, Llantrisant, 
Wales, UK), (see Figure 7.3)
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Figure 7.3: Bio-VOC® breath sampler
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The Bio-VOC® harnesses the fact that the concentration of VOCs in the blood is 
in equilibrium with the concentration in the air in the alveolar portion of the 
lungs. This assumes that free exchange of chemicals can occur through the 
thin alveolar wall and capillary blood vessel walls and subject’s alveolar (end- 
tidal) VOC concentrations are proportional to those in their blood.
Before using the Bio-VOC® sampler the container was cleansed by repeatedly 
pumping air in and out with the plunger, 10 times, to ensure any previous 
patients VOCs had been removed. When using the Bio-VOC® breath sampler, 
the subject was asked to take a deep breath in and then exhale slowly into the 
sampler via a disposable mouth piece until full expiration was completed (a 
slow vital capacity breath). An individual exhaling fully can usually expel over 4 
litres (L) of air, although this may be reduced in patients with lung disease. 
2000ml of this air comes from the alveolar component of the breath and it is this 
later air that is the most important to trap. The sampler holds 129ml of air, so 
typically 1L of alveolar air needs to pass through the sampler to ensure the 
presence of undiluted alveolar air.
Once the air was trapped, the plunger replaced the mouthpiece again and the 
air pushed into a 2-bedded thermal desorption tube (Markes International 
Limited, Llantrisant, Wales, UK) as demonstrated in Figures 7.4 and 7.5.
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Figure 7.4: Pushing the trapped alveolar air with 
the plunger into the 2-bedded thermal desorption 
tube
mem
Figure 7.5: The 2-bedded thermal desorption tubes
Figure 7.6: Screwing the brass caps onto the sorbent tubes
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Once the trapped alveolar air was pushed into the desorption tube, an airtight 
2-piece, brass, % inch screw cap was fitted to each end to prevent gases 
entering or leaving the tube, and these caps were tightened with a spanner 
(Figure 7.6). These types of seals have been evaluated in several studies and 
have been demonstrated to ensure minimal ingress of external artefacts and 
minimal loss of the sample over a 27 month period. [275-277] The thermal 
desorption tube contained two graphitized carbon black sorbents (Carbograph 
1TD and Carbopack X) with a total sorbent mass approximately 470mg which 
absorbed the volatile compounds with the more volatile being trapped first. 
Each tube was preconditioned by flowing helium through at 75 ml/min at 320°C 
to ensure there were no residual VOCs within them. Each tube had a unique 
number that was recorded on the participant’s data sheet. The procedure was 
repeated two further times so that we had 3 alveolar breath samples per 
patient. (Following external review on early pilot data, we amended our protocol 
and collected the patient samples in triplicate after the first 16 patients). Each 
tube number was recorded on the patient data sheet in the order in which they 
were taken. The tubes were stored in lined steel cans in between desorption 
stages to reduce contamination.
An ambient air sample was taken each time a new set of patient samples was 
taken. The eventual readings of ambient air sample’s VOCs would be 
subtracted from the subject’s sample to give the true proportion of VOCs from 
the subject’s body to allow for the changing levels of VOCs from day to day 
within the same environment. For example, within a bronchoscopy suite, which 
is in close proximity to operating theatres and an intensive care unit, there is 
likely to be an increased background concentration of anaesthetic gases.
Within Outpatient departments, smokers may be walking through the area even 
if the subject is a non-smoker. Thus background changes in VOCs as a 
confounder is reduced as much as possible.
After the VOCs had been sampled, the patient’s current smoking status and 
number of cigarettes currently smoked per day was recorded. Smoking status 
was validated using a CO monitor (Bedfont-Micro Smokerlyzer ®) using the 
technique described in Chapter 6.
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Processing the samples
The samples were analysed using GC-MS. In this method, as the sample gets 
heated up, the more volatile gases are detected first. Analysis of the gas is then 
performed by mass spectrometry. The schematic flow chart is illustrated in 
Figure 7.7, with the actual GC-MS machine used illustrated in Figure 7.8.
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Sample
injector
Aa_
Flow controller
Column oven
Figure 7.7: Schematic of components of GC-MS (image taken from 
www.wikibooks.org)
Figure 7.8: Actual GC-MS used for sample processing in Swansea University 
(Markes International, Llantrisant, Wales)
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Batches of tubes were loaded into an Ultra unit (Markes International, 
Llantrisant, Wales) for automated processing via a Unity thermal desorption unit 
(Markes International, Llantrisant, Wales) and fed with inert helium at 10 psi 
which was used to desorb the tubes in a 30 ml/min stream of inert helium at 
300°C for 5 minutes. The flow was driven onto a cold trap (U-T11GPC, general 
purpose graphitized carbon C4/5-C30/32) set at -10°C. The trap was then 
desorbed at 300°C for 3 minutes. To allow sufficient flow through the trap, 5ml 
of the sample was vented and the remainder injected onto an Agilent 
Technologies 6890N gas chromatograph. The VOCs were then separated 
using a capillary column 30m x 0.25mm id coated with a film thickness of 
0.25um. The column temperature was initially set at 40°C and then increased to 
200°C at a rate of 5°C/min.
As the volatile compounds are separated from the sample (the more volatile 
being separated first) they undergo electronic ionization which leaves the 
compound positively charged. When a gas undergoes electronic ionization, it is 
bombarded with electrons resulting in the gas molecule becoming a positive 
ion. [278] The following describes the electron ionization process. [279] The 
VOC is represented by M and electrons by e.
M + e —► M* + 2e
Passing through a magnet, the compound is then deflected, with the degree of 
deflection being influenced by the mass-to-charge ratio of the ionized 
compound. [280] Figure 7.9 is a schematic of a simple mass spectrometer.
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DETECTION
Faraday
ool actofB
lten4S<
Magnet
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I  ION SOURCE
I  Beam focussing
3Sc«— ton accalaralor 
Electron trap 
Ion rtpeier 
\  Gas Inflow (flora behind)
Ionizing Iflament
Figure 7.9: Schematic of simple mass spectrometer. (Image taken from 
www.wikipedia.org)
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Mass spectral data were obtained in the SCAN mode range between 40 - 550 
amu (atomic mass units). The 40 amu cut-off was used to eliminate water, air 
etc from the spectra. Data is outputted as a chromatogram, a plot of abundance 
against retention time. Automated peak detection was used to calculate peak 
area (area under the curve) and retention time for each compound, with the 
same peak integration parameters used for all samples using an automated 
library search report by Chemstation (©Agilent Technologies, 1999). The area 
under the curve (AUC) in the retention time/abundance chromatogram is 
analogous to the amount of a VOC for a particular sample and the retention 
time (RT) is the time at which the VOC exits the column and is detected. This 
also aids its identity as the same compound occurring in different samples 
should have the same retention time if settings are unchanged. The National 
Institute of Standards and Technology (NIST) 98 mass spectral library (Version 
1.7a, build 07 /18 / 2000 Distributed by the Standard Reference Data Program 
of the National Institute of Standards and Technology © 1997-1998) was used 
to identify the compounds using the spectra obtained at the apex of each peak 
and utilising probability based matching (PBM). [281] Each match was also 
assigned a quality rating based (from 1 to 100) on how well it matched the 
library. Extensive manual peak identification was also performed, within the 
NIST program, to check the validity of the automated matches. Automated 
matches are tentative and should ideally be confirmed by comparing retention 
times and mass spectra of pure chemicals injected directly into a sorbent tube.
Each tube was run twice with the first run used for analysis and the second 
analysed to ensure that there was no carry-over of volatiles onto subsequent 
tubes and to check for VOCs inherent in the system such as siloxanes from the 
column. After each set of tubes was desorbed an additional tube conditioning 
stage was used with 75ml/min helium at 320°C to ensure complete removal of 
any residual VOCs.
In order to monitor system performance over the duration of the experimental 
program, a solution of toluene in methanol (10pL per 100ml of methanol) was 
directly injected (in varying quantities) into sorbent tube with a stream of helium 
passed over the tube for 2 minutes. The tube was then desorbed and analysed
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using the same methodology as the sample testing. There was no drift in 
detected levels over time.
c) STATISTICS
Sociodemographic data was analysed using the Statistical Package for Social 
Sciences (SPSS) version 13.0 (© 2000, The Apache Software Foundation, 
Chicago, Illinois). Mann-Whitney U Test, non-paired Student’s t-test and Chi- 
squared were all used depending on the data distribution. Graphs of AUC 
against RT, polynomial equations and compound-by-compound analysis of 
VOCs were performed using Microsoft Excel for Windows, version 2003 (© 
1985-2003 Microsoft corporation). [282]
Assessing clusters of VOCs
All the cancer and control samples were analysed for VOCs and all VOCs that 
occurred greater than 5 times overall were deemed valid. This was an arbitrary 
figure chosen as it was felt by our VOC lead technician (personal 
communication with Dr Chris Phillips, 2010), that those VOCs occurring less 
than 5 times were generally low quality matches and were unlikely to be 
relevant. We plotted graphs of AUC against RT, in order to identify visually any 
clusters of VOCs. As the patterns obtained clearly did not follow a linear or 
exponential relationship, we applied polynomial equations to develop 
mathematical curves that best separated lung cancer cases from controls. 
These equations represent the closest mathematical relationship that could be 
established between AUC and RT for lung cancer cases, and separately for 
controls. The entire spectrum for each individual (lung cancer and controls) was 
tested against these equations, using the relative deviation from each of the 
curves to check a final discrimination method and we used multiregression 
analysis to develop the R squared value. The R squared value is an indicator of 
the correlation of all the points relating to the compounds with that polynomial 
expression. If the R squared value is close to 1 then the correlation (percentage 
variability) is statistically significant suggesting that the majority of points lie
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close to or on the polynomial trendline. The equation lines are also very useful 
to identify particular zones for discriminating cancer patients.
Identification of discriminating VOCs by compound-by-compound analysis
All of the cancer samples were initially included (i.e. VOCs from all 3 samples 
when the majority of patients were taken in triplicate and all of the single (very 
early) samples). However, it was felt appropriate to use only the first tube of the 
triplicates of the control samples (or the single sample if only one was 
collected) in this statistical analysis as there was no guidance in the literature 
with regards to which tubes to use and there was little variability across the 3 
control samples of VOCs. We could find no published guidelines or indeed any 
studies where samples were taken in triplicate. A comparison was then made 
between the total VOCs detected in the cancer group and those in the control 
group. Any VOCs that were present in any one of the samples for the individual 
cancer patients (for example one of the 3 triplicates, or in the single sample for 
the early subjects) and in none of the control subjects samples were deemed 
cancer-exclusive VOCs. These cancer-exclusive VOCs were then combined to 
see how many of the cancer patients could be correctly identified by the panel. 
The same approach was taken for those VOCs present in the control patients’ 
tube but not present in any of the cancer patients sets of samples, and these 
were control-exclusive VOCs. Again we assessed how many controls could be 
correctly classified using these VOCs.
We performed similar analysis of VOCs that were universally higher in (but not 
exclusive to) cancer patients and then for VOCs that were universally higher in 
(but not exclusive to) controls.
Analysing the ambient air samples
All the discriminatory VOCs were individually compared with their concurrent 
ambient air sample. If the VOCs consistently appeared in the ambient air 
samples then a subtraction process would take place, subtracting the ambient 
air VOCs from the alveolar air VOCs (alveolar-air gradient). [283]
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PART 3: RESULTS
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Chapter 8. Fourier Transform Infra-Red and
Immunohistochemical analysis of 
sputum in lung cancer
EVALUATION OF SPUTUM WITH FTIR 
Patient Demographics
120 patients referred for bronchoscopy with a possible diagnosis of lung cancer 
were approached. 8 refused consent and 2 were unable to give informed 
consent. Of the remaining 110 patients whom were recruited, we were only 
able to obtain sputum (either self-expectorated or suctioned) in 99.
63 of the 99 patients were given a formal diagnosis of lung cancer by the lung 
MDT.
The remaining 36 patients did not have any evidence of lung cancer on 1-year 
clinical and radiological follow up (diagnosis made: pneumonia, n=13; 
pulmonary fibrosis, n=5; old TB, n=3; Mycobacterium Avium Intracellulare 
(MAI), n=1; haemoptysis on background of COPD bronchiectasis / asthma, 
n=12 ; B-cell lymphoma, n=1; empyema, n=1).
93 people were approached to be healthy controls. 4 refused and 11 were not 
eligible after completing the screening questionnaire (symptoms suggestive of 
an underlying respiratory disease, n=3; pre-existing respiratory disease, n=5; 
symptoms consistent with current respiratory tract infection, n=3). 8 were 
unable to provide a sputum sample.
After analysis of the spectra, 9 of the cancer group, 16 of the healthy control 
and 12 of the high-risk spectra were excluded. This was because the initial part 
of the spectra was completely different (in fact inverted) from all other spectra 
suggesting a technical problem. The fingerprint region of the spectra we were 
to be interested in (wavenumbers 1800 -  900 cm'1) appeared consistent with all 
other tracings, however due to the inconsistent early component of the spectra
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they were excluded from further analysis to ensure the least confounders for 
the model. On further investigation it was identified that a film was on the 
processing tray where the cell pellets lay and probably affected the spectra 
detection.
Thus the 3 cohorts consisted of cancer subjects (n=54); high-risk subjects 
(n=24) and healthy controls (n=54). Table 8.1 compares the baseline 
sociodemographic characteristics of the 3 cohorts.
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Cancer 
group 
n = 54
High-risk 
group 
n = 24
Control 
group 
n = 54
p-value
Mean Age (yrs) 66.6 +/- 8.7 65.1 +/-13.6 51.1 +/-15.3 <0.001
% male 52 75 52 0.12
Smoking Status
Current 19 9 24
Former 28 15 1 <0.001“
Never 7 0 29
Median no. of
pack years 30 40 n/a
* * *
0.18
(IQR) (20 -  45) (22 -  50)
Mean predicted 0.48 (Cl
FEVi (%)“ “ 69.5 +/-17 65.8 +/- 20 n/a -6.8 to 14.1)
Table 8.1: Demographic of the cancer, high-risk and controls cohorts
*post-hoc tests show no significant difference between ages of cancer and 
high-risk group, but controls were significantly younger than both.
**calculated using chi-squared
***data not normally distributed, thus Mann-Whitney U test applied
****n=38 in cancer group and n=18 in high-risk group, 22 were not recorded 
across the two cohorts
n/a = not available as we did not have ethics to do spirometry and pack-year 
history on healthy controls
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The diagnosis of cancer was confirmed histologically in 46 cases and clinico- 
radiologically in 8. Of the 54 patients with a diagnosis of primary lung cancer 
(cancer group), 39 were NSCLC, 9 were small cell lung cancer, 5 were clinical 
diagnosis and 1 had carcinoid.
Table 8.2 has the histological breakdown of the cancers and Table 8.3 has the 
details of the cancer cohort. Tables 8.4 and 8.5 have the details of the high-risk 
and healthy control cohorts respectively.
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Lung Cancer Type Histologic Sub-Type Number
Non-small cell (NSCLC) Squamous Cell Carcinoma (SCC) 17
Adenocarcinoma 10
Large cell 2
Unknown subtype 9
Broncho-alveolar Cell 1
Small Cell (SCLC) 9
Lung -  clinical diagnosis 5
Carcinoid 1
Total 54
Table 8.2: Breakdown of histological subtypes within the cancer cohort
* This group were noted to have cells consistent with NSCLC but the 
pathologists was unable to identify the histological subtype
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Case
ID Age Sex
Smoking
Status
Smoking 
history 
pack years Previous Cancer? Final clinical diagnosis Final histology
LC04 67 M ex 30 No NSCLC Bronchoalveolar
LC06 77 M ex 15 No Lung -  clinical diagnosis Not known (NK)
LC07 61 M ex 30 No NSCLC SCC
LC08 60 M ex 20 No NSCLC SCC
LC10 58 F current 48 No NSCLC Adenocarcinoma
LC11 81 M current 120 No NSCLC SCC
LC14 83 F ex 25 No Lung -  clinical diagnosis NK
LC15 56 current 30 No NSCLC NK
LC16 55 F current 20 No NSCLC Adenocarcinoma
LC30 69 current 90 No NSCLC SCC
LC33 68 F ex 20 breast NSCLC SCC
LC36 70 F ex 12 No Lung -  clinical diagnosis NK
LC37 67 ex 10 No NSCLC Adenocarcinoma
LC42 69 F never 0 No carcinoma in lung Carcinoid
LC43 64 ex 25 No NSCLC NK
LC44 58 current 45 No Small Cell small cell
LC49 66 F ex 45 breast NSCLC SCC
LC50 68 ex 40 No Small Cell small cell
LC54 77 F ex 60 No NSCLC SCC
LC56 67 current 77 Dukes A colon Small Cell small cell
LC58 87 F never 0 colon/ovarian NSCLC Adenocarcinoma
LC61 52 current 40 No Small Cell small cell
LC62 50 F ex 36 No NSCLC Adenocarcinoma
LC64 71 F ex 30 skin Lung -  clinical diagnosis NK
LC68 72 F current 60 colon NSCLC Adenocarcinoma
LC69 48 F never 0 No NSCLC Large cell
LC70 62 ex 100 No NSCLC NK
LC71 77 F ex 7 No NSCLC Adenocarcinoma
LC72 69 current 25 No NSCLC SCC
LC75 81 F current 30 No Lung -  clinical diagnosis NK
LC76 77 M ex 25 No NSCLC SCC
LC77 69 M current 40 No Small Cell small cell
LC78 81 M ex 60 larynx; bladder NSCLC SCC
LC79 62 M current 47 No NSCLC SCC
LC80 66 M ex 20 No Small Cell small cell
LC81 66 F never 0 No NSCLC Large cell
LC82 71 M ex 50 No NSCLC SCC
LC85 54 M never 0 No NSCLC Adenocarcinoma
LC86 60 M ex 30 No Small Cell small cell
LC87 68 F ex 30 No NSCLC NK
LC89 60 F ex 40 No NSCLC Adenocarcinoma
LC91 62 F current 40 breast NSCLC NK
LC92 81 F current 30 No NSCLC SCC
LC93 63 F ex 40 No NSCLC NK
LC94 65 F never 0 lung NSCLC SCC
LC95 74 M ex 50 No NSCLC SCC
LC97 62 F current 45 No NSCLC NK
LC101 54 M ex 40 No NSCLC NK
LC103 69 M current 40 No NSCLC NK
LC105 57 F never 0 No Small Cell small cell
LC107 68 M current 50 No Small Cell small cell
LC108 62 F current 30 No NSCLC SCC
LC109 64 F ex 20 No NSCLC Adenocarcinoma
LC110 69 M ex 20 No NSCLC SCC
Table 8.3: Details of the cancer cohort
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Case ID Age Sex Smoking Status
Smoking History pack 
years
Previous
Cancer?
LC03 78 M ex 10 No
LC19 65 M ex 100 No
LC34 84 M ex 20 No
LC40 59 M ex 40 No
LC48 59 M current 20 No
LC52 42 F current 20 No
LC53 73 M ex 110 prostate
LC55 69 M current 53 No
LC57 73 F current 25 No
LC59 48 M current 30 No
LC60 69 F ex 50 No
LC65 60 M current 40 No
LC67 78 M ex 45 No
LC73 48 M ex 20 No
LC74 58 M ex 50 No
LC83 88 M current 21 No
LC84 61 M ex 35 No
LC88 82 M ex 45 No
LC90 44 M ex 33 No
LC96 70 F current 25 No
LC98 84 M ex 60 No
LC100 43 F current 40 No
LC102 64 F ex 40 No
LC106 64 M ex 120 No
Table 8.4: Details of the high-risk cohort
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Smoked period longer 10
Control ID Age Sex Smoker? yrs
SC01 58 F N N
SC04 24 M N N
SC05 53 M Y Y
SC06 79 M Y Y
SC07 39 M N N
SC08 61 M Y N
SC09 59 M Y N
SC10 67 F N N
SC12 35 F Y Y
SC13 55 M N N
SC14 47 M N N
SC15 45 F Y N
SC16 76 F N N
SC17 55 M Y N
SC18 44 M N N
SC19 68 M Y N
SC20 30 M N N
SC21 58 M N N
SC22 43 M Y Y
SC23 55 M Y Y
SC24 49 M N Y
SC25 26 F Y N
SC26 66 F N N
SC27 43 F Y Y
SC28 32 M N N
SC29 50 M Y Y
SC30 38 M N N
SC32 83 F Y Y
SC34 79 F N N
SC35 75 F Y Y
SC36 66 F N N
SC37 56 F Y Y
SC39 30 F Y N
SC41 50 F N N
SC42 38 M N N
SC43 61 F Y Y
SC44 39 F N N
SC45 41 M Y Y
SC46 27 M N N
SC47 59 M Y Y
SC48 41 F N N
SC49 72 F Y Y
SC50 43 F Y Y
SC51 35 F N N
SC52 26 F Y N
SC53 71 F N N
SC54 69 M Y Y
SC55 39 F N N
SC56 64 M N N
SC57 62 M Y Y
SC58 55 M N N
SC59 39 F N N
SC60 51 M Y Y
SC61 43 M N N
SC62 54 F N N
Table 8.5: Details of the healthy control cohort
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Estimating the proportion of bronchial epithelial cells per sputum sample
All samples, regardless of group, contained bronchial epithelial cells within the 
section. Although difficult to predict (given variation in cell pellet size), we 
estimated that the likely concentration of bronchial epithelial cells per sample 
would lie between 10,000 and 100,000.
As a quality control check, we counted 1000 total cells from sections created 
from randomly selected sputum sample pellets (40 lung cancer, 36 high risk 
and 40 healthy controls from the original 169 study participants). The proportion 
of bronchial epithelial cells for that sample was then estimated from this total 
count. The scores were recorded (Table 8.6) and comparisons were made 
between groups for mean counts (Table 8.7) using the Mann-Whitney U Test.
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Samples N Induced Mean % SE Range (%)
Cancer 20 Yes 3.8 1.0 2.1-8.4
20 No 3.6 0.9 3.0-7.6
High-risk 13 Yes 4.0 1.0 1.4-10.2
23 No 3.8 1.0 2.9-10.6
Control 40 No 3.3 1.1 0.8-8.2
Table 8.6: Mean counts for bronchial epithelial cells in groups: cancer, high-risk 
patients and healthy control
Group comparison p-value
cancer v. high-risk 0.5057
cancer v. healthy control 0.3547
high-risk v. healthy control 0.6395
cancer induced v. cancer non-induced 0.7704
non-cancer induced v. non-cancer non­
induced
0.9352
Table 8.7: Statistical comparison of groups for bronchial epithelial counts
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Table 8.7 shows that when all groups were compared there was no statistically 
significant difference in cell counts between any groups for mean cell count. 
Importantly, Table 8.7 also shows there was no significant difference within the 
cancer (or high-risk) groups when the sputum had been obtained by induction / 
endobronchial suction or just coughed up naturally (self-expectorated).
FTIR ANALYSIS OF SPUTUM
FTIR spectra were generated for all 63 cancer (54 histological and 9 clinical 
diagnosis), 36 high-risk and 70 healthy control cases. FTIR processing and 
analysis was repeated three times for each case as a measure of internal 
consistency. Spectra contained data for 1763 data points within the mid infrared 
wavenumber range 599.75 and 3997.7 cm'1 range. All spectra were 
standardised (sometimes referred to as normalised) by zero centering using the 
2264 cm'1 wavenumber as this always approximates 0 in absorbance in studies 
on human tissue. Certain spectra were excluded as described earlier, leaving 
54 cancer, 24 high-risk and 54 healthy control spectra.
Assessing the reproducibility of FTIR on sputum samples
All samples were processed in triplicate and spectra were assessed for 
similarity in pattern of wavenumber absorbance using principal component 
analysis (PCA). PCA allowed a visual inspection of the similarity of replicates 
on a case by case basis using a scatterplot of scores for each spectrum on the 
first two principal components. An example of such an analysis on 50 randomly 
selected triplicate spectra is shown in Figure 8.1.
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Figure 8.1: PCA of example set of triplicate FTIR spectra. Triplicates of 50 
samples are shown. For example, samples 17a, b and c from the same 
sputum, aggregate together
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Using this type of approach we observed that over all 507 FTIR runs, only 16 
samples showed a replicate that deviated in position from other replicates in a 
scatterplot. Even then, these samples showed close similarity by position for 
the remaining two replicates and deviations were not consistent over further 
runs. An example of such a deviation is shown in Figure 8.1 by the replicate 
44a which is observed in a different position to the other replicates 44b and 
44c. Using this approach we were able to establish that the overall 
reproducibility for FTIR in producing similar patterns for the same samples 
within the same run and between runs was at least 99%.
Analysis of FTIR spectra from cancer versus healthy control sputa
Representative raw FTIR spectra were selected for the 54 cancer and 54 
healthy sputum samples (Figure 8.2). The median absorbances for each 
wavenumber across the 3 cohorts based on the raw spectra shows potential 
wavenumbers with potential differences between the groups. (Figure 8.3)
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Figure 8.3 which represents the median absorbance values across the three 
groups show in particular how the healthy controls and cancer cases differ 
particularly in the regions: 1400 -  1060 cm'1; 1060 - 1025 cm'1 and 1400 -  
1670 cm'1. Our spectral images show that many cancer spectra differed from 
healthy control spectra at a number of wavelength ranges. More specific 
spectral differences for shorter ranges of wavenumbers can be identified using 
the 2nd derivative spectra represented by Figure 8.4. The wavenumbers below 
900 cm'1 usually display a degree of variability so are difficult to interpret.
Principal component analysis to determine how the 3 cohorts FTIR spectra 
cluster
Prior to determining which wavenumbers differed by absorbance between 
groups, an overall assessment of the similarity between all spectra, regardless 
of group, using PCA, was made. This gave an idea of how many groupings of 
similar spectra existed and whether there was a separation between cancer, 
healthy controls and high-risk for these groupings. In this analysis, the first 
three principal components explained more than 90% of the variation in the 
data and were thus retained for interpretation. Loading scores of all spectra in 
the 3 cohorts are shown on the first 2 principal components in Figure 8.5 and 
8.6. The third principal component is shown in Figure 8.7.
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Figure 8.5: PCA of cancer (c), healthy control (s) and high-risk (h) spectra. The 
image shows a 2D scatterplot of the first 2 principals. Two arms representing 
the controls and cancers can be identified
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Figure 8.6: The PCA scatterplot represented in figure 8.5 but the cases are 
labelled with their study numbers for identification.
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Figure 8.7: 1st and 3rd principal components showing separation of controls (s) 
from the cancer (c) and high-risk (h). The controls are seen to bunch closer 
together than the more widely spread cancer cohort.
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A pattern emerged between the cancer and healthy control cases within the 
scatterplot. The first and second components yield a pattern whereby the 
cancer and healthy control cases begin to separate in different directions away 
from a closely clustered group of spectra from both groups. There appear to be 
two ‘branches’ of spectra separating in different directions from a general group 
where one branch represents cancer spectra and the other healthy controls. 
Two cancers cases sit away from all other cases, LC33 and LC49. It emerges 
that these subjects both have a history of breast cancer.
HCA also shows 3 distinct clusters (see Figure 8.8). The 1st cluster seen at the 
top consists predominantly of cancer cases although there are also some high- 
risk cases included. The middle group consists almost entirely of controls, with 
occasional cancer cases in the cluster. The 3rd cluster (see at the bottom) is a 
heterogeneous group consisting of all the cohorts. The two cancer cases with a 
history of breast cancer group separately from the rest and are deemed very 
different as they are the last to be linked with the rest of the study cohort.
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Figure 8.8: HCA of the 3 cohorts, cancer (c), high-risk (h), controls (s). The 
controls are seen to group together, as do many of the cancer cases with a few 
of the high-risk also mixed in
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Although the PCA and HCA results gave an encouraging sign as to separation 
especially between cancer and healthy control spectra the findings were based 
on all wavenumbers and the next step was to determine which wavenumbers 
were significantly different between the cancer and control groups. In the initial 
analysis and modelling we used only the cancer and healthy control subjects as 
the high-risk may have underlying metabolic changes which could introduce 
confounders. The cancer and control groups represented the “cleanest” data.
Determination of discriminating wavenumbers between cancer and healthy 
controls
The initial step in analysis of individual wavenumbers was to determine the 
corresponding data distributions. Using the Shapiro Wilk test for normality, the 
distribution of the median absorbance values for every wavenumber was found 
to be non-normally distributed. Thus, differences within each wavenumber 
between cancer and healthy control groups were assessed using the non- 
parametric Mann-Whitney U Test using the median absorbance value for each 
wavenumber for the cancer and healthy control groups. There were 624 
significant wavenumbers (p=0.05) and after applying Holm’s sequential 
Bonferroni correction to the list, we generated a reduced list of 126 
wavenumbers. These wavenumbers and adjusted p values are shown in Table 
8.8.
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Wave
Number P-Value
Wave
Number P-Value
Wave
Number P-Value
Wave
Number P-Value
640.25 8.01E-05 875.52 8.7E-05 1569.8 9.51E-05 1068.4 9.9E-05
1031.7 8.03E-05 863.95 8.71E-05 1201.4 9.52E-05 960.38 9.92E-05
655.68 8.04E-05 1589.1 8.73E-05 1639.2 9.54E-05 860.1 9.94E-05
1392.4 8.05E-05 1151.3 8.74E-05 1307.5 9.56E-05 740.53 9.96E-05
1409.7 8.06E-05 877.45 8.76E-05 869.74 9.58E-05 910.24 9.98E-05
1413.6 8.08E-05 1332.6 8.77E-05 663.39 9.6E-05 842.74 0.0001
1411.6 8.09E-05 1575.6 8.79E-05 1400.1 9.62E-05 790.67 0.0001
1394.3 8.1E-05 1637.3 8.8E-05 692.32 9.63E-05
1049.1 8.12E-05 1635.3 8.82E-05 1147.4 9.65E-05
1045.2 8.13E-05 1386.6 8.83E-05 1064.5 9.67E-05
661.46 8.14E-05 879.38 8.85E-05 1571.7 9.69E-05
1390.4 8.16E-05 997.02 8.87E-05 1382.7 9.71E-05
1047.2 8.17E-05 1035.6 8.88E-05 1344.1 9.73E-05
1033.7 8.18E-05 644.11 8.9E-05 1012.4 9.75E-05
1407.8 8.2E-05 1027.9 8.91E-05 1556.3 9.77E-05
1051 8.21E-05 1429 8.93E-05 1419.4 9.78E-05
1018.2 8.22E-05 1022.1 8.94E-05 1417.4 9.8E-05
1396.2 8.24E-05 1421.3 8.96E-05 1199.5 9.82E-05
1020.2 8.25E-05 1205.3 8.98E-05 651.82 9.84E-05
1016.3 8.26E-05 1041.4 8.99E-05 1313.3 9.86E-05
1043.3 8.28E-05 912.16 9.01E-05 755.96 9.88E-05
642.18 8.29E-05 1153.2 9.03E-05 1068.4 6.734E-05
1004.7 8.31E-05 1633.4 9.04E-05 960.38 6.752E-05
659.54 8.32E-05 1311.4 9.06E-05 860.1 4.901E-05
1388.5 8.33E-05 865.88 9.07E-05 740.53 6.717E-05
1002.8 8.35E-05 1384.6 9.09E-05 910.24 6.787E-05
788.74 8.36E-05 1149.4 9.11E-05 842.74 4.697E-05
657.61 8.38E-05 784.89 9.12E-05 790.67 7.283E-05
1581.3 8.39E-05 862.02 9.14E-05 1569.8 3.201E-05
1398.1 8.4E-05 796.46 9.16E-05 1201.4 6.682E-05
1052.9 8.42E-05 1554.3 9.17E-05 1639.2 6.7E-05
786.81 8.43E-05 1203.4 9.19E-05 1307.5 4.911E-05
1000.9 8.45E-05 1209.1 9.21E-05 869.74 7.717E-05
1587.1 8.46E-05 881.31 9.23E-05 663.39 8.052E-05
1579.4 8.47E-05 653.75 9.24E-05 1400.1 7.242E-05
1577.5 8.49E-05 867.81 9.26E-05 692.32 6.648E-05
1006.7 8.5E-05 1309.4 9.28E-05 1147.4 6.665E-05
1585.2 8.52E-05 1591 9.29E-05 1064.5 1.547E-05
1583.3 8.53E-05 1573.6 9.31E-05 1571.7 6.805E-05
1207.2 8.55E-05 1334.5 9.33E-05 1382.7 7.263E-05
1014.4 8.56E-05 1631.5 9.35E-05 1344.1 1.548E-05
998.95 8.58E-05 995.09 9.36E-05 1012.4 1.549E-05
1405.9 8.59E-05 1155.2 9.38E-05 1556.3 8.077E-05
638.32 8.61E-05 1066.4 9.4E-05 1419.4 1.575E-05
1425.1 8.62E-05 1054.9 9.42E-05 1417.4 1.573E-05
1415.5 8.64E-05 1025.9 9.43E-05 1199.5 3.333E-05
1423.2 8.65E-05 914.09 9.45E-05 651.82 1.576E-05
1427.1 8.67E-05 798.38 9.47E-05 1313.3 1.546E-05
1029.8 8.68E-05 1346.1 9.49E-05 755.96 6.823E-05
Table 8.8:126 significant wavenumbers after Holm’s sequential Bonferroni p 
value correction (p<0.0001)
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significance (i.e. 1 = most significant wavenumber)
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Figure 8.9 shows the 3 main regions which are represented by significant 
wavenumbers. These involve 2 areas within 1400 -  1700 cm"1 (which 
represents proteins including amide I and amide II regions). The other region is 
from 1000 -  1080 cm"1 which includes the glycogen-rich and DNA / RNA 
regions (for example around 1080 cm"1 is the phosphodiester groups of nucleic 
acid). Lipids have typical absorbance values greater than 3000 cm'1. [194, 207, 
284, 285]
Determination of optimal pair of wavenumbers that discriminate between 
cancer and healthy controls.
The list of 126 wavenumbers was used to find a pair of wavenumbers that 
could discriminate between cancer and healthy controls with the highest 
accuracy.
Using logistical regression described in the statistical methods in Chapter 6, we 
determined that the most optimal discriminating pair of wavenumbers between 
cancer and healthy controls was 1031.7 cm"1 and 1409.7 cm"1. The 1031.7 cm"1 
wavenumber falls within a region assigned to C-0 stretching coupled with 
bending of C-OH groups of glycogen. The 1409.7 cm"1 wavenumber signifies a 
carboxylate (COO-) group typically found on amino acids (and thus protein).
The logistical regression model using 1031.7 cm"1 and 1409.7 cm'1 was plotted 
as in Figure 8.10. The cancer cases (circles) can be seen to be more widely 
scattered above the discriminating line and this may well represent biological 
differences. The controls (triangles) appear to be less scattered and more 
grouped together. The false positive (controls which appear on the cancer side) 
lie in close proximity to the discriminating line.
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Overall sensitivity and specificity was measured for the model based on the 
data used to generate the model (i.e. the training data set). Numbers of True 
Positives (TP), True Negatives (TN), False Positives (FP) and False Negatives 
(FN) are shown in Table 8.9. The sensitivity [TP/(TP+FN)] of the model was 
92.6% and the specificity [TN/(TN+FP)] was 90.7% when comparing lung 
cancer against healthy controls.
The strength of the model was assessed by cross-validation. The results of the 
leave-one-out cross validation are in Figure 8.11. The leave-one-out technique 
shows that the using this particular pair of wavenumbers continues to give a 
consistently high level of sensitivity, at close to 90% with little variation.
Predicted
Cancer Non-cancer
Actual Cancer 50 (TP) 4 (FN)
Non-cancer 5 (FP) 49 (TN)
Table 8.9: Calculating sensitivity / specificity for cancer and healthy control 
cases for our discriminatory model
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Figure 8.11: The leave-one-out cross validation of sensitivity
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Analysis of FTIR spectra of high-risk cohort using predictive model
Once the model had been developed using the wavenumbers 1031.7 cm-1 and 
1409.7 cm'1, we added the high-risk cases to it to assess how the model would 
predict their outcome based of their FTIR spectra using the equations:
z = (-2337.0649 x value for 1031.7 cm'1) + (4636.0538 x value for 1409.7 cm'1) 
-1.51444
then, probability of cancer = 1/(1 +e'z)
Values > 0.5 predict cancer;
Values < 0.5 predict no cancer.
There were 24 high-risk spectra included in the analysis and of those 17 (71%) 
would be predicted from the model to have ‘cancer’.
Of these 17 cases, 3 had pneumonia, 1 had pulmonary fibrosis, 1 had B-cell 
lymphoma, 1 had MAI, 2 had old TB and 3 of the others had a history of 
asthma. The sensitivity and specificity when comparing the high-risk and 
cancer groups with the developed model are 92.6% and 29.3% respectively 
(i.e. 71% predicted to have cancer).
Table 8.10 represents the data for ali study groups based on the discriminating 
model developed. The overall sensitivity and specificity of the model developed 
is 92.6% and 69% respectively.
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Predicted
Cancer Non-cancer
Actual Cancer 50 4
Non-cancer 22 56
Table 8.10 Calculating sensitivity / specificity for cancer versus non-cancer 
(combining high-risk and healthy controls as a single group) for discriminatory 
model
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EVALUATION OF SPUTUM WITH IMMUNOHISTOCHEMISTRY
Patient demographics
The patients consist of the same high-risk and cancer cohort described earlier 
in this chapter. Only 83 of the original 99 patients had enough of a sputum cell 
pellet to be used for IHC after the FTIR processing. Analysis was therefore 
limited to 51 in the lung cancer cohort and 32 in the high-risk cohort.
Of the 51 patients with lung cancer, 36 had NSCLC (16 squamous cell 
carcinoma, 11 adenocarcinoma, 3 large cell, 6 were of unknown subtype); 9 
had small cell lung cancer; 1 eventually was proved to have carcinoid and 5 
had a clinico-radiological diagnosis of lung cancer. The full demographic data of 
the groups are shown in Table 8.11.
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Cancer group 
n = 51
High-risk group 
n = 32
p-value
Mean Age (yrs) 66.8 +/- 8.6 62.0 +/-14.2 0.59 
Cl -0.19 to 9.8
% Male 51.0 71.9 0.06
Smoking Status
Current 18 12 0.60*
Former 25 18
Never 7 2
Unknown 1 0
Table 8.11: Demographics of cancer and high-risk groups that underwent 
sputum IHC analysis
* Chi-squared
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Analysis of IHC scoring of the biomarkers
The 5 antibodies that were used to stain the antigens were:
Cell membrane antigen -  EGFR 
Nuclear antigens -  cyclin D1; p16; p53; p63
Figures 8.12 and 8.13 represent the actual control and patient sample for cell 
membrane staining and Figures 8.14 and 8.15 represent nuclear staining with 
p63.
Mrs Christine Davies and I scored the first 66 slides (cases) together and then 
the last 17 slides independently. Statistically there was no difference in our 
scores using the Cohen kappa data test (Table 8.12).
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Figure 8.12: Control sample (skin) of EGFR (cell-membrane) staining
Figure 8.13: Sputum from one of our lung cancer patients staining
*
with EGFR
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Figure 8.14: Control sample (skin) immunostained with p63 (nuclear staining)
$  ■ '<■- . . X - ,
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Figure 8.15: Sputum from lung cancer patient stained with p63
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Antibody
Concordance between independent 
scorers assessed by Cohens kappa 
data test: p value
Cyclin D1 0.61
p53 0.54
EGFR 0.54
p16 0.63
p63 0.51
Table 8.12: Cohens kappa data test comparing the concordance in IHC scoring 
between the two independent scorers
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Table 8.13 shows there was no statistical difference between the two cohorts 
for any of the stains on sputum cells and the sensitivities of the antibodies was 
very low (i.e. only a small number of the cancer sputa stained positively).
Some of the sputum slides were deemed uninterpretable (n=16) due to a 
paucity of bronchial cells or the sample not being of good enough quality.
Importantly, the relatively low number of slides that had positive staining gives 
rise to the higher specificity (i.e. very few non-cancer cases stained positively) 
(Table 8.14).
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Antibody
Statistical 
difference in 
number of 
positive cells of 
antibody: p- 
value
Sensitivity
(%)
Specificity
(%)
Cyclin D1 0.58 7.8 93
P53 0.71 5.9 96.9
EGFR 0.06 35.3 87.5
P16 0.10 25.5 81.3
P63 0.93 17.6 78.1
Table 8.13: Differences between the cancer and high-risk cohort sputum 
staining for each antibody using Mann-Whitney U Test
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Antibody
Sensitivity
(%)
Specificity
(%)
Cyclin D1 9.8 93
P53 7.7 96
EGFR 41.9 85.7
P16 31.7 79.3
P63 23.1 72.0
Table 8.14: Sensitivity and specificity of antibodies in sputum of cancer and 
high-risk cohort (with the uninterpretable sputum slides removed from analysis)
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Figure 8.16: Hierarchal cluster analysis of the sputa based on IHC scores, 
in = non-cancer and c = cancer
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Cluster Dendrogram
The hierarchal cluster analysis (Figure 8.16) shows similar cases that group 
together with the largest cluster in the middle. These very ‘similar’ cases are 
clustered since there were a large number of slides with zero positively stained 
cells from both the cancer and high-risk cohorts. The other clusters are a 
mixture of both cohorts in the majority of cases, again showing that the 
antibodies have not been able to show much differentiation between the cancer 
and non-cancer groups.
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Chapter 9. Analysis of Volatile Organic Compounds
in exhaled breath in lung cancer
Patient Demographics
57 patients who had a provisional diagnosis of lung cancer were approached. 5 
patients refused participation, none (approached) were unable to give informed 
consent and one patient was unable to perform the test with adequate 
technique so was excluded. Of the 51 patients recruited into the study, 3 more 
were excluded; 1 patient was thought to have endobronchial disease 
(squamous dysplasia noted on biopsy) but subsequently had two normal 
bronchoscopies; 2 other patients had their histology (lymph node biopsies) re­
examined and it was felt that they had metastatic breast cancer rather than a 
primary lung cancer. 4 further patients were excluded from analysis as their 
final VOC profiles had less than 20 peaks, which was significantly less than the 
other subjects. The reasons for this are discussed below.
50 subjects were approached to be healthy controls. All agreed to be included 
in the study but 3 were excluded from analysis as their final VOC profiles again 
had less than 20 peaks.
A review of the 7 patients with less than 20 peaks on their VOC profile revealed 
their samples were all processed at the same time. On this occasion, the GC- 
MS had developed a pressure loss in the helium supply during the cold trap 
secondary desorption phase leading to a leak within the system.
The sociodemographic data comparison of the cancer cohort (n=44) and 
healthy controls (n=47) is shown in Table 9.1.
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Cancer 
n = 44
Healthy controls 
n = 47
p-value
Mean Age (yrs) 70.5 +/- 8.1 52.1 +/-11.6 < 0.001**
% Male 45.5 34 0.27
Smoking Status
Current 19 9
Former 22 14 <0.001*
Never 3 24
% smoked within
24 hours of 15 12 0.83*
sampling (eCO > 
10 ppm)
Table 9.1: Comparison of baseline demographic data of the cancer and healthy 
control cohorts.
** Data normally distributed. 95% Cl for difference 14.2 to 22.5 
* chi-squared
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Diagnosis of cancer was confirmed histo-cytologically in 35 cases and clinico- 
radiologically in 9. Of the 44 patients with a diagnosis of primary lung cancer 
(cancer group), 31 were NSCLC, 4 were small cell lung cancer and 9 were 
clinical diagnosis. Table 9.2 has the histological breakdown of the cancers. 
Table 9.3 has a summary of the characteristics of the cancer cohort, and Table 
9.4 of the healthy control group.
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Lung Cancer Type Histologic Sub-Type Number
Non-small cell (NSCLC) Squamous Cell Carcinoma (SCC) 10
Adenocarcinoma 6
Large cell 9
Unknown subtype 6
Small Cell (SCLC) 4
Lung -  clinical diagnosis 9
Total 44
Table 9.2: Breakdown of histological subtypes within the cancer cohort.
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Study
No. Sex Age Hx of Cancer*
Smoking Hx 
(pack yr) smoking status Diagnosis Cancer subtype
S01 m 68 N 50 current SCLC small
S02 f 62 N 30 current NSCLC squamous
S03 f 64 N 20 ex NSCLC adenocarcinoma
S04 f 65 N 90 ex Ca (radiological)
S05 m 64 N 100 current Ca (radiological)
S06 m 78 Y - skin 120 ex NSCLC squamous
S07 f 71 Y - breast 40 ex NSCLC unknown
S08 f 57 N 0 never SCLC small
S09 f 67 N 25 ex NSCLC large cell
S10 f 69 N 40 current NSCLC large cell
S12 f 73 N 50 current Ca (radiological)
S14 f 61 N 45 current NSCLC squamous
S15 m 64 N 100 ex NSCLC large cell
S16 f 82 Y - breast 64 current NSCLC unknown
S18 f 76 N 8 ex NSCLC squamous
S19 f 73 N 90 ex NSCLC large cell
S20 m 67 N 40 ex NSCLC squamous
S21 f 63 N 20 ex NSCLC adenocarcinoma
S23 m 78 N 25 ex Ca (radiological)
S24 f 74 N 60 current Ca (radiological)
S25 f 71 N 8 current NSCLC squamous
S26 m 78 Y - bladder 65 current NSCLC squamous
S27 m 65 N 100 ex NSCLC large cell
S28 m 69 N 75 ex NSCLC unknown
S29 f 67 N 40 current NSCLC adenocarcinoma
S  S30 m 64 N 100 current NSCLC adenocarcinoma
S31 f 62 Y - skin 20 ex NSCLC adenocarcinoma
S32 m 59 Y - leukaemia 25 current NSCLC squamous
S33 f 68 N 40 current NSCLC squamous
S34 m 81 N 60 ex Ca (radiological)
S35 f 75 N 0 never Ca (radiological)
S36 f 78 N 64 current Ca (radiological)
S37 m 77 N 15 current NSCLC large cell
S38 f 73 N 20 ex NSCLC large cell
S39 m 75 N 30 ex SCLC small cell
S40 m 79 N 70 ex NSCLC unknown
S41 f 61 N 15 current NSCLC large cell
S42 m 77 Y - leukaemia 30 current NSCLC squamous
S43 m 46 N 30 current SCLC small cell
S44 m 82 Y - prostate 45 ex NSCLC adenocarcinoma
S45 m 73 N 100 ex NSCLC unknown
S46 m 85 Y - breast 0 never Ca (radiological)
S49 f 81 N 50 ex NSCLC large cell
S51 f 78 N 30 ex NSCLC unknown
Table 9.3: Summary of the VOC profile cancer cohort 
* Only co-existent cancers at recruitment were patients with leukaemia
190
Study No. Sex Age Smoking status
C01 f 52 current
C02 m 37 never
C03 f 74 never
C04 m 32 never
C05 f 56 never
C06 m 38 never
C07 m 38 never
C08 f 61 never
C09 f 58 ex
C10 f 33 ex
C11 f 76 ex
C12 m 77 ex
C14 m 62 ex
C15 f 37 never
C16 f 61 ex
C17 m 68 ex
C18 f 62 never
C19 m 76 never
C20 f 61 ex
C21 f 53 ex
C22 f 50 never
C23 f 48 current
C24 f 55 ex
C25 m 56 never
C26 f 44 current
C27 m 36 current
C28 m 44 current
C29 f 51 never
C30 f 56 never
C31 f 41 never
C32 f 43 ex
C33 f 47 current
C34 m 59 ex
C35 f 51 current
C36 m 45 never
C37 m 38 never
C38 f 44 current
C39 f 51 never
C40 f 45 never
C41 m 57 never
C42 f 53 never
C43 f 47 ex
C44 f 52 never
C45 f 53 never
C46 f 55 ex
C47 m 50 never
C50 f 65 current
Table 9.4: Summary of healthy control group
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Scatterplot of VOCs and polynomial equations
A scatterplot of area under the curve (AUC) on the y-axis against retention time 
(RT) on the x-axis was created. (Figure 9.1) Two distinct polynomial equations 
were then generated representing different overall patterns between lung 
cancer cases and controls.
Lung cancer: y = -14.259x6 + 1217.3x4 - 37821 x3 + 517134x2 - 3E+06x +
6E+06 
R2 = 0.0512
Controls: y = -8.5934x5 + 731,48x4 - 22939x3 + 324106X2 - 2E+06x + 4E+06 
R2 = 0.1064
The R squared (R2) value for the lung cancer polynomial was close to 0 
(R2=0.051), as was the R2 value for the control polynomial (R2=0.1), thus not 
statistically significant, which suggests that the scatter around the lines for each 
cohort may have occurred by chance. There is no strong correlation presented 
here and the line would not be a good predictor of cancer patients or controls. 
The lack of statistical significance is not surprising as the variance for the 
majority of compounds is so high. However, the lines were useful in identifying 
particular zones for discriminating cancer patients.
Polynomial equations and curves for lung cancer cases and controls identified 
a period of 8-17 seconds retention time in the GC-MS, representing certain 
VOCs, which corresponded to the greatest deviation between the two curves 
for lung cancer and control data sets.
P1 and P2 represent two zones that are exclusive to VOCs from lung cancer 
patients, accounting for approximately 27% of the lung cancer cohort and 0% of 
controls. This data is represented in Figure 9.1.
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Compound-by-compound analysis for identification of specific 
discriminating VOCs
246 VOCs were identified in total from all samples (all subjects).
29 compounds were found to be exclusively in lung cancer patients (see Figure 
9.2). Using these 29 VOCs, 70% (31 of 44) of lung cancer patients could be 
correctly classified. Thus using these 29 cancer-exclusive VOCs on the study 
group gives a sensitivity of 70% and specificity of 100%. Interestingly, the 
points in zones P1 and P2 correspond to a proportion of the cancer-exclusive 
compounds.
However, no cancer subject had more than 5 of the 29 exclusive VOCs in their 
breath suggesting the heterogeneous nature of lung cancer pathways.
A further 25 VOCs were universally higher in lung cancer patients and although 
present in 23 of the 47 controls the levels of VOCs were low. Thus using the 25 
VOCs we were able to correctly identify a further 18% (8 of 44) of lung cancer 
patients. These compounds are represented in Figure 9.3.
Thus using these 54 VOCs allowed the correct classification of 39 out of 44 
(88.6%) of lung cancer patients. There were 5 cancer patients who were not 
identified with the panel, i.e. false negatives S06, S19, S25, S34, S42. Looking 
at the individual cases that were false negatives, 3 were SCC and 1 large cell 
with the other a clinical diagnosis. There were no other similarities identified.
The overall sensitivity and specificity using the 54 VOCs was 88.6% and 100% 
respectively.
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{Compounds Cases with exclusive VOCs
i -
1-Heptene S16 S20 S24 S45
2-Propanol, 1-methoxy- S49 S36
Cyclohexane, 1,2,4-trimethyl- S08 S15
Cyclohexane, 1-methyl-2-propyl- S07 S08 S10 S15
Cyclohexane, butyl- S08 S10 S15
Cyclohexene, 1-butyl- S09 S18 S26
Cyclopentane, 1 -methyl-3-(2-methyl-1 -
propenyl)- S08 S43
Decane, 2-methyl- S08 S10 S15
Decane, 3-methyl- S08 S10 S15
Decane, 4-methyl- S08 S10 S15
Dotriacontane S02 S12 S26 S32 S51
Heptane, 2,2,4,6,6-pentamethyl- S08 S10 S33
Hexane, 1-(hexyloxy)-5-methyl- S10 S27 S38
Naphthalene, 2-methyl- S38 S43
N-Benzyloxycarbonyl-L-tyrosine S18 S23 S33
Nonane, 3-methyl- S08 S10 S15
Piperazine S39 S40
Piperazine adipate S09 S23 S28 S39 S40
Vinyl Ether S46
Table 9.5: List of 29 VOCs exclusive to lung cancer cohort and the patients 
which they occurred
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Compounds
1,4-Dioxaspiro[4.5]decane, 8- 
(methylthio)-
1-Octanol, 2-butyl-
2-Cyclohexen-1 -one, 5-methyl-2-(1 - 
methylethyl)-
2-Pyrrolidinone
3-Heptanone
5H-Naphtho[2,3-c]carbazole, 5- 
methyl-
Benzene, 1,3,5-trimethyl- 
Benzene, 1 -methyl-2-(1 -methylethyl)- 
Benzene, 1-methyl-4-(1- 
methylethenyl)- 
Butane, 2-methyl- 
Cyclobutene, 2-propenylidene- 
Cyclohexanone, 5-methyl-2-(1- 
methylethyl)-, trans- 
Cyclohexene, 3-methyl-6-(1- 
methylethyl)- 
Cyclopentane, ethyl- 
Ethanol
Heptane, 2-methyl-
Hexadecane, 2,6,11,15-tetramethyl-
Hexane, 3-methyl-
Hydrazine, 1,2-dimethyl-
Nonane, 2,2,4,4,6,8,8-heptamethyl-
Oxirane, 2,3-dimethyl-, trans-
Propanamide
Thiirane
Tricosane
Undecanal
Cases with higher levels 
of specific VOCS
S03 S05
S15 S44
S43
S24
S02 S08 S09
S04
S15 S26 S35
S08 S23 S35
S43
S30
S45 S50
S43
S08 S43
S29
S16
S29
S26 S35
S08 S10 S29
S09 S39
S04 S08 S37
S37
S01 S35 S39
S28 S45
S02 S41
S04
Table 9.6: 25 VOCs which were universally higher in the lung cancer cohort 
compared to healthy controls
12 VOCs were found to be exclusive to control subjects and were able to 
correctly classify 21 of 47 (45%) as controls (Figure 9.4).
A further 15 VOCs were universally higher in the control group compared to the 
cancer cohort and when applied were able to correctly classify 7 of 47 (15%) as 
healthy controls (Figure 9.5).
Thus 27 VOCs allowed 60% of subjects to be correctly classified into the 
healthy control group.
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Figure 9.4: 12 VOCs which are exclusive to healthy control subjects and allow 
correct identification of 21 (45%) as controls.
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Compounds Cases with exclusive VOCs
1-Octanol ” C33~”
Benzene, 1-methyl-3-
propyl- C03 C50
Benzene, 2-ethyl-1,3-
dimethyl- C30 C50
Benzene, methyl(1-
methylethyl)- C35 C37
Butanal C05 C11 C17
Cyclobutanone, 2-
methyl-2-oxiranyl- C05 C50
Eucalyptol C24 C28 C35
Hexanoic acid C10
Nitrous Oxide C44
Non-2-en-1-ol C10 C19 C23 C40 C42
Pentane, 2-chloro- C04 C25
Propanedioic acid,
propyl- C10 C12 C14 C23
Table 9.7: 12 VOCs that were exclusive to the healthy control cohort and the 
controls in which they were detected.
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Figure 9.5: 15 VOCs which were universally higher in the healthy controls 
compare to the lung cancer subjects and allowed 7 (15%) subjects to be 
correctly classified as controls.
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Compounds i
1-Dotriacontanol "H c T i”
Arsenous acid, tris(trimethylsilyl) ester C18 C37
Benzene, 1-ethyl-2,3-dimethyl- C03 C12
Benzene, 1 -ethyl-2,4-dim ethyl- C03 C04
Benzene, 1-ethyl-4-methyl- C15
Benzenecarbothioic acid C33 C38 C43
Butanal C05 C11 C17
Butylated Hydroxytoluene C16
Cyclohexane, 1,4-dimethyl- C17
Ethene, 1,1 -difluoro- C12
Isothiazole C16
Nonacosane C08
Phthalic anhydride C23
Propanenitrile, 3-(methylamino)- C06
Vinylsulfonamide C40
Table 9.8: 15 VOCs that were universally higher in healthy controls compared 
to lung cancer subjects
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PART 4: DISCUSSION
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Chapter 10 FTIR and Immunohistochemistry 
Assessment of sputum -  Discussion
Summary of key findings
The main objective of the study on sputum was to assess the role of FTIR in 
distinguishing between cancer patients and those who were cancer-free. 
Sputum can be obtained in a non-invasive manner and FTIR provides a cost- 
effective high-throughput method of analysis, thus addressing two criteria when 
considering screening a population or part of it. We generated FTIR spectra on 
all sputum samples from three cohorts, cancer, those deemed high-risk enough 
of having lung cancer to warrant a diagnostic bronchoscopy and healthy 
controls, with very little smoking history and no respiratory or constitutional 
symptoms. The spectra were obtained within the mid-infrared range between 
wavenumbers at 600 cm'1 and 4000 cm'1. We focused on this range as it 
represents the wavenumbers attributed to most biological differences observed 
in cancerous human tissues. It was evident that cancer spectra yielded higher 
absorbances than healthy control spectra at different regions of wavenumbers. 
The areas of clear differences were in the regions of wavenumbers 1400 to 
1060 cm'1; 1060 to 1025 cm'1 and 1400 to 1670 cm'1. These wavelengths 
reflect chemical signature bonds representing protein areas (especially amides 
I and II), glycogen-rich and RNA / DNA regions. The fact that most of the 
sputum samples gave good quality FTIR spectra strongly suggests that this 
biofluid is a useful non-invasive tissue source for FTIR analysis in the detection 
of lung cancer. We encountered and were able to identify the technical flaws 
that led to the grossly abnormal spectra and have since modified our laboratory 
training. This compares with similar difficulties encountered with the 
immunohistochemistry staining.
Multivariate analysis (PCA) was able to demonstrate the reproducibility of FTIR 
on sputum samples at different times as well as consistency in processing 
replicates of the same sample. We did not observe groupings of cancer cases
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according to sub-types such as squamous, adenocarcinoma or small cell 
carcinomas but are looking at sub-group patterns in more samples.
A preliminary analysis of entire FTIR spectra for cancer and healthy control 
cases provided initial insight into whether FTIR could discriminate these two 
groups. By retaining the first three principal components we observed, using 
scatterplots, a pattern of cancer and healthy control spectra ‘branches’ 
separating in different directions. This approach was useful as it allowed us to 
quantitatively assess the variation in absorbance values across spectra across 
cancer and control cases. The first three principal components alone explained 
greater than 90% of the overall variation across the spectra meaning that the 
separating pattern we were observing really was attributable to metabolic 
differences between cancer and healthy control cases.
The next step involved identification of a small number of infrared 
wavenumbers that could optimally discriminate between cancer and healthy 
control cases. The number of wavenumbers needed to evaluate in combination 
was unknown at the time and the analysis process started with just two 
wavenumbers. We envisaged that if two wavenumbers in combination could not 
discriminate between cancer and healthy control cases with a high degree of 
accuracy then we would incrementally increase the wavenumbers accordingly. 
Using the R statistical software, we were able to arrive at a combination of just 
two wavenumbers, 1031.7 cm'1 and 1409.7 cm'1, which discriminated cancer 
and healthy controls with a high degree of sensitivity and specificity. The 
discriminatory model developed using wavenumbers 1031.7 cm'1 and 1409.7 
cm'1 had a sensitivity of 92.6%, a specificity of 90.7%. This compares very well 
with the immunohistochemistry analysis of sputum which had a sensitivity 
ranging from 10 to 42% and specificity of 72 to 96%.
When the patients who underwent bronchoscopy and lung cancer was written 
as potential differential diagnosis - but ultimately turned out not to have lung 
cancer after 1 year clinical / bacteriological and radiological follow up (high-risk 
cohort) were added to the discriminatory model, 71% of these were predicted to 
have cancer. Although this figure appears high (i.e. a lot of false positives), this
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group were already deemed of high enough risk to warrant an invasive 
investigation such as bronchoscopy. All had radiographic changes or symptoms 
compatible with lung cancer together with risk factors such as a significant 
smoking history or a family history of cancer. Although at 1 year follow up there 
was no evidence of lung cancer, they may still have early biological changes of 
cancer that are not detectable by current means. We continue to monitor the 
clinical progress of this very important sub-group.
How do the results compare with previous studies of FTIR in cancer?
The ability of FTIR to detect cancer has been tested in a small number of 
studies. In our study, the 1409.7 cm"1 wavenumber signified a difference in 
concentration of amino acids and consequently protein(s). 1409.7 cm"1 is 
associated with carbon (C) oxygen (O), COO- stretching and C-(hydrogen)H 
bending. Our other important number, the 1031.7 cm"1 wavenumber falls within 
a region assigned to C-0 stretching coupled with bending of C-OH groups of 
glycogen. [206]
This result is quite intriguing as glycogen has previously been investigated in 
lung cancer tissue using FTIR by Yano et al. [192, 193] Using a sample size of 
26 patients, they found that absorbances at 1045 cm"1 wavenumber, 
representing glycogen, were significantly higher in lung cancer biopsy 
specimens relative to non-cancer control tissue from the same patients. They 
also found that absorbances for this wavenumber were higher for 
adenocarcinoma than for SCC although we did not observe this for 
wavenumber 1031.7 cm"1. Wang et al reported that there were large differences 
in peak absorbance at wavenumber 1030 cm"1 (which represents glycogen rich 
region) between lung tumour and normal lung cells in pleural fluid of the same 
patients although this was assessed on only 8 subjects. [194] They also 
identified differences at 1080 cm'1 which represents the phosphodiesters. Light 
and electron microscopic studies have shown that glycogen is mostly free 
within cells in different types of malignant lung tumours but in benign tumours it 
is mostly membrane-bound. [286, 287] The results of this study as well as the 
previous studies suggest that glycogen levels are raised in lung tumours
207
relative to normal lung tissue and that glycogen is not confined to membranes 
within the cell. Interestingly, the higher absorbance in phosphodiesters 
(1080cm'1) is also a notable difference when comparing oesophageal 
cancerous cells with its normal counterpart. [203]
Greater levels of glycogen detected by FTIR (wavenumber 1030 cm'1) were 
also identified when comparing nine gastric cancerous tissues with normal 
gastric tissue from the same patients with samples obtained immediately post 
gastrectomy. Phosphodiesters (1081 cm'1) were again greater in the malignant 
samples. [204]
Cervical cancer appears to have a reduced absorption within the wavenumbers 
representing glycogen. A study in Australia assessed FTIR on exfoliated 
cervical cells of 227 patients. Six spectra were recorded for each patient and 
the spectra were described as either type 1 or type 2. Spectra designated type 
1 exhibited a profile characteristic of normal epithelial cells, with intense 
glycogen bands at 1022 cm'1 and 1150 cm'1, and a pronounced symmetric 
phosphate stretch at 1078 cm'1. Spectra designated type 2 exhibited features 
suggestive of dysplastic or malignant transformation, with pronounced 
symmetric and asymmetric phosphate modes and a reduction in glycogen-band 
intensity. Of the 272 patients, 68.6% of samples exhibited only type 1 profiles 
for all six recorded spectra, 29.4% of samples yielded had at least one type 2 
spectrum and 2% of samples were inconclusive. Of the 68.6% with normal type 
1 spectra, 86% were diagnosed normal by Papanicolaou smear with no follow 
up biopsy ordered, 7% were diagnosed abnormal by biopsy, 5% normal by 
biopsy and 2% were still inconclusive. For the remaining 29.4% of abnormal 
type 2 spectra on FTIR testing, most (71%) had shown an abnormal smear 
result. These 71% were subsequently biopsied, and 87% were confirmed 
abnormal or cancer by traditional histopathological methods. [195]
The lowering of cellular glycogen content during carcinogenesis of the cervix 
has been well documented. [288, 289] In 1991, a study looked at exfoliated 
cervical cells collected from 156 women by brushing. The cell pellets were split 
so that one could undergo FTIR, the other microscopic examination by two
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pathologists. 136 of the samples was normal, 12 were cancerous and 8 
dysplastic. The normal samples had FTIR spectral peaks particularly at 1025 
cm'1 and 1047 cm'1, thus corresponding to the glycogen rich area.
The infrared spectrum of glycogen from mammalian liver lies within the 
frequency region 975 -1060 cm'1. Glycogen, therefore, made a large 
contribution to the intensity of these two IR bands of the normal cervical cells. 
When the 12 cancer samples underwent FTIR, there were significantly reduced 
absorptions at the 1025 cm'1 and 1047 cm'1 wavenumbers, represented in 
Figure 10.1. [289]
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Figure 10.1: Comparison of FTIR of normal and malignant exfoliated cervical 
cells. Malignant cells have much less absorption in the glycogen-rich area, 
1025 cm'1 and 1047 cm'1, compared to normal cervical cells. [289]
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All the studies of FTIR in cancer described above follow similar techniques with 
regard to FTIR analysis. The difference between this study and the others is 
that they all involve analysis on biopsy tissue that offers no comfort advantage 
to the patient undergoing a surgical biopsy. In such histological specimens, 
FTIR could still look for signs of early dysplasia, or as an adjunct to improve 
receiver operator curves for histological staining alone.
The main advantage of our study is that the sputum is obtained in a non- 
invasive manner. Moreover, most people at risk of lung cancer should be able 
to produce sputum -  even if they are too frail to undergo endobronchial / CT- 
guided or even open-lung biopsies.
FTIR applied to sputum in other diseases
A recent paper looked at the role of FTIR in sputum of COPD patients to help 
monitor the disease status. 15 consecutive patients with moderate to severe 
COPD were enrolled along with 15 healthy controls who had never smoked. 
Sputum was collected by induction with nebulised hypertonic (3%) saline. 
Similar to our data, as their data was not normally distributed, they performed a 
Mann-Whitney U Test to detect any statistical differences between the COPD 
and control sputum. Within the COPD group, no statistical difference was 
identified between current or former smokers. Slightly different to the other 
FTIR studies, this group looked at the shift in the peak of absorbance as well as 
the intensity of absorbance. They noted, in the glycogen-rich area, a shift in 
peak from normal of around 1077 cm'1 towards around 1073 cm'1 in 66% of 
patients with COPD (10/15). They also found a three-fold increase in 
absorbance of the same 10 COPD patients at wavenumber 1073 cm'1and a 
shift in peak from 1559 cm'1 to 1561 cm'1, compared to controls - which is in the 
amide II region. [207] The authors also concluded that sputum is a suitable 
biofluid for FTIR.
This study as well as our own shows an increase absorbance in the glycogen- 
rich region as previously noted in the lung cancer studies, although the peak 
absorbances were in a different position. In our study the key wavenumber from
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the glycogen-rich region is 1031.7 cm'1 with the key wavenumbers from the 
other studies being close to but not identical to this. Although the FTIR 
technique is similar, our sputum collection and processing was different. We 
relied on self-expectorated sputum and for study purposes suctioned sputum 
from bronchoscopy. For large screening studies in the community, the ideal 
would be self-expectorated sputum only. Inducing sputum with nebulised 
hypertonic saline adds to cost, and time (14 minutes based on this particular 
study protocol). The study numbers are small and they haven’t taken into 
account the subjects that smoke but do not have COPD. Although there was no 
statistical difference between the spectra of former and current smokers within 
the COPD cohort, smoking status was not validated, and simply taken on 
asking the individuals.
Strengths and weaknesses of FTIR and sputum study
We tried a novel approach. We could find no published data on the use of FTIR 
in the sputum of lung cancer patients. Sputum is a good biofluid to study as it 
can be obtained in a non-invasive manner for the subject and poses less 
infectious risk to researchers than blood. When one considers a screening 
modality these are important issues to consider.
Strengths of the study:
Participant selection:
The patients were recruited in a prospective manner from respiratory clinics in 
district general and teaching hospitals and are typical of those undergoing 
bronchoscopy in an everyday clinical setting. Patients were recruited prior to 
definitive diagnosis. In targeting this group of patients we have assessed the 
molecular changes at the earliest point possible using untested technology. All 
the patients in the cancer and high-risk group underwent bronchoscopy, thus 
the Respiratory Physician assessing the patient must have felt there was a 
potential for lung cancer to be present for the patient to undergo an invasive 
procedure. Usually this group of patients will have smoked for many years or
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have a family history of cancers. It is likely that should any screening modality 
be developed for lung cancer then this population of patients could be targeted.
The healthy controls consisted of those with no respiratory disease, cancer or 
worrying symptoms that may indicate underlying cancer. The cohort consisted 
of a mixture of current, former and never smokers.
Sample size:
As the study was experimental it was difficult to power the study initially. 
However by having 169 patients in the study (132 of the 169 spectra were used 
in analysis), it provided a large enough sample to see if the technology worked 
in principle. The model was developed after analysis of 108 spectra (54 cancer 
and 54 healthy control). This compared favourably with Yano (n=26), Wang 
(n=8), Wang (n=27), Wong (n=12) and Whiteman (n=30) all of whom had 
smaller sample sizes. [192, 194, 203, 207, 289]
Demographics:
There were no significant differences between the 3 cohorts with regards 
gender. Although the high-risk group appeared to have a much larger 
proportion of males compared to the other 2 groups, this was not significant. 
The high-risk and cancer groups were well matched for number of smoking 
pack years and FEVi.
Sputum:
Sputum is an ideal specimen to assess in this group of patients. Often with 
many years of smoking, sputum expectoration is increased (chronic bronchitis) 
thus making it a potentially accessible biofluid to test. The samples can be 
stored in normal multi-specimen containers which are readily available and 
cheap so in practice can be collected by the bedside or in the GP surgery.
FTIR process:
The advantage of FTIR is that it is cost-effective and high-throughput. Although 
the FTIR equipment is expensive, the processing only costs 5-10 pence per 
sample each. Moreover the process is automated and each specimen tray has
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96 ‘wells’ that can be used for up to 96 individual samples (or still 32 patients, if 
taken in triplicate). The process itself takes approximately 2 hours for all 96 
samples compared with 5-10 minutes per sample for cytopathology review.
Statistics:
We applied standard statistics and tested for normality throughout. PCA has 
been used previously in the analysis of FTIR data. PCA allowed us to get an 
idea about the pattern of data, particularly how compounds of similar molecular 
structures group together. Logistical regression allows the formation of a linear 
model based on the differences between two objects (in this case cancer and 
healthy control cohorts). In multivariate statistical analysis, these methods are 
well used and recognised. We specifically used the ‘leave-one-out cross 
validation’ method to test how robust our model using the optimal discriminating 
pair of wavenumbers was. By taking cases out in sequence and still confirming 
that the sensitivity maintained a high level of consistency, we were satisfied that 
the two chosen wavenumbers were a good model.
Weaknesses of the study
Participants:
The cancer and high risk cohorts were recruited from secondary care and all 
had symptoms and/or abnormal radiology that was recognised both by them 
and their General Practitioners / hospital specialists. They do not represent the 
majority of smokers e.g. over 50 years in the community, where a large 
screening trial would be based. Our healthy control age group were significantly 
younger than both the cancer and the high-risk group and this represents the 
Swansea University students and bias to a working-age population of hospital 
staff. We know of no published work that sputum or any FTIR spectra are 
influenced by age per se but ideally the groups should all have been matched 
for age.
Advanced stage of disease within cancer group:
As one would expect, most of the patients presented when they had already 
developed symptoms and in 41 (76%) the cancer was in an advanced stage of
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the disease (Radiological TNM stage > III). Although the aim of the study was 
to see how FTIR could differentiate cancer from non-cancer cases, the ideal in 
the future is to produce a screening test that is applicable to all stages of lung 
cancer, particularly the early forms amenable to curative treatment. The 
changes in wavenumbers maybe more pronounced in a more advanced 
disease state as greater tumour load should result in more metabolic changes. 
It is hoped that these changes will still be present to a high enough degree in 
the very early, curative, stages of the disease, as only then will this have an 
impact on reducing mortality rates. In further studies, or as the number of 
recruited patients increase, analysis of the early disease states can be 
assessed. This may well continue to prove difficult for the reasons explained 
throughout the thesis with regards to these patients presenting late. We do not 
have large enough numbers yet to make meaningful comparisons according to 
tumour histology or TNM staging.
Smoking status:
There were statistically significant differences in the smoking status between 
the 3 groups. Although the cancer and healthy controls had a similar number of 
current smokers (19 vs. 24), there were very few former smokers in the control 
group (n=1) compared to the cancer group (n=28). Although exhaled CO levels 
in the high-risk and cancer cohort validated smoking status, it was not 
performed in the healthy control group. Future studies should always 
biologically validate smoking status, perhaps even long-term abstinence with 
(much more expensive) markers such as salivary or urinary cotinine, as eCO 
only reflects smoking within 24 hours.
Size of high-risk cohort:
Although there were similar number of patients in the cancer and healthy 
control cohorts (n=54), the high-risk group had fewer than half the number of 
patients (n=24). We could not predict at the time of recruitment and 
bronchoscopy which of the 99 patients would have lung cancer. Our eventual 
cancer rate of 2/3 from all those undergoing bronchoscopy reflects national 
practice. [290]
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Location of tumour
The patients were selected as those who were fit enough and had appropriate 
radiology to undergo bronchoscopy. Thus they were selected as tending to be 
fitter and to have more central lesions. We initially wanted to recruit these 
patients as
a) We thought they would have the highest histopathological diagnostic 
rate
b) We had ethics to obtain biopsy material (a future comparison is biopsy 
FTIR spectra versus sputa FTIR spectra)
c) It was a preset time and focal point for me to attend and recruit from 
(given my other clinical commitments, I could not always attend CT 
sessions, clinics etc).
This meant that patients with more peripheral lesions, e.g. who underwent CT- 
guided biopsy or those refusing or often deemed unfit for bronchoscopy, were 
not approached and this should be acknowledged. The sputa from more central 
lesions are more likely to contain dysplastic / malignant cells, and thus 
potentially show greater biological changes in their sputum. Even after 
selection, there were some patients who had a diagnosis of lung cancer but 
had no visible endobronchial lesion. These were too few in number to allow 
meaningful analysis at this point. It can be difficult to diagnose early lung 
cancer in subjects who have a small peripheral nodule in the middle of their 
lung which is too peripheral to see endobronchially but often too small to safely 
perform a CT-guided biopsy / fine needle aspiration. These patients are now 
being included in a modified study to see if they also have changes in their 
sputum FTIR spectra as those with more central lesions, particularly as many of 
these will have early stage disease.
Sputum in those unable to self-expectorate:
When collecting the sputum, not all the samples were self-expectorated. Some 
of the samples had to be collected at the time of bronchoscopy via suction and 
this may have meant that some of the samples contained normal saline or e.g. 
cleaning chemicals from the bronchoscope collection channel. Importantly, 
these samples did not show a statistically significant difference in the number of
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bronchial cells present when a random selection of sputa were assessed. 
Ideally, all the sputum samples should be examined for the presence of 
adequate numbers of bronchial cells, however, this would have taken several 
days to be performed and would still require an experienced pathologist to do it 
optimally. This was not feasible within the constraints of this study. There were 
some delays in freezing some of the sputum samples which may have led 
deterioration of the samples. In an ideal situation, all samples should be 
immediately frozen.
Histological diagnosis missing:
Excluding those patients who were too unwell to undergo invasive 
investigations and were therefore given a clinico-radiological diagnosis of lung 
cancer, there remained 9 patients out of 54 who had no definite histological 
subtype identified. The lung cancer MDT, diagnosed these as having NSCLC, 
according to typical clinical findings and radiological appearances. We wanted 
to maintain numbers and use a final (clinical) diagnosis of lung cancer reflecting 
a clinical service.
Sputum cell preparation for FTIR:
Preparation of the samples for FTIR took between one and two hours (for 20 
samples) requiring manual laboratory trained technicians. This again may 
change as technology advances and more automated facilities are developed 
but limits its general applicability.
Spectral anomalies
A small number of spectra were fundamentally different from most samples and 
also from the recognised patterns from medical literature. By cross checking 
records and sample coordinates, we realised that these spectra were analysed 
in one particular batch and all the abnormal spectra came from samples that 
were grouped in a corner of a single tray upon which there was a bio film 
(probably contamination bacteria) present which altered the absorptions thus 
resulting in very different spectra. These spectra were not included in the final 
analysis, as they were deemed uninterpretable.
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Transforming the raw spectra:
The raw spectra underwent various transformations to create the 2nd derivative 
spectra. This included a baseline correction, which altered some of the sloping 
and negative values derived. Although recognised techniques were used in the 
process, whilst transforming data there is always the potential for ‘losing’ data. 
Although this is a potential weakness, the overall process is standard technique 
and important in order to standardise the data and thus allow sensible 
interpretation. Although we validated our model internally, a better test of our 
model would be to apply it to a new set of prospectively gathered data 
(preferably where we are blinded to the clinical diagnosis).
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The way forward: FTIR and sputum
We have shown that there are significant spectral differences between cancer, 
high-risk and healthy controls when applying FTIR to sputum. Our most 
significant wavenumbers are similar to those reported in other studies looking 
at cancers of other organs and using a variety of tissue samples. We have 
generated a predictive model with good sensitivity and specificity and the future 
plans are to further test the accuracy of the model of all stages of lung cancer 
and more smokers over the age of 50 years that are more likely to represent 
the screened ‘at risk’ population.
Recruitment:
We are continuing to recruit with two English NHS Trusts and a further Welsh 
Health Board gaining site-specific approval. By studying a larger number of 
patients within each cohort (especially those at high risk), we will be able to see 
how successful the model is at predicting cancer. It is plausible that the 
wavenumbers used in the model may change slightly.
Methodology:
Rather than recruit solely the patients who are undergoing bronchoscopy, we 
have amended our ethics application to just collect sputum. We are now 
collecting samples from people with peripheral lesions and those not deemed fit 
for bronchoscopy. The location of the lesion on CT and findings (proximal 
lesion, distal lesion, no lesion) at any bronchoscopy are being noted.
Internal quality control checks and accurate sample labelling detected some 
technical errors, encountered in the sputum processing. We hope to learn from 
these errors.
Further assessment of spectral breakdown according to cancer subtype and 
staging should provide additional information. Staging is particularly important 
to identify if the predictive model maintains the sensitivity and specificity in 
early, potentially curative, stages of disease. Identification of these early cases
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will be the most likely way to impact the mortality rates from lung cancer as 
there are few new treatment regimes being developed.
Further analysis of the actual compounds in the sputum by mass spectrometry 
and DNA analysis is being undertaken in Swansea University. We hope to 
more accurately identify the actual important molecular differences between the 
three clinical cohorts and confirm if the FTIR signals representing chemical 
bonds do identify specific compounds that relate to carcinogenesis. This could 
lead to a better understanding of lung cancer molecular pathways and even 
provide targets for future therapies.
These improvements in study design are essential to further validate our early 
results. It is important that this work evolves, as a cost-effective, high- 
throughput screening technique for lung cancer, using a non-invasive biofluid, 
remains elusive.
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IMMUNOHISTOCHEMISTRY AND SPUTUM
Summary of key findings
An additional arm of the main study was assessing established 
immunohistochemistry techniques but in two original ways. We tested a panel 
of antibodies, which have not been evaluated in combination, and we looked at 
sputum cells. We assessed antibodies to 5 established lung cancer markers; 
p16, p53, p63, cyclin D1 and EGFR. In comparing the cancer and high-risk 
cohorts (we did not collect sputum for this test of healthy controls), there were 
no significant differences in the staining for the individual antibodies. Although 
the specificity was high, they had very low sensitivity. Thus, although very few 
without cancer would be wrongly diagnosed as having lung cancer there were 
an unacceptably high number who actually did have lung cancer but had 
negative IHC (low sensitivity). This continued to be the case even when all the 
samples that were deemed uninterpretable were removed from the dataset.
This was further proven when hierarchial cluster analysis continued to show 
heterogeneity of groups. As a statistical modality it can be used as a visual 
inspection of how similar results group together. No clear-cut group of all lung 
cancer cases were seen to branch together, confirming that this particular 
group of antibodies do not differentiate well between cancer and non-cancer 
cases based on sputum.
How do the results compare with other studies?
p16
P16 is thought to be a tumour suppressor gene. Its alteration or inactivation has 
been implicated in various malignant tumours, including the lung. [291, 292] 
p16 expression in 135 lung cancer specimens was studied to evaluate the 
presence of genetic alterations. P16 alteration was found to be a frequent event 
and independent of histological subtype of lung cancer. The reduction or loss of 
p16 expression was also associated with a worse prognosis in lung cancer. 
[293] A study performed on 171 patients with NSCLC who underwent surgery, 
had p16 immunoanalysis of their tumour specimens. 62 (36.3%) were classed
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as p16-negative. There were significantly more p16-negative squamous cell 
carcinoma (SCC) compared to adenocarcinomas (p=0.039) and these p16- 
negative SCC had a significantly lower survival compared to those with pie- 
positive SCC (p=0.001). [294] One particular way of inactivating the p16 gene is 
by promoter methylation. A study in Chile found 59 out of 74 (79.7%) patients 
with NSCLC had their p16 inactivated by promotor methylation and this was 
significantly higher in those with SCC (91%) compared with adenocarcinoma 
(70%, p=0.029). [295]
P16 evaluation in sputum has been discussed in Chapter 2.
Methylation of p16 and 0 6-methylguanine-DNA methyltransferase (MGMT) in a 
high-risk population was studied. The sputum samples of 21 patients with 
squamous carcinoma were investigated. The presence of one or both gene 
promoters was found in all 21 sputum samples irrespective of whether they 
were taken up to 3 years (n=10) before or at the time of diagnosis (n=11). This 
compares to 15% (methylation of p16) and 25% (methylation of MGMT) in 123 
controls, deemed high risk through a smoking history and/or radon exposure. 
48% of the squamous cell cancer patients had methylation of both genes 
compared to only 4% of controls (p<0.001). [142]
Belinsky et al studied 3,259 subjects who provided pooled sputum for 3 days in 
1 container and the next 3 days in a second container. The sputum from the 
second container was used as samples for the study. 182 subjects were 
diagnosed with (incident) lung cancer with 1,353 cohort deaths. Once sufficient 
quality of DNA was analysed the study cohort consisted of 98 subjects (cases) 
and the non-cancer cohort was used to form a group of 92 controls matched for 
age, gender and month of enrolment. P16 was one of the fourteen genes 
analysed for promoter methylation. They found that 6 (including p16) of the 14 
genes were individually associated with a > 50% increased risk of lung cancer. 
Sputum collected within 18 months of a diagnosis of lung cancer had more 
methylated gene promoters than sputum from the same subject collected more 
than 18 months before the diagnosis. The concomitant methylation of 3 or more 
genes was associated with a 6.5-fold increased risk of lung cancer with receiver 
operating characteristics of a specificity of 64% and sensitivity of 64%. [143]
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A more recent study looked at a heavy smoking but cancer-free cohort of 
subjects. Sputum samples were collected from 820 Caucasian subjects by self­
expectoration on 3 consecutive days. They were all current or former smokers 
having built up at least a 20-pack year smoking history and were cytologically 
and radiologically free of cancer. The analysis of the sputum with various 
antibodies including p53 and p16 identified 56 individuals (6.9%) with at least 
one molecular alteration. P16 methylation occurred in 5.1%, which was the 
most prevalent of all the alterations. P53 mutation was the next most common 
with 1.9% and one of the patients with the p53 mutations developed early lung 
cancer on follow-up within 3 years. [296]
p53
p53 is a tumour suppressor gene. It has an important role, especially in 
multicellular organisms, where it regulates the cell cycle and thus acts as a 
tumour suppressor. [297] The role of p53 has been studied previously, and like 
p16, has also been shown to have an independent effect on lung cancer 
prognosis.
A study of 156 resected NSCLC cases was carried out using immunostaining 
with p53. 103 specimens (66%) expressed p53 with greater expression in SCC 
compared to adenocarcinomas. The cases were divided into three groups, as 
follows: p53-negative (< or = 0.1% stained, n=53), low p53 (0.1% to 50%, 
n=54), and high p53 (> 50%, n=49). Overall, patients in thehigh-p53 group 
survived longer than those in the low or negative groups, with respective 
median survival durations of more than 65, 26, and 33 months (p=0.002). The 
survival difference among the three groups was statistically significant for non- 
squamous cell (p=0.008), but not for SCC (p=0.17). The authors concluded that 
high expression of the p53 oncoprotein is a favourable prognostic factor in a 
subset of patients with NSCLC. [298] These findings were further evaluated on 
179 surgically resected NSCLC specimens where a significant relationship 
between strong p53 expression and patient survival was identified. In a 
multivariate analysis, strong expression (> 50%) of the p53 oncoprotein is an 
independently favourable prognostic factor. [299]
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It has been postulated that p53 mutation / alteration has a role in the aetiology 
of lung cancer. Persistent smoking dramatically increases the risk of death from 
lung cancer. [300] Of all of the carcinogenic effects of tobacco smoke, its 
mutagenic action is certainly believed to be the major cause of human lung 
malignancy. [301, 302] This has been discussed in detail in Chapter 3. The 
tobacco carcinogen Benzo[a]pyrene has been shown to have direct effects on 
mutating p53, with these mutations being greater in lung cancer patients. Most 
specifically these patterns of p53 mutations are greater in the smoking cancer 
group compared to non-smokers. The studies suggest that p53 mutations in 
lung cancers can be attributed to direct DNA damage from cigarette smoke 
carcinogens rather than to selection of pre-existing endogenous mutations.
[171, 303, 304] Other studies have continued to confirm the presence of p53 
alterations and its increased levels in NSCLC surgical specimens at a greater 
rate than normal tissue and most commonly in SCC. [305-307]
The role of p53 alterations in sputum has also been studied. As a follow-up of 
the John Hopkins Lung Project [130], 15 patients were identified who later 
developed adenocarcinoma or large cell cancer of the lung. The primary lung 
carcinomas from 10 of these 15 patients contained either a ras or a p53 gene 
mutation. Using a polymerase chain reaction-based assay (PCR), stored 
sputum samples obtained prior to clinical diagnosis were examined for the 
presence of these same oncogene mutations. In 8 of 10 patients, the identical 
mutation identified in the primary tumour was also detected in at least one 
sputum sample. The earliest that these were detected were in a sputum sample 
obtained 1 year prior to clinical diagnosis. [308] A study analysed sputum from 
15 Chinese women with lung cancer. Of the 15 patients there were mutations 
in 7 (46.7%) patients, including 5 patients with p53 mutations, 1 patient with a 
K-ras mutation, and 1 patient with K-ras and p53 mutations. [309]
EGFR
Epidermal Growth Factor Receptor (EGFR) is a cell-surface receptor and is 
activated by ligands such as epidermal growth factor and transforming growth 
factor a. Once activated, a signalling pathway is commenced which ultimately 
leads to DNA synthesis and cell proliferation. Thus EGFR signalling pathway is
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one of the most important pathways that regulate growth, survival, proliferation, 
and differentiation in mammalian cells. [310] Over-expression of EGFR 
(upregulation) has been associated with lung cancer.
EGFR is most frequently expressed in SCC but also frequently expressed in 
adenocarcinoma and large cell cancer. This was identified when 183 NSCLC 
tumour specimens were assessed for EGFR expression by IHC and gene copy 
numbers were identified by fluorescent in situ hybridization (FISH). FISH is a 
cytogenetic technique used to detect and localize the presence or absence of 
specific DNA sequences on chromosomes. EGFR protein over-expression was 
observed in 62% of the NSCLC, more frequently in SCC than non-SCC (82% v 
44%; p<0.001), and in 80% of the bronchoalveolar carcinomas. The prevalent 
FISH patterns were balanced disomy (40%) for EGFR gene which meant that 
60% had an increased number of gene copies per cell, most of which were 
balance trisomy or polysomy. Gene amplification was seen in 9% of the 
patients. Gene copy number correlated with protein expression (r = 0.4; 
p<0.001) but EGFR over-expression or high gene copy numbers had no 
significant influence on prognosis. [311]
Further studies showed the over-expression of EGFR in lung cancer. 57 
consecutive patients who underwent surgical resection of NSCLC had paired 
samples of cancerous tissue and uninvolved lung. Over-expression was 
identified by IHC. 88 (44 pairs) samples were of good enough quality to be 
examined for EGFR over-expression of which 82 exhibited EGFR expression. 
20 of the 44 tumour samples (45%) had EGFR over-expression. [312] A 
comparison study looking at EGFR expression by IHC in SCC tumour samples 
compared to normal lung tissue, again showed a much higher rate of 
expression in the SCC group. In fact, a statistically significant stepwise increase 
in expression from uninvolved bronchial epithelium to precancerous lesions 
ultimately to SCC was observed. [313]
A meta-analysis of 18 studies, involving close to 3,000 patients analysed the 
role of EGFR over-expression and survival prognosis. EGFR over-expression 
differed between histological types: 39% in adenocarcinomas, 58% in
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squamous cell carcinomas, 38% in large cell carcinomas, and 32% in cancers 
in a miscellaneous category (p<0.0001). The combined hazard ratio (HR) was 
1.14 (95% Cl 0.97 to 1.34; p=0.103), indicating that EGFR over-expression has 
no significant impact on survival. When only the 15 IHC-based studies were 
considered, the combined HR was 1.08 (95% Cl 0.92 to 1.28; p=0.356), again 
suggesting that EGFR over-expression has no impact on survival. [314]
Studies involving sputum and EGFR expression are limited. In one of the few 
studies looking to identify cells that carry chromosomal alterations indicative of 
malignancy, the overall sensitivity of the FISH assay on induced-sputum from 
52 lung cancer patients was 71% and the specificity was 100%. The most 
frequently detected gains were at 7p12 (EGFR) in 17 of 24 completely 
resectable early-stage (ll+IIIA) non-small cell lung cancers (NSCLC). There 
was a statistically significant increase in the proportion of cases with gains of 
EGFR in SCC, compared with adenocarcinomas (p=0.017), and a higher 
average EGFR gene copy number in the SCCs than in the adenocarcinomas 
(p=0.013). [315]
Cyclin D1
Cyclin D1 has a key role in the cell cycle being of particular importance in the 
G1 to S-phase transition. Mutations, amplification and overexpression of this 
gene, which alters cell cycle progression, are observed frequently in a variety of 
tumors and may contribute to tumorigenesis.
Cyclin D1 was studied in 60 surgically resected NSCLC specimens. There was 
expression in all the samples and over-expression in 50% but there were no 
statistical differences within the different histological subtypes or with different 
stages of disease. [316] When examined on 135 surgically resected lung 
cancer specimens, cyclin D1 expression was found to be a negative prognostic 
marker (p<0.00005) whose expression correlated with a shorter patient survival 
time. [317] The relationship of cyclin D1 over-expression and shorter survival in 
lung cancer was further evidenced by a study of 69 surgically resected NSCLC 
specimens examined by IHC, ranging from stage I and Ilia. 24 samples stained 
positive for cyclin D1 with over-expression being significantly higher in those 
with lymph node metastases (50.0% v 14.4%, p=0.002). The patients with
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cyclin D1 expression had a significantly shorter survival time (29.7 +6.1 months 
vs. 74.6 ±8.6 months, p=0.0066). [318]
We could find no publications relating to cyclin D1 expression in sputum 
samples from lung cancer patients.
p63
p63 is part of the same family of genes as p53. Since they are structurally very 
similar, p63 is thought to have a similar role to p53 with regards to cell cycle 
arrest and apoptosis. In 89 subjects who underwent potentially curative surgery 
for lung cancer, the resected specimens were analysed for p63 expression 
using IHC. p63 expression was found in 47 and in 37/40 of the squamous cell 
carcinomas (SCC), 7/39 of the adenocarcinomas, 1/5 of the small cell 
carcinomas, and 0/5 of the large cell carcinomas. The authors concluded that 
p63 may have a role in the pathogenesis of SCC of the lung. [319] This was 
further evaluated and concluded on a study of 221 tumour specimens from 
patients with stage I NSCLC. p63 expression was seen in 109/118 (92%) 
squamous cell carcinomas, 2/2 (100%) adenosquamous carcinomas and 4/6 
(67%) large cell carcinomas but only 15/95 (16%) adenocarcinomas. 
Furthermore, the prevalence of p63-immunoreactive cells increased 
progressively from pre-neoplastic and pre-invasive lesions to invasive 
squamous cell carcinomas. [320]
A study by Pierre Massion et al suggested that p63 over-expression was 
associated with prolonged survival. They also found that p63 expression was 
amplified in 88% of SCC, 42% of large cell carcinomas, and in 11% of 
adenocarcinomas of the lung. Both, p63 genomic amplification and protein 
staining intensity was associated with better survival. They also found a 
significant increase in the copy numbers, as assessed by FISH, in preinvasive 
lesions that were graded as being severe dysplasia or higher. [321, 322]
We could find no publications on p63 staining in sputum of lung cancer 
patients.
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Strengths and weaknesses of IHC and sputum study
The strengths and weaknesses regarding patient selection are similar to those 
discussed earlier in the FTIR and sputum section of this Chapter.
The two cohorts had similar age, number of smokers with the high-risk cohort 
tending towards having more males (p=0.06). It is important to match for 
smoking status as it is biologically plausible that smoking independently affects 
gene methylation and pre-neoplastic differences in marker expression, before 
progressing to cancer.
Strengths of the study
Unique panel of gene markers:
We chose antibodies that have all been studied in cancer and more specifically 
lung cancer. The theoretical action of each gene makes it plausible that if 
altered in any way this can have a biological role in carcinogenesis. It is also 
more likely that a combination of alterations can lead to cancer (the ‘dual hit’ 
hypothesis) so a combination of markers may at least improve diagnostic 
sensitivity. Most previous studies have looked at IHC staining on tissue 
biopsies and surgically resected specimens. Very few studies have looked at 
sputum IHC in lung cancer and none have used this panel of biomarkers on 
sputum.
Validation of scoring:
I performed the initial scoring alongside Christine Davies (who has over 20 
years experience in cytology and IHC) in order learn the scoring system and 
cell recognition. We then performed the second half (n=17) independently and 
these later scores were assessed for agreement. Scoring independently is 
important as any subjective process can be influenced by the comments or 
immediate presence of others. In normal clinical practice, scoring is generally 
performed on two separate occasions to aim for a consensus.
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Weaknesses of the study
No healthy control cohort:
We did not use a healthy control group. Although a potential weakness, the 
need for healthy controls to retest an established method is debatable. The 
high-risk group acted as ‘controls’ and to a better degree represent the 
background target population for any screening validation.
Time consuming:
The process of immunostaining and interpretation is not only time consuming 
but the antibodies are also very expensive. It takes time to process the cells 
and then subsequently cut and stain the samples, and again more time to 
interpret and score the individual slides. Each sample required staining by 5 
individual antibodies (5 x 83) giving 415 slides that required scoring. 
Preparation of the slides from start to finish can take 2 hours and then it takes 
approximately 4 hours to process an IHC slide, although 30 can be done in a 
single batch.
Poor quality slides:
It became increasingly apparent during the scoring process that some of the 
samples were of poor quality. This was either through the technical process of 
staining and slide preparation or through the sputum cells themselves being of 
low viability for staining. (The good quality cell pellets were allocated to the 
FTIR study first).
229
The way forward: IHC and sputum
This study suggests that our techniques applying this panel of antibodies for 
IHC analysis of sputum, is not accurate in differentiating lung cancer from non­
cancer cases. Although each of the antibodies has a potential role in different 
aspects of the cell cycle and possibly carcinogenesis, they had very poor 
sensitivity and were negative in many cancer cases. Moreover, IHC is currently 
an expensive and labour intensive technique. It has an important role in 
defining certain types of cancer and will remain a necessary tool in medicine, 
but as a screening modality, its role is far less certain. Following this study, we 
do not feel that continued assessment on sputum with this panel of antibodies 
is worthwhile.
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Chapter 11 Exhaled Breath in Lung Cancer-
discussion
Summary of key findings
The main objective of this study was to assess if volatile organic compounds 
detected in (resting) exhaled breath can be used to distinguish subjects with 
newly diagnosed lung cancer from healthy controls. As breath is easily 
obtained non-invasively, it is again more favourable to patients when 
considering a screening / diagnostic modality. It also has less infectious 
potential than sputum or serum. Importantly, the technology allows storage of 
the breath samples at room temperature in non-expensive (and reusable) 
facilities for long periods of time. The apparatus used for sampling was also 
portable which is also desirable in clinical practice for example in General 
Practice / nearside testing.
We prospectively collected 51 breath samples from patients at the time they 
were diagnosed with lung cancer (i.e. before any treatment had been 
commenced). We also collected 50 controls that had no pre-existing history or 
symptoms of respiratory disease or cancer. After exclusions, the spectra from 
the breaths of 47 controls and 44 lung cancers were measured.
Polynomial equations were used to develop mathematical curves that best 
separated lung cancer cases from controls. These equations represented the 
closest mathematical relationship that could be established between retention 
time and area under the curve for lung cancer cases, and separately, controls. 
On visualising the curves, two distinct zones, P1 and P2, are identified 
representing chemical compounds with a retention time from 8 to 17 seconds in 
the GC-MS. These zones contained VOCs only from lung cancer patients 
(27%) and no controls. We could find no other papers using this statistical 
approach to VOCs in lung cancer.
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When all the individual VOCs were identified and a discriminating panel 
considered, 29 VOCs were noted to be exclusive to lung cancer patients (i.e. 
present in patients with lung cancer but not at all in the control cohort). Using a 
panel of 54 VOCs gave a sensitivity of 88.6% and specificity of 100% of 
diagnosing lung cancer from healthy controls.
The cellular pathway of many endogenous VOCs is unknown and needs further 
research, however their endogenous production can be potentially explained by 
whether the VOC is a saturated hydrocarbon, unsaturated hydrocarbon, 
oxygen-containing VOC or nitrogen-containing VOC. [323] These chemical 
groups will now be discussed:
a. The production of VOCs which are saturated hydrocarbons (the 
cyclohexanes; cyclopentanes; decanes; dotriacontane; heptanes; 
nonane,3-methyl) arise from lipid peroxidation of fatty acid components 
of cell membranes, triggered by reactive oxygen species (ROS). This 
pathway is discussed in Chapter 5. Smaller quantities may result from 
protein oxidation and colonic bacterial metabolism. Due to their low 
solubility in the blood they are excreted within minutes of formation. [324]
b. Unsaturated hydrocarbons (1-heptene;napththalene,2-methyl-) may be 
produced by the mevalonic pathway of cholesterol synthesis. An 
example of this pathway is in the use of isoprene (an unsaturated 
hydrocarbon) which is normally found in human breath. The presence of 
isoprene in breath was noted to decrease once subjects had 
commenced cholesterol-limited diets and cholesterol lowering drugs. 
[325] There is also experimental evidence that isoprene exhalation may 
be produced by damage to the fluid lining of the lung and the body. [326, 
327]
c. Oxygen-containing compounds (2-propanol, 1-methoxy-; vinyl ether; N- 
benzyloxcarbonyl-L-tyrosine; hexane, 1-(hexyloxy)-5-methyl-) such as 
acetone are found in the breath and are produced by decarboxylation of 
acetoacetate which is derived from lipolysis or lipid peroxidation. [323] 2- 
propanol is postulated to be a product of an enzyme-mediated reduction
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of acetone. [328] Endogenous ethanol is probably produced by intestinal 
bacterial flora. [329]
d. Nitrogen-containing compounds (piperazine; piperazine adipate) can be 
elevated in the breath of subjects with liver failure or uraemia (high urea 
levels). The odour of uraemic breath is due to elevated levels of 
dimethylamine and trimethylamine. [330]
Although we still do not fully understand how VOCs are made and metabolised, 
or how VOCs are involved in certain molecular pathways, tentative links can be 
postulated. A study looking at exhaled aldehydes in 12 lung cancer, 12 healthy 
controls and 12 healthy smokers found that the cancer patients had higher 
levels of pentanal, nonanal, octanal and hexanal compared to the other 2 
cohorts. They noted that hexanal is known to be generated through oxidative 
cleavage of unsaturated fatty acids, for example, arachidonic acid. [331, 332] In 
recent years, there has been increasing evidence suggesting that the 
arachidonic acid pathway plays a role in lung cancer proliferation. [333-335]
In interpreting the presence of VOCs, one can also look at the absence of 
certain compounds, since carcinogenesis may be causing suppression of 
particular VOCs. 12 VOCs were found only in the breath of our controls and 
absent from all the cancer subjects. Using these 12 VOCs, 45% of controls 
were correctly identified. A further 15 VOCs were universally higher in the 
control group and these VOCs allowed another 15% to be identified as controls. 
Therefore this panel of 27 VOCs unique or universally higher in controls were 
able to correctly identify 60% of controls. These VOCs were either metabolised 
more quickly by those with lung cancer, were absorbed into tissues or simply 
had their production suppressed / diverted into other pathways.
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Comparison with other studies of exhaled breath
There are several techniques that have been used in exhaled VOC analysis in 
lung cancer. Many of these techniques have been discussed in Chapter 5. Our 
study involved GC-MS that is still the most widely used method of measuring 
VOCs.
In the mid-1970s a method of sampling exhaled breath was developed using a 
new sorbent called Tenax (a polymer based on 2,6-diphenyl-p-phenylene 
oxide). [336, 337] This method was capable of measuring sub-parts per billion 
levels. The subject inhales pure humidified and charcoal-scrubbed air from a 
20L Tedlar bag that has previously been filled from a pure air cylinder and then 
exhales into a second 20L Tedlar bag. This bag is then emptied by pumping 
through a glass cartridge containing 1.5g Tenax. [338] An early study was 
carried out based on this by Gordon et al, looking at the exhaled breath of 12 
lung cancer patients and 17 healthy controls. The patients had to inhale purified 
air for 5 minutes and then exhaled 40L of breath into a sampling bag on two 
occasions. On the third occasion this sample was drawn into the cartridge. The 
Tenax cartridges were analysed for volatile organic compounds by a thermal 
desorption GC-MS procedure. The frequency of peak generation was noted 
and the peaks were then matched against a historical library program. [339] 49 
peaks were identified which had statistically significant difference in peak 
occurrence. 4 peaks were present in more than half the lung cancer cohort but 
were absent from the healthy controls. [159]
Phillips et al developed the technique further. They recruited patients who had 
a suspicious CXR and were undergoing bronchoscopy for this. Exhaled breath 
samples were collected within 24 hours pre-bronchoscopy after the subjects 
being fasted overnight, using a portable electrical device. [340] Patients wore a 
nose clip while breathing in and out of the device for 5 minutes. A 1.0L sample 
of breath was pumped through a sorbent trap that contained activated carbon 
and captured the VOCs for analysis. Ambient air samples were also collected 
after each patient sample. The VOCs were then separated by gas 
chromatography and analysed by mass spectrometry. 108 patients were
234
recruited to the study, lung cancer being confirmed histologically in 60 patients 
(50 NSCLC, 10 SCLC) and excluded in 48. Many VOCs were common to both 
sets of breath samples but a group of 22 of these VOCs (identified by 
discriminant analysis) were able to distinguish between lung cancer and control 
cases according to risk weighting attached to the test. For example, the VOCs 
had 100% sensitivity (i.e. no false negatives) and 81% specificity for stage I 
lung cancer if the receiver operator accepted a post-test probability of 0.46 (see 
Figure 11.2). A post-test probability of 0.9 yielded lower 66.7% sensitivity but 
100% specificity (no false positives). The abnormal VOCs consisted of mainly 
alkanes and benzene derivatives. Smoking status alone did not account for the 
benzene derivatives since these were also present in the breath of non- 
smokers and ex-smokers, so it was likely to be a genuine marker for lung 
cancer. Of the 22 VOCs they used as their panel, 3 were exact compounds in 
our 29 cancer-exclusive panel (heptane, 2,2,4,6,6-pentamethyl; nonane,3- 
methyl; 1-heptene) and 3 were similar VOCs (decane; cyclohexane; 
cyclopentane,methyl-) which accounted for a further 7 of our VOC panel. A 
further 3 VOCs from their panel of 22 appear in our VOCs which were “higher in 
cancer” group, either identically (heptane,3-methyl-) or similar (benzene; 
benzene, 1,2,3-trimethyl-). [160]
Using similar methodology, the same researchers compared exhaled VOCs in 
patients with biopsy proven primary lung cancer (n=67); non-lung cancer 
metastasising to the lungs (n=15), abnormal CXRs but no histological evidence 
of lung cancer (n=5) and healthy volunteers from the general population (n=41). 
The breath test identified over 80 different alkanes and mono-methylated 
alkanes that were then used via discriminant functional analysis to generate a 
predictive model using a panel of 9 VOCs. These 9 VOCs, in combination 
yielded a sensitivity of 89.6% and a specificity of 82.9% (using a post-test 
probability of 0.5) of identifying primary or secondary lung cancer. Again, there 
were only minor differences when subjects were stratified according to history 
of tobacco smoking, histological cancer type, or lung cancer staging. 
Interestingly, none of our cancer-exclusive VOCs was in their panel of 9, 
although they did have decane and hexane compounds, which were present in 
our 29. Butane was their best single discriminator, and although not present in
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the 29 exclusive VOCs, we had butane, 2-methyl- present in the higher in 
cancer group as well as hexane,3-methyl-. [161]
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Figure 11.1: An example of the breath collection apparatus used by Phillips et 
al. [161]
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Figure 11.2: Post-test probability of lung cancer by breath VOC assay [160]
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An Italian research group had previously completed a study using the most 
similar apparatus to ours on 36 patients with surgically resected NSCLC, 25 
COPD controls and 50 healthy controls. The cancer breath samples were all 
collected pre-operatively. They used the same breath collection apparatus i.e. 
the BioVOC sampler (Markes International Ltd, Rhondda Cynon Taff, UK) as 
us. After 60 minutes rest, the subjects were asked to perform a single slow vital 
capacity breath into a one-way valve connected to a Teflon®-bulb, which traps 
the last portion of exhaled air (150 ml) (see Figure 11.3). It was not reported 
whether the patients were fasted. Twenty environmental samples were taken 
from the rooms in which the subjects performed the test, in order to compare 
breath and ambient air VOC levels - but the timing of these samples was not 
published. The VOCs were extracted by gas chromatography and analysed by 
mass spectrometry. The NSCLC, COPD and smoking controls had generally 
higher levels of exhaled VOCs than the non-smoking controls suggesting, 
unlike Phillips’ group, that smoking status was very important. Although no 
single VOC could distinguish NSCLC from the other groups, a panel of 13 
VOCs could be used to correctly classify 72.2% of subjects as having NSCLC. 
On the basis of the results the overall sensitivity was 72.2% and specificity 
93.6%. Of their panel of VOCs they included pentamethylheptane and decane 
which were similar to our panel of cancer exclusive VOCs. They also recorded 
trimethyl-benzene, which in our study was one of the VOCs universally higher 
in cancer cases; they also had octane, heptane and benzene and we found 
similar if not exact compounds in the “universally higher in cancer” panel. [162]
Early this year, 2010, Song et al published a study looking at exhaled breath 
from 43 NSCLC patients and 41 healthy controls who were non-smokers, all 
from China. Of the cancer group, 11 patients received 1 cycle of chemotherapy 
and the breath sample was obtained 4 weeks after the treatment, and the rest 
of the cancer cohort did not receive any type of treatment. The patients were 
fasted overnight and 15 ambient air samples were taken from the room where 
the patients gave their samples. The subjects were then asked to breathe 
deeply onto 4L Tedlar® bags. Mixed expiratory samples were collected with no 
restriction on the particular part of breath. All the samples were analysed using 
standard GC-MS. Statistical analysis between the two groups was performed
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using Wilcoxon rank sum test (Mann-Whitney U test). They identified 2 
particular VOCs, 1-butanol and 3-hydoxy-2-butanone which were significantly 
higher in the cancer group compared to the controls (p<0.001). There was no 
significant difference between the level of the 2 VOCs and the different stages 
of lung cancer. They noted that the VOCs they identified were not seen in 
previous panels of VOCs (and are not present in ours), and suggested the 
differences maybe due to the ethnicity of the study population or the fact that 
the study population was small with some of the patients having late stage lung 
cancer. They also commented that their differences may be due to different 
extraction methods, but interestingly did not comment on the fact that 11 of the 
43 cancer patients had undergone chemotherapy, which in itself may have 
altered the endogenous VOC profile. [163]
The main finding from our study was the presence of 29 cancer-exclusive 
VOCs. Many were similar to VOCs reported others but our panel also included 
previously unreported VOCs.
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Figure 11.3: Breath collection and VOC extraction. The subjects performed a 
single slow vital capacity into a Teflon® bulb (Bio-VOC® breath sampler) (a) 
which traps the last portion of exhaled air (150 ml_); the VOCs were extracted 
by directly inserting a 75 mm Carboxen/PDMS SPME fiber (30 min) into the 
bulb (b). [162]
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Strength and weaknesses of exhaled VOCs study
Strengths of the study 
Sample size:
Although we recruited 101 patients initially, for various reasons only 91 patients 
were included in the data analysis. This sample size compares well with others. 
Gordon eta l had a study population of 29 (12 cancers vs. 17 controls); Poli et 
al had 111 (36 cancers vs. 25 COPD vs. 50 healthy controls) and Phillips et al 
initially had 108 (60 cancers vs. 48 controls) and then subsequently changed 
the arms of his study to the have 128. [159-162]
Timing of recruitment:
The patients were recruited as early as possible i.e. at the time of diagnosis 
and before treatment that could change levels of VOCs.
Control group:
The healthy control group consisted of subjects who had no symptoms or 
history of respiratory disease including infection or cancer which may affect 
VOCs. The groups had similar gender distribution helping to eliminate this as a 
potential confounder. Although there was a significant difference in self- 
reported smoking status (especially never smokers) between the two groups 
(p<0.001), similar proportions had smoked within 24 hours of their breath 
sampling as judged by eCO levels >10 ppm (p=0.83). This is probably of more 
direct relevance, as smoking within 24 hours should have greater effect on the 
exhaled VOCs. Some previous studies have shown no significant effect of 
smoking status on VOCs, whilst others have shown increased levels of a large 
number of VOCs when comparing smoking controls with their non-smoking 
counterparts. [161,162] It is possible that although some subjects said they 
were smokers at time of diagnosis / recruitment, the fear of having cancer may 
have shocked them into stopping smoking prior to further investigations.
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Validation of smoking status:
All previous studies on lung cancer and VOCs did not vaildate smoking status 
but relied on self-reporting. We are the first to validate smoking status using a 
standard definition of exhaled CO level above 10 ppm to confirm the 
consumption of a cigarette in the preceding 24 hours. 15% of our cancer 
subjects and 12% of controls had smoked within 24 hours prior to sampling. As 
each cigarette contains over 4000 noxious chemicals and burns at over 400° 
centigrade, it seems plausible they will acutely affect VOCs but the timescale 
taken for VOCs to return to baseline after each cigarette is unknown.
Fasting participants pre-test:
We fasted all our patients for 4 hours, which we felt was both feasible and 
realistic bearing in mind our study population, many of whom had co­
morbidities. Although there was no clear guidance in the literature over fasting, 
it was felt that eating certain foods or drinking certain beverages might alter the 
VOC components of the breath. Phillips etal, found evidence in 12 healthy 
subjects that many VOCs had higher alveolar concentrations than ambient air 
concentrations suggesting these VOCs were either synthesised in the body, or 
absorbed from another site, possibly as a drug or in the food. Figure 5.3 is a 
schematic of the potential mechanisms of endogenous / exogenous VOC 
production postulated by Phillips et al. [250] There are other studies which 
have also reported the presence of VOCs in food products. [341, 342] 
Unfortunately the dietary intake of the subjects was not recorded.
Resting participants pre-test:
It was important that all subjects were rested for 20 minutes pre breath test for 
three reasons.
1) strenuous exertion can cause increased oxidative stress and thus 
changes in VOC concentration [273, 274]
2) by remaining in a single room for 20 minutes the subject was able to 
inhale the surrounding environmental air to allow better equilibrium for 
alveolar air. Although there is no clear indication from the literature as to 
how long a subject should be inside a room, pharmacokinetic models
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assumes that inhaled air resides inside the alveoli for sufficient time to 
allow VOCs to reach equilibrium with arterial blood. [338]
3) blood flow rate through the alveoli is not linear with breathing rate, thus 
different levels of exertion could potentially have an effect on equilibrium 
being reached.
We felt that 20 minutes provided enough time for the individual to fully recover 
from any exertion and for them to return back to their resting heart and 
respiratory rate whilst also keeping the methodology simple and time efficient.
Ambient air sampling:
We took ambient air samples from the same room immediately before each set 
of breath samples were taken. This allowed us to analyse how many of the 
discriminating VOCs were present in the air and if these were affecting the 
results. A study looking at the variation of VOCs within normal human breath 
took 50 fasted subjects and analysed their exhaled breath using GC-MS. There 
was a mean of 204 VOCs (range 157 -  241) per individual breath, and a total of 
3,481 VOCs were observed at least once (the majority were only identified 
once). Only 27 VOCs were present in all subjects. Ambient air samples were 
taken for each individual and any VOCs were subtracted from their 
corresponding breath sample to create “alveolar gradients”. A positive alveolar 
gradient suggests there was more in the breath than in the air and vice versa 
for the negative alveolar gradient. Of the 3,481 VOCs detected, 1,753 had 
positive alveolar gradients and 1,728 had negative ones, although the majority 
of the negatives were found in only one subject. It has been postulated that 
when there is more of a certain VOC in the ambient air sample compared to the 
exhaled breath (i.e. negative alveolar gradient) then this corresponds with 
increased clearance of the VOCs via hepatic and/or renal pathways. [283]
Phillips et al, has considered how researchers have approached the situation of 
when VOCs are present in both the ambient air sample and the subject’s 
exhaled breath, raising the question of whether the VOC originated from within 
the body or whether it is just contamination from inhaling the surrounding air. 
They considered three approaches [283]:
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1) Ignore the problem, either by not collecting a corresponding ambient air 
sample like some [159, 164], or by collecting them but not fully 
incorporating the air samples in the overall analysis. [162, 256]
2) Provide the subjects with VOC-free air to breathe or to breathe through 
apparatus to filter out VOCs, prior to sample collection. [252, 343]. 
Although this seems reasonable, Phillips felt that it is virtually impossible 
to achieve VOC-free air in practice.
3) Correct for VOCs in the ambient air by, subtracting it from the exhaled 
breath VOCs [160, 161, 283], or by filtering out those VOCs which are 
higher in the air sample or only marginally less than the exhaled breath 
sample. [344]
In the studies discussed earlier in this Chapter, Poli et al took twenty ambient 
air samples from the rooms in which the subject samples were taken but it was 
not commented whether this was done at the same time as the subject sample 
or randomly or even on different days. [162] Song et al, took 15 ambient air 
samples from the rooms that the patients samples were collected, however, it 
was not clear at which point in time these air samples were taken. [163] Phillips 
et al did take ambient air samples at the same time as the subject samples. 
[160, 161]
In our study, when considering the 29 cancer-exclusive VOCs, some of these 
were only present in the corresponding air samples of 2 patients. In fact S15 
accounted for the majority of the cancer-exclusive VOCs found in their air 
samples, with the air and patient samples being taken at the subject’s home. 
We cannot recall anything unusual about his home and it was not next to a 
main road or near a factory and the background (ambient air sample) showed 
no unusual spectra. S15 was a male who was previously fit and well. He had an 
extensive smoking history of greater than 100-pack year history. Thus in the 31 
patients correctly classified as having lung cancer based on the panel of 29 
VOCs, 29 had none of the discriminating VOCs in their ambient air samples, so 
subtraction or calculation of ambient gradients is not needed. Of the 12 VOCs, 
found exclusively in controls, only in 2 patients were some VOCs found in their
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corresponding air sample meaning that at least 19/21 of the controls had these 
exclusive VOCs from an endogenous source rather than from background air. 
Reassuringly, none of the VOCs that were universally higher in controls were 
present in their corresponding air samples.
We believe that only by simultaneously assessing the ambient air samples for 
every single breath test can we really be sure that compounds are endogenous 
rather than contaminants.
Triplicate samples:
Following external review on early pilot data, we amended our protocol and 
collected the patient samples in triplicate after the first 16 patients. This was to 
evaluate the consistency of VOC production / exhalation and measurement 
within the individual subjects in the same 5 minute session. This does not 
appear to have been done before in lung cancer using GC-MS. The other 
advantage of performing multiple samples is to ensure that important VOCs are 
not missed due to poor subject technique (for example not full exhalation) or 
individual tube leaks.
After taking the triplicate samples, we noticed some inconsistencies in VOCs 
measured for each subject. Although the actual (qualitative measurements) 
VOCs themselves appeared similar across the three samples, after the first 
sample some of the subsequent samples appeared to have lower levels of the 
same VOCs. There were other occasions when the 2nd or 3rd patient sample 
contained the higher level of VOCs. Possible explanations could be some of the 
patients providing good slow vital capacity initially but then becoming fatigued 
with subsequent attempts to fully exhale not being as good quality.
Alternatively, where the VOCs concentrations were higher in the later tubes 
participants could be improving their technique with practice. There may also 
be variations in the sealing of the tubes and connecting tubes to the GC-MS.
Breath sample collection apparatus:
The apparatus used for sample collection was small, lightweight so very 
portable. (Indeed we have sent some equipment to Canada recently). It was
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also straightforward to use for the investigator and patient. The subjects were 
merely required to perform a slow vital capacity breath and then the sample 
could be stored at room temperature (in a tin) for up to several months and not 
require freezing or specialist storage facilities. Such a technique would be 
feasible to use in clinical practice (e.g. as a bedside test).
Weaknesses of the study
Sample size:
I discussed our sample size with Michael Phillips, Clinical Professor of Clinical 
Medicine, New York Medical College; he stated:
“A good rule of thumb in multivariate analysis is that you need at least 6 
subjects in the disease group for each variable in your predictive algorithm”
Taking this into account, using each of the 29 cancer-exclusive VOCs as a 
variable, we would ideally require at least 174 (i.e. 29 x 6) lung cancer patients. 
For multivariate analysis, our study is likely to be underpowered.
Participant demographics:
Our control group was significantly younger than the lung cancer group 
(p<0.001). Phillips et al studied the effect of aging on VOCs, where they 
investigated 102 subjects ranging from the ages of 9 to 89. The abundance of 
VOCs increased significantly with advancing age (p<0.001), which could 
represent increased oxidative stress as one gets older although there may be 
contribution from the decline in clearance of the cytochrome P450 system.
[242] Bearing this in mind, it would be ideal to have a more age-matched group 
(e.g. spouses rather than medical staff) to eliminate this confounder.
Sampling from multiple rooms:
Ideally the subject samples should all have been taken in a single room to 
minimise the effect of different ambient air mixtures on the VOCs. Not only can 
these directly ‘contaminate’ the collection apparatus (e.g. tubes and plunger) 
but they are inhaled and then exhaled by subjects. However, even in the same 
room, there are continuous changes in VOC concentrations, so we relied on
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taking ambient air samples before each set of breath samples. We did not take 
ambient air samples in triplicate because of resource implications (number of 
tubes and GC-MS technician time). Phillips et a/took ambient air samples in 
the bronchoscopy suite after the patient samples. Poli et al took 20 ambient air 
samples from the room but did not state at which point these were taken and 
neither did Song e ta l(See previous section comparing other studies).
Equipment failure:
During late April 2009, a set of 7(x3) patient samples and their ambient air 
samples (28 tubes in total) were processed but were identified to have a very 
diminished level of total VOCs (<20 VOC peaks) and low levels of each VOC 
detected. Laboratory procedure records were reviewed and it was noted that 
there was a pressure loss in the helium supply during the secondary desorption 
phase on this sample run. Also, the heavy use of the equipment at this time 
required the cold trap to be reconditioned. Replacing the helium cylinder and 
reconditioning of the cold trap later corrected this. These 28 samples were not 
included in the analysis.
Improving trapping of VOCs:
The Teflon bulb used only collected the last 129ml of exhaled breath. If we had 
a larger collection device or a method of collecting multiple breaths on to one 
tube, this would mean a greater volume of breath and a larger number of 
VOCs. There is also the problem of breath condensation within the tubes. The 
human breath contains much more vapour than VOCs and although the 
sorbents within the tubes that trap the VOCs are hydrophobic and should repel 
the vapour, it is thought that the water can compete with the VOCs in reaching 
the binding sites of the sorbent thus interfering with the trapping of the VOCs. 
One solution to this potential issue would be having equipment which removes 
the water vapour from the exhaled breath prior to VOC sampling. The breath 
vapour itself might also contain VOCs.
One further technical issue which may have affected the trapping of VOCs was 
the varying speeds at which the plunger was pushed to transfer the exhaled
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breath into the sorbent tube. Excessive speed will prevent trapping of 
VOCs. An automated system would remove operator influence.
Separation column:
We used non-polar columns in the GC-MS. If we had used a combination of 
non-polar and polar columns in series, then polar VOCs such as alcohols would 
be more readily detected and better separated. Also, the starting temperature in 
the column was 40°C which was then heated to 200°C. By having a GC 
oven which started at a lower temperature, for example 0°C, more highly 
volatile compounds might be detected. This requires an additional cooling unit 
which was not present on the equipment.
Mass spectrometer:
Some mass spectrometers are more sensitive and thus pick up lower 
concentration VOCs and also have less background noise. This might offer 
improvements given the low abundance of VOCs in breath.
VOC identification and validation:
Automated peak detection was used to calculate peak area (area under the 
curve) and retention time for each compound. Each match was also assigned a 
quality rating based on how well it matched the chemical library. There is some 
debate on what is deemed an acceptable quality rating and in this preliminary 
analysis we wanted to include all VOCs before excluding a potentially key 
compound. [281] Further analysis is being planned where we will include only 
those compounds with a quality rating above 50% (most of our VOCs) to see if 
this alters any key findings. Extensive manual peak identification was also 
performed to check the validity of the automated matches; ideally however, the 
identity of the compounds should be verified by comparing retention times of 
pure chemicals injected into the sorbent tubes (and tested as with the breath 
samples) allowing precision and accuracy testing in our environment. 
Unfortunately we did not have the resources for this, as each standard VOC 
sample is expensive and calibration is time consuming.
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Number of VOCs detected:
Having discarded VOCs which occurred on less than 5 occasions overall, the 
total number of VOCs identified was 246. In comparison, using Phillips’ 
technique, we have already discussed how in normal healthy human breath he 
was able to detect 3,481 VOCs in total and a mean of 204 VOCs per patient 
from the 50 patients sampled. [283] The relative lack of total number of VOCs 
may well represent trapping difficulties when the patients are giving exhaled 
breath, or GC-MS detection difficulties especially of VOCs low in concentration. 
The fact that we discarded those VOCs which occurred less than 5 times will 
have some impact on the total number of VOCs but this impact is likely to be 
small, with these compounds tending to be poor quality matches.
Validation of cancer-exclusive compounds and statistical techniques:
Although 29 cancer-exclusive VOCs were identified some occurred in just 1 
lung cancer patient and not in the other 43 and it may have occurred in only 1 
out of that patient’s triplicate samples. The validity of these VOCs is difficult to 
assess at this stage but we are considering further collaborations with the 
Department of Engineering to apply further discriminatory statistics based on 
categorical clusters on larger sample numbers. Here for example, we would 
first concentrate on VOCs found in all 3 samples of lung cancer subjects but in 
0/3 samples of all controls. A secondary analysis would be looking at a VOC 
found in 2/3 samples of lung cancer patients and 0/3 of controls etc. Another 
approach which is being undertaken is to take the median values of each VOC 
across the triplicates and compare them between the cancer and control 
cohorts to see if any are exclusive or universally higher.
With sufficient data available for these 29-54 VOCs, a further way to validate 
these tentative findings is to use a method such as logistic regression 
to generate a linear model using a training dataset and test it prospectively on 
many more subjects. The resulting linear model equation would allow 
prediction of cases as being either lung cancer or non-lung cancer.
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The way forward: exhaled VOCs and lung cancer
This study has identified certain volatile organic compounds, which are present 
exclusively in lung cancer patients and are able to classify a high percentage of 
them correctly. Even on 50-80 samples, two distinct polynomial equations 
representing lung cancer and controls could be developed. Further testing on at 
least 180 treatment naive patients with lung cancer, together with refinements 
in technique (single room for collection, comparing against age / smoking- 
matched controls, continuous monitoring for helium leaks) should test the 
specificity and sensitivity of our test. Recruitment continues locally with other 
centres (e.g. Canada) joining the project.
The various studies assessing VOCs in lung cancer have developed varying 
panels and this will continue to be the case until technology is refined and 
clinical sampling is standardised. We too have applied unique techniques 
(triplicate samples, simultaneous ambient air and novel statistical modelling) 
and added to the body of knowledge in VOC analysis in lung cancer to show 
some promising results. Our group wants to pursue and expand on the early 
pilot work with the ultimate goal of developing non-invasive diagnostic and 
ultimately screening tests for lung cancer. However, the concepts remain 
experimental at this stage, and the optimal methodology is still being worked 
out. Better understanding of VOCs may even give some ideas of the biological 
pathways for lung cancer opening up new targets for future therapies.
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Closing statement
Lung cancer is a common and devastating disease for which most people will 
have no cure. During the last 4 years I have developed a better understanding 
of research and how to approach it. I have learnt laboratory skills such as slide 
preparation and scoring for immunohistochemistry as well as techniques such 
as Fourier Transform Infra-Red and gas chromatography -  mass spectrometry. 
It has also given me an opportunity to learn complex multivariate statistical 
analysis as well as more standard statistical methods and to identify 
weaknesses of the methodology in order to strengthen the studies. The studies 
are to be pursued with the ultimate goal of developing a screening test that can 
identify lung cancer patients early enough to have a positive impact in reducing 
mortality rates.
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Appendix 1
HEADED NOTEPAPER 
PATIENT INFORMATION SHEET -version 2, 8th February 2006
Title: Assessing early detection biomarkers in lung cancer
You are being invited to take part in a research study. Before you decide it is 
important to explain why the research is being done and what it will involve. 
Please take time to read the following information carefully and discuss it with 
friends, relatives and your GP if you wish. Ask us if there is anything that is not 
clear or if you would like more information. Take time to decide whether or not 
you wish to take part.
Consumers for Ethics in Research (CERES) publish a leaflet entitled “Medical 
Research and You”. This leaflet gives more information about medical research 
and looks at some questions you may want to ask. A copy may be obtained 
without charge from CERES, PO BOX 1365, LONDON N16 OBW.
1. What is the purpose of the study?
We believe that chemicals and tiny cell abnormalities may be important in 
detecting lung cancer. These chemicals or biomarkers may be detectable 
even before patients develop symptoms or abnormal chest x-rays. We 
want to test if these chemicals can be detected in the spit and biopsy 
specimens of lung cancer and also if they are detectable in patients who 
do not yet have visible lung cancers.
2. Why have I been chosen?
Your doctor is concerned that you may be suffering from lung cancer and 
we would like you to be one of our trial subjects whilst you attend our 
clinic and bronchoscopy.
3. Do I have to take part?
It’s up to you to decide whether or not to take part. If you do decide to 
take part, you will be given this information sheet to keep and be asked to 
sign a consent form. If you decide to take part you are still free to 
withdraw at any time and without giving a reason. If you withdraw after a 
long period of time, you must be aware that we may have already 
measured your samples. Withdrawal will not affect the standard of care 
you receive.
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4. What will happen to me if I take part?
Following standard assessment and care in our clinic, we would like to 
send 2 extra samples of your spit for chemical analysis, when you attend 
for bronchoscopy. During the bronchoscopy, we will also take 2-4 small 
samples in addition to the standard tests. These samples will be taken to 
Swansea University for special analysis and disposed of after 10 years.
After the bronchoscopy, you will receive our standard treatment for your 
condition. Normally, if all our tests are clear and you get better, we would 
discharge you after 1 year. For this research however, we would like to 
see you in clinic for a clinical review once a year for 5 years, even after all 
other tests and treatment, or simply for a check-up. This research does 
not involve any extra or different treatment to normal but we will take 
extra samples in the beginning and follow you over a longer time.
5. What do I have to do?
There are no lifestyle restrictions and we want you to continue with 
standard treatment at all times.
6. What are the side-effects of taking part?
We are not trying out any new treatments but this would involve the 
inconvenience of providing an extra spit test and extra samples at 
bronchoscopy.
You will not feel the extra samples being taken at bronchoscopy.
Each sample is about 1-2 mm in size. Normally there is a small (1 in 100) 
chance of bleeding but the extra research biopsies are 1 in 50 chance of 
bleeding. The procedure will be performed by an experienced doctor and 
won’t be performed until standard samples are taken and only if you are 
still well. It should not mean any extra time in hospital. You will be asked 
to attend clinic 1 year later and once a year for five years, even if you are 
well. This is to see if any of the biomarkers predict disease developing 
later on. These annual visits may entail extra inconvenience.
7. What are the possible benefits of taking part?
The extra annual appointments for five years may detect future cancer 
early, before it causes symptoms or spreads. The results of the research 
using your samples, and those from others -  may benefit lung cancer 
patients in the future. We cannot pay you for your participation in the 
study.
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8. What happens when the research study stops?
After five years, we will review you in clinic only if needed as part of 
standard NHS care.
9. What happens if something goes wrong?
If you have reason to complain about any aspect of the way you have 
been approached or treated during the course of the study, the normal 
National Health Service complaints mechanisms are available to you.
10. Will my taking part in this study be kept confidential?
All information collected about you during the course of the research will 
be kept strictly confidential. Any information that leaves the hospital will 
be coded so that you cannot be recognised from it. Your GP will be 
notified that you have helped us with this study but won’t know the 
results of the research. Information will not be made available to any life 
insurance or private medical insurance companies.
11. What will happen to the results of the research study?
The results may be published in scientific journals and presented at 
conferences. You are welcome to contact the researchers for a report, 
when this study ends (2014). Individuals will not be identified in any 
report/publication. The researchers in the hospital or those giving 
treatment will not know the results of the biomarker tests because these 
biomarkers are not currently part of standard treatment.
12. Who is organising and funding the research?
This is jointly organised through our local hospitals and University of 
Wales Swansea.
13. Who has reviewed the study?
This has undergone peer review by academic colleagues within Wales 
and has been presented to the Research Ethics Committees in Swansea 
and Dyfed Powys.
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Contact for further information.
If you have any further queries please contact: 
Dr Keir Lewis
Consultant Physician in Respiratory Medicine, 
Carmarthenshire NHS Trust and 
Senior Lecturer,
School of Medicine,
Swansea University.
*  01554 783133
Fax: 01792-513054
Email k.e.lewisdcbswansea.ac. uk
Or
Dr Philip Kloer
Consultant Physician in Respiratory Medicine, 
Carmarthenshire NHS Trust
9  01554 783569
Or
Dr Carol Llewellyn Jones
Consultant Physician in Respiratory Medicine, 
Carmarthenshire NHS Trust
a  01267 227616
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Appendix 2 
HEADED PAPER
CONSENT FORM-Version 1. 8th November 2005
Study Number ...05/WMW01/75
Patient Identification number for this trial............................... N.B. Three copies will be
made For
(1) patient
(2) researcher
(3) hospital notes
Title of Project: Assessing early detection biomarkers in lung cancer
Name of Researchers: Dr Keir Lewis, Dr Paul Lewis, Dr Phil Kloer, Dr Carol
Llewellyn -Jones, Dr Robin Ghosal.
Contact Telephone Number: 01554 783133
Please Initial
Box
1. I confirm that I have read and understood the information sheet
for the above study and have had the
opportunity to ask questions.
2. I understand that my participation is voluntary and that I am free
to withdraw at any time, without giving any reason, without my 
medical care or legal rights being affected.
3. I understand that sections of any of my medical notes may be looked
at by responsible individuals from Dr Lewis’ research team
or from regulatory authorities where it is relevant to my taking part 
in research. I give permission for these individuals to have access to 
my records.
4. I agree to take part in the above study.
Name of Patient Date Signature
Name of Person taking consent Date Signature
Researcher Date Signature
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Appendix 3
HEADED NOTEPAPER
GP INFORMATION SHEET (version 2: 8th February 2006)
Title of study: 
Assessing early detection biomarkers in lung cancer 
(LREC number 05/W M W 01/75)
Your patient has agreed to participate in the
above study that is being organised through Carmarthenshire NHS Trust and 
Swansea University.
This involves standard assessment in our lung cancer clinic but an extra 
sputum test prior to bronchoscopy and 2-4 extra biopsies taken during standard 
bronchoscopy. They will then also be asked to attend chest clinic, annually for 
five years, to see if certain biomarkers predict later development of lung cancer.
This is an observational study and all standard NHS treatment will continue 
throughout the study. Management will not be compromised in any way.
All information will be kept in the strictest confidence and no individual patients 
can be identified by anyone other than the lead researcher.
Subjects have provided written consent and can withdraw at any time from the 
study.
Dr Keir E Lewis
Senior Lecturer Swansea School of Medicine and Consultant in 
Respiratory Medicine 
Carmarthenshire NHS Trust
Dr Paul Lewis
Lecturer South West Wales Cancer Institute
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Appendix 4
Clinical Record Form (version 2: 15th Aug 2007 )
ID Number  Surname........................ Forename..................
Hospital No.............  Consent Date.................
Consent Taker  Visit No  Hospital... POW/PPH/WWGH
Medical Hx: .......................................................................................
Past Hx of Cancer....Y/ N Type of Cancer
Drug Hx: ..................................................
Smoking H x  Current/ Ex/ Never No. of Pack Yrs......
Occupation................................... Hx of Asbestos Exposure... Y/ N
FHx of Cancer Y/ N Type/Relative........................
FEVi ..n/a o r ...........% of Pred
Performance Status ...0/1/ 2/ 3/ 4 Suspected Infection Y/ N
CO level...................ppm O2 Sats pre-bronch %
CXR.................................................................................................
Symptoms
Wt loss....Y/ N Haemoptysis....Y/ N Unexplained SOB....Y/N 
Cough....Y/N Chest Pain.... Y/ N Hoarse Voice....Y/N
Examination
Clubbing....Y/N Lymphadenopathy....Y/ N SVCO... Y/N
Organomegaly... Y/N Cachexia...Y/N Monophonic Wheeze. Y/N 
Pleural Effusion...Y/ N
Bronchoscopic View.........................................................................
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Diagnosis
Clinical / Radiological diagnosis of Lung Cancer.... Y/ N
Sputum Cytology....Positive/ Negative/ Not applicable 
(report)................................................................................
Bronchoscopy Histology.....................................................
Final Diagnosis (histology) ...NSCLC / SCLC/ Other 
Other details..............................................
Lung Cancer Staging.... (NSCLC) T N M
(SCLC) Limited / Extensive
Sample Collection
Sputum
Biopsy
□ Time:
□ Time:
Samples Collected by Date
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Appendix 5
HEADED NOTEPAPER 
HEALTHY CONTROLS INFORMATION SHEET- version 2, 30th September
2008
Title: Assessing early detection biomarkers in lung cancer
You are being invited to take part in a research study. Before you decide it is 
important to explain why the research is being done and what it will involve. 
Please take time to read the following information carefully and discuss it with 
friends, relatives and your GP if you wish. Ask us if there is anything that is not 
clear or if you would like more information. Take time to decide whether or not 
you wish to take part.
1. What is the purpose of the study?
We believe that chemicals and tiny cell abnormalities may be important in 
detecting lung cancer. These chemicals or biomarkers may be detectable 
even before patients develop symptoms or abnormal chest x-rays. We 
want to test if these chemicals can be detected in breath, spit and biopsy 
specimens of patients suspected of having lung cancer compared to 
healthy controls and patients with chronic lung disease.
2. Why have I been chosen?
We would like you to be one of our healthy control subjects.
3. Do I have to take part?
It’s up to you to decide whether or not to take part. If you do decide to 
take part, you will be given this information sheet to keep and be asked to 
sign a consent form. If you decide to take part you are still free to 
withdraw at any time and without giving a reason.
4. What will happen to me if I take part?
Following screening questions, we will ask you for your age and then will 
ask you to breathe deeply into a container that measures the amount of 
carbon monoxide in your breath. This number will be recorded on a data 
sheet and is a marker of pollution and cigarette smoke exposure that can
262
alter chemicals in your breath. We will then ask you to spit into a 
collection container and these sputum samples will be taken to Swansea 
University for special analysis looking at different types ‘biomarkers’ 
before being stored in freezers. The samples will disposed of after 10 
years.
5. What do I have to do?
There are no lifestyle restrictions and we want you to continue with your 
normal activities unchanged.
6. What are the side-effects of taking part?
There is the inconvenience of taking 5 minutes of your time to answer the 
6 simple screening questions.
7. What are the possible benefits of taking part?
The results of the research using your samples, and those from others -  
may benefit lung cancer patients in the future. We cannot pay you for 
your participation in the study.
8. What happens when the research study stops?
Your sputum will be stored in the University but there is no other clinical 
contact needed.
9. What happens if something goes wrong?
If you have reason to complain about any aspect of the way you have 
been approached or treated during the course of the study, the normal 
National Health Service complaints mechanisms are available to you.
10. Will my taking part in this study be kept confidential?
All information collected about you during the course of the research will 
be kept strictly confidential. Any information that leaves the hospital will 
be coded so that you cannot be recognised from it. Information will not 
be made available to any life insurance or private medical insurance 
companies.
11. What will happen to the results of the research study?
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The results may be published in scientific journals and presented at 
conferences. You are welcome to contact the researchers for a report, 
when this study ends (2009/10). Individuals will not be identified in any 
report/publication. The researchers will not know the results of the 
biomarker tests because these biomarkers are not currently part of 
standard treatment.
12. Who is organising and funding the research?
This is jointly organised through our local hospitals, Swansea University 
and funded by the Welsh Assembly Government.
13. Who has reviewed the study?
This has undergone peer review by academic colleagues within Wales 
and has been presented to the Research Ethics Committees in Swansea 
and Dyfed Powys.
Contact for further information.
If you have any further queries please contact:
Dr Keir Lewis
Consultant Physician in Respiratory Medicine, 
Carmarthenshire NHS Trust and 
Senior Lecturer,
School of Medicine,
Swansea University.
«  01554 783133
Fax: 01792-513054
Email k. e. Iewis(a)swansea. ac. uk
Or
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Dr Philip Kloer
Consultant Physician in Respiratory Medicine, 
Carmarthenshire NHS Trust
9 01554 783569
Or
Dr Paul Lewis,
Lecturer in Biomedical Science,
Institute of Life Science,
Swansea School of Medicine,
Swansea University,
SA2 8PP 
9  01792 295222
Appendix 6 
HEADED NOTEPAPER 
PATIENT INFORMATION SHEET- version 2, 3rd June 2008
Title: Smoking status, exhaled volatile organic compounds and lung
cancer
You are being invited to take part in a research study. Before you 
decide it is important to explain why the research is being done and 
what it will involve. Please take time to read the following 
information carefully and discuss it with friends, relatives and your 
GP if you wish. Ask us if there is anything that is not clear or if you 
would like more information. Take time to decide whether or not you 
wish to take part.
1. What is the purpose of the study?
We believe that smoking status at the time of diagnosis of lung 
cancer and after may have an impact on the course of the condition, 
and we want to test to see if this is the case. Smoking is one of the 
main causes of lung cancer and we believe that continued smoking 
even after diagnosis may “fuel” the cancer as well as interfere with 
treatment compared with not smoking. We also want to see if 
chemicals present in your breath (but not detected by routine tests) 
will have an impact on your condition and whether these chemicals 
change over time.
2. Why have I been chosen?
Your doctor is concerned that you may be suffering from lung 
cancer and we would like you to be one of our trial subjects if this 
diagnosis is confirmed.
3. Do I have to take part?
It’s up to you to decide whether or not to take part. If you do decide 
to take part, you will be given this information sheet to keep and be 
asked to sign a consent form. If you decide to take part you are still 
free to withdraw at any time and without giving a reason. If you 
withdraw after a long period of time, you must be aware that we may 
have already measured your samples. Withdrawal will not affect the 
standard of care you receive.
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4. What will happen to me if I take part?
If, following standard assessment and care in our clinic, we believe 
you do have lung cancer, we will obtain special breath test samples. 
The first of these will involve you taking a breath in and then holding 
it for 15 seconds before slowing breathing out into a monitor, which 
has a disposable mouthpiece. The second breath test will involve 
you simply taking a couple of deep breaths in and out, then blowing 
slowly into a piece of measuring apparatus. Together, these 
procedures should take under 3 minutes.
We will see you once a month in the hospital (this will coincide with 
your normal clinic appointments wherever possible). On each visit, 
the two breath tests are repeated and you will have a brief 
examination and any problems will be addressed. Should you 
become unwell or are unable to attend hospital, two of the doctors 
can come to your home if you are happy for the breath tests to be 
performed there and this visit could be at the same time as any other 
planned home visits by e.g. specialist nurses, to avoid further 
inconvenience. All extra travelling and car parking costs as a result 
of the study will be reimbursed by the research team.
5. What do I have to do?
There are no lifestyle restrictions and we want you to continue with 
standard treatment at all times.
6. What are the side-effects of taking part?
We are not trying out any new treatments but participation in the 
study will involve the inconvenience of attending the hospital once a 
month for the next 12 months. These consultations will only lasts 10 
minutes, and you will not have to wait around for too long prior to 
being seen. The breath tests do not hurt.
7. What are the possible benefits of taking part?
The extra monthly appointments during the year will allow us to 
assess your general health and address any problems. It will give 
you more contacts than usual with the doctors treating you. The 
results of the research may benefit lung cancer patients in the 
future.
8. What happens when the research study stops?
After one year, we will review you in clinic only if needed as part of 
standard NHS care.
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9. What happens if something goes wrong?
If you have reason to complain about any aspect of the way you 
have been approached or treated during the course of the study, the 
normal National Health Service complaints mechanisms are 
available to you.
10. Will my taking part in this study be kept confidential?
All information collected about you during the course of the 
research will be kept strictly confidential. Any information that 
leaves the hospital will be coded so that you cannot be recognised 
from it. If you agree, your GP will be notified that you have helped 
us with this study and they will be allowed access to any published 
results, although individual patients results will not be available to 
them. Information will not be made available to any life insurance or 
private medical insurance companies.
11. What will happen to the results of the research study?
The results may be published in scientific journals and presented at 
conferences. You are welcome to contact the researchers for a 
report, when this study ends (2009). Individuals will not be identified 
in any report/publication.
12. Who is organising and funding the research?
This is jointly organised through Carmarthenshire NHS Trust and 
Swansea University.
13. Who has reviewed the study?
This has undergone peer review by academic colleagues within 
Wales and has been presented to the Research Ethics Committees 
in Dyfed Powys.
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Contact for further information.
If you have any further queries please contact:
Dr Robin Ghosal,
Clinical Research Fellow,
Hywel Dda NHS Trust,
9 01554 756 567 pager 873
Or
Dr Keir Lewis
Consultant Physician in Respiratory Medicine, 
Hywel Dda NHS Trust and 
Senior Lecturer,
School of Medicine,
Swansea University.
9 01554 783133
Fax: 01554 783597
Email k . e . l e w i s d c b s w a n s e a . a c . u k
Or
Dr Philip Kloer
Consultant Physician in Respiratory Medicine, 
Hywel Dda NHS Trust
9  01554 783569
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Appendix 7 
Lung Cancer Clinical Data Proforma
Pt Name..................................................... DOB...................
Patient Number......................Telephone number.
Age....................................
Date of consultation..........................  Consultant
CXR........................................................................................................
Symptoms: Cough / Wt loss / Haemoptysis / Hoarse voice / Chest pain / SOB
Co-morbidities COPD IHD DM CVA Obesity tBP Ca 
Other...................................
Tumour Position : Central / Peripheral FHx Y /N
Occupation...............................  Asbestos exposure Y /N
FEVi %ofPred Performance Status 0 1 2  3 4
CO level at clinic .....................ppm Date of 1st C O ...................
Smoking Hx Current / Ex / Never / Passive No. of pack years....................
Current no. cigarettes per day................. Referred for smoking cessation
Y N Declined
Final Diagnosis No Ca / Small Cell / NSCLC / Other
i
Date of diagnosis
I
i
| Subtype Squamous / Adenocarcinoma / Large cell / Undifferentiated
CT scan staging T N M Stage.......... Limited / Extensive
Cancer treatment Surgery / Radical Radiotherapy / Chemotherapy / 
Radiotherapy / Palliative
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Smoking Status Validation:
Month CO level 
(PPM)
Current no. of 
Cigarettes/ day
Date Month CO level 
(PPM)
Current no. of 
Cigarettes/ day
Date
1 5
2 6
3 7
4 8
D o D....................................... Signed
Version 1. Ghosal R / Kloer PJ / Guy C. Feb 2008
Appendix 8 
HEADED PAPER 
C O N S E N T  FORM-Version 1, 23rd March 2008
Study Number ...08/WMW01/21
Patient Identification number for this tria l............................... N.B. Three copies will be
made for
(1) patient
(2) researcher
(3) hospital notes
Title of Project: Smoking status, exhaled volatile organic compounds and lung
cancer
Name of Researchers: Dr Robin Ghosal, Dr Keir Lewis, Dr Phil Kloer, Dr Elinor
Young, Dr Jacqui Orme
Contact Telephone Number: 01554 783133
Please Initial
Box
1. I confirm that I have read and understood the information sheet I I
for the above study and have had the I---------1
opportunity to ask questions.
2. I understand that my participation is voluntary and that I am free I---------.
to withdraw at any time, without giving any reason, without my I_____ |
medical care or legal rights being affected.
3. I understand that sections of any of my medical notes may be looked
at by responsible individuals from Dr Ghosal’s research team I I
or from regulatory authorities where it is relevant to my taking part 
in research. I give permission for these individuals to have access to 
my records.
4. I agree to my GP being informed of my participation in the study.
5. I agree to take part in the study.
Name of Patient Date Signature
Name of Person taking consent Date Signature
Researcher Date Signature
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Appendix 9
HEADED NOTEPAPER 
GP INFORMATION SHEET (version 1: 23rd March 2008)
Title of study: 
Smoking status, exhaled volatile compounds and lung cancer
(R EC  number: 08/W M W 01/21)
Your patient has agreed to participate in the
above study that is being organised through Carmarthenshire NHS Trust and 
Swansea University.
This involves standard assessment in our lung cancer clinic plus two additional 
breath tests, to measure exhaled carbon monoxide and volatile compounds. 
Patients are then also asked to attend for assessment and follow up breath 
tests on monthly basis for the next 12 months, to see if these volatile 
compounds in their breath and validated smoking status have any ability to 
predict clinical outcomes (survival or response to treatment). If patients cannot 
come to hospital for these extra tests, we will seek their permission to visit them 
in their home.
This is an observational study only and all standard NHS treatment will 
continue throughout. Management will not be compromised in any way.
All information will be kept in the strictest confidence and no individual patients 
can be identified by anyone other than the lead researcher.
Your patient has provided written consent and has agreed that you be informed 
of their participation. They are fully aware that they can withdraw at any time 
from the study without giving a reason.
Dr Robin Ghosal 
Clinical Research Fellow 
Carmarthenshire NHS Trust
Dr Keir E Lewis
Senior Lecturer, Swansea School of Medicine and Consultant in 
Respiratory Medicine,
Carmarthenshire NHS Trust
Dr Philip Kloer
Consultant in Respiratory Medicine and Clinical Lead in Lung Cancer, 
Carmarthenshire NHS Trust
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Appendix 10 
HEADED NOTEPAPER
HEALTHY CONTROL INFORMATION SHEET- version 1,
10™ October 2008
Title: Smoking status, exhaled volatile organic compounds and lung
cancer
You are being invited to take part in a research study. Before you 
decide it is important to explain why the research is being done and 
what it will involve. Please take time to read the following 
information carefully and discuss it with friends, relatives and your 
GP if you wish. Ask us if there is anything that is not clear or if you 
would like more information. Take time to decide whether or not you 
wish to take part.
1. What is the purpose of the study?
We want to see if smoking status at the time of diagnosis of lung 
cancer and afterwards has an impact on the course of the illness 
and response to treatment. We also want to see if chemicals present 
in patient’s breath (but not detected by routine tests) will help 
determine diagnosis and longer term outcome and whether these 
chemicals change over time.
2. Why have I been chosen?
We would like you to be one of our 50 or so healthy control subjects 
to compare levels of these chemicals in your breath with 50 patients 
diagnosed with lung cancer.
3. Do I have to take part?
It’s up to you to decide whether or not to take part. If you do decide to take 
part, you will be given this information sheet to keep and be asked to sign a 
consent form. If you decide to take part you are still free to withdraw at any 
time and without giving a reason.
4. What will happen to me if I take part?
Following screening questions (see attached), to check if you are 
eligible, we will ask you for your age and then will ask you to breathe 
deeply into a container that measures the amount of carbon 
monoxide in your breath. This number will be recorded on a data
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sheet and is a marker of pollution and cigarette smoke exposure that 
can determine chemicals in your breath. We will then ask you to take 
a deep breath in and exhale fully into another container where we 
will trap your breath and these samples will be analysed at Swansea 
University fro levels of these chemicals in their mass spectrometry 
department. We will only be required to these tests on one occasion 
and your active participation will end at this point.
5. What do I have to do?
In order to take part you must be fasting (only had water) for the 
previous 4 hours. You must also not exert yourself beyond light 
walking for 20 minutes just before the breath tests.
6. What are the side-effects of taking part?
There is the inconvenience of taking 5 minutes of your time to 
answer the 6 simple screening questions and do two breath tests.
7. What are the possible benefits of taking part?
The results of the research using your samples, and those from others - 
may help develop less invasive screening and monitoring tools to benefit 
lung cancer patients in the future. We cannot pay you for your participation 
in the study.
8. What happens when the research study stops?
Your breath samples will have been analysed, but no further clinical 
follow up is required. The samples will be discarded immediately 
after analysis but the (anonymous) results will be kept on file for ten 
years.
9. What happens if something goes wrong?
If you have reason to complain about any aspect of the way you 
have been approached or treated during the course of the study, the 
normal National Health Service complaints mechanisms are 
available to you.
10. Will my taking part in this study be kept confidential?
All information collected about you during the course of the research will 
be kept strictly confidential. Any information that leaves the hospital will 
be coded so that you cannot be recognised from it. Information will not be
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made available to any life insurance or private medical insurance 
companies.
11. What will happen to the results of the research study?
The results may be published in scientific journals and presented at 
conferences. You are welcome to contact the researchers for a 
report summary, when this study ends (2009). Individuals will not be 
identified in any report/publication.
12. Who is organising and funding the research?
This is jointly organised through Hywel Dda NHS Trust and Swansea 
University.
13. Who has reviewed the study?
This has undergone peer review by academic colleagues within 
Wales and has been presented to the Research Ethics Committees 
in Dyfed Powys.
Contact for further information.
If you have any further queries please contact:
Dr Robin Ghosal,
Clinical Research Fellow, 
Hywel DDa NHS Trust,
8  01554 756 567 pager 873
Dr Keir Lewis
Consultant Physician in Respiratory Medicine, 
Hywel Dda NHS Trust and 
Senior Lecturer,
School of Medicine,
Swansea University.
8  01554 783133
Fax: 01554 783597
Email k.e.Iewis(a)swansea.ac.uk
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Or
Dr Philip Kloer
Consultant Physician in Respiratory Medicine, 
Hywel Dda NHS Trust
*  01554 783569
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